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Definitions
Asthma is a common non-communicable respiratory disease, characterised by epi-
sodic shortness of breath and wheezing. The US National Heart Lung and Blood Institute 
(NHLBI) defines asthma as follows in their National Asthma Education and Prevention 
Program NAEPP [1]: ‘Asthma is a common chronic disorder of the airways that is complex 
and characterised by variable and recurring symptoms, airflow obstruction, bronchial 
hyperresponsiveness and an underlying inflammation. The interaction of these features 
of asthma determines the clinical manifestations and severity of asthma and the 
response to treatment’. Symptoms of asthma include recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in the early morn-
ing. These episodes are usually associated with airflow obstruction within the lung that 
is often reversible, either spontaneously or with treatment.
Asthma symptoms can gradually increase over time, slowly increasing the burden 
of asthma on daily life. Asthma symptoms can also increase more rapidly, sometimes 
within a day, and this is referred to as an asthma attack, or asthma exacerbation. Exacer-
bations are characterised by a combination of an increase in shortness of breath, cough, 
wheezing and chest tightness and they are potentially life threatening, depending on 
their severity.
Organisation of healthcare
The Accurate trial, on which most chapters in this manuscript are based, was performed 
in the Netherlands with patients with asthma currently being treated in primary care. 
In the Dutch healthcare system primary care serves as a gatekeeper. This means that all 
patients and all illnesses are diagnosed and treated in primary care, unless the primary 
care physician refers a patient to secondary care for analysis or treatment. Therefore, in 
contrast to other countries, most patients with asthma in the Netherlands are treated 
in primary care, while patients with severe or difficult-to-treat asthma, or patients in 
whom the diagnosis is uncertain, will be treated in secondary or tertiary care. Another 
difference with some other countries is that in recent years primary care physicians have 
employed practice nurses to aid in the management of chronic diseases. Traditionally, 
practice nurses primarily assessed patients for cardiovascular disease management and 
for diabetes. Nowadays, COPD management is also largely performed by practice nurses 
and there is a significant increase in the management of asthma as well. Usually a prac-
tice nurse will assess a patient regularly and discuss outcomes and possible treatment 
changes with the primary care physician. Intercurrent worsening of disease, such as an 
asthma exacerbation, is still treated by the primary care physician.
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Trials
The chapters in this manuscript are based on data from several different trials. Chapters 
2, 4 and 6 and most of Chapter 3 are based on the Accurate trial [2]. Part of chapter 3 is 
based on a cohort of patients who were referred by their GP for lung function testing in 
a primary care diagnostic centre in the Nijmegen area. Chapter 5 is based on the data 
from two trials that were originally conducted in New Zealand [3,4].
Epidemiology
Asthma is a worldwide problem, and globally, the prevalence ranges from 1-24% of the 
population in different countries and races [5]. The prevalence is still increasing in most 
countries, especially in children, along with a similar increase in other atopy-related 
diseases such as eczema and rhinitis [5-8]. In the Netherlands the prevalence is roughly 
28 per 1000 persons and the number of newly diagnosed adult asthma patients in Dutch 
primary care is 6 per 1000 per year [9]. The prevalence of asthma changes with age, from 
more than 30 per 1000 in young adults to approximately 20 per 1000 in the elderly [9]. 
In primary care males are diagnosed with asthma 1.5 times as often as females. Most 
importantly, even though asthma is a relatively well-manageable disease, asthma still 
accounts for approximately 1 in every 250 deaths worldwide, especially in areas with low 
access to healthcare [5,6].
Mechanisms of asthma
As has been outlined above, asthma is characterised by several processes: airway inflam-
mation, airway hyper responsiveness and airway obstruction. The interaction between 
these processes will determine the frequency and severity of the symptoms a patient 
will experience [figure 1.1].
Central to asthma is the continuous presence of underlying airway inflammation, 
which is caused by an inappropriate response to environmental stimuli, such as aller-
gens, cigarette smoke, certain drugs or air pollutants [10]. Although airway inflammation 
varies in intensity, it remains persistent in asthma, even when symptoms are not present. 
Therefore, there is no clearly established relationship between the severity of asthma 
symptoms and the intensity of inflammation [11,12].Inflammation affects the calibre of 
the airways leading to airway obstruction and in addition affects (hyper)responsiveness 
of airways to stimuli, which leads to an increased sensitivity to bronchospasm [11]. The 
relationship between bronchospasm and patients’ symptoms is more clear, especially 
when bronchospasm occurs acutely.
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Diagnosis
In primary care the diagnosis of asthma is based on the presence of a characteristic 
clinical history, which includes recurrent episodes of dyspnoea, wheezing and/or cough 
[10]. An additional measurement of lung function can enhance diagnostic confi dence, 
if it shows reversibility, which is defi ned as an increase of ≥12% and 200 ml in FEV1 
after bronchodilator therapy [13,14]. If the sole symptom is recurrent cough, without 
dyspnoea or wheezing, reversibility is obligatory to diagnose asthma, to diff erentiate 
it from other diagnostic possibilities such as eosinophilic bronchitis, gastroesophageal 
refl ux, postnasal drip, chronic sinusitis, and vocal cord dysfunction [15]. Other fi ndings in 
history taking and physical examination include a family history of asthma or allergies, 
atopy, fatigue, deterioration of physical abilities, wheezing on auscultation and pro-
longed expiratory time. Increased breathing frequency, and use of accessory muscles 
can also occur if asthma symptoms are more severe. Typically the symptoms in asthma 
are variable and intermittent, they may be exacerbated by exercise, viral infections, 
exposure to irritants or allergens, changes in weather, strong emotional expressions and 
menstrual cycles [1, 16]. Based on symptom frequency, there is a distinction between 
intermittent (symptoms ≤ 2 times a week) and persistent (symptoms > 2 times a week) 
asthma. A special subcategory of intermittent asthma is exercise-induced asthma, in 
which symptoms only occur during or shortly after physical exercise.
Figure 1.1. Interplay between airway infl ammation and clinical symptoms.
Adapted from fi gure 2-1 of the NAEPP guideline 2007 [1].
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Treatment
An important and integral part of asthma treatment consists of lifestyle advices. 
Smoking-cessation is the key component, since smoking results in a more rapid decline 
of forced expiratory volume in one second (FEV1), worsens the natural course of asthma 
and decreases the effectiveness of inhaled corticosteroids (ICS) [17]. Physical activity 
should be encouraged, since it increases oxygen uptake and expiratory volume [18]. The 
exposure to allergens should be limited, especially for relevant allergies. With regards to 
domestic mite allergy there is no convincing evidence that reducing exposure benefits 
patients with asthma [19]. However, based on experienced improvements of asthma 
control in clinical practice, Dutch guidelines state that in patients with difficult to control 
asthma and a proven allergy, an integrated approach including barrier methods, dust 
removal and reduction of microhabitats favourable to mites might improve symptoms 
[13, 20, 21].
The mainstay of asthma treatment is medication. In the management of asthma 
two types of medication exist, namely ‘controllers’ and ‘relievers’. Controllers are daily 
medications, developed to keep asthma under clinical control, mainly through their an-
ti-inflammatory effects. They include inhaled and systemic corticosteroids, leukotriene 
modifiers, combinations between inhaled corticosteroids and long-acting beta agonists 
(LABA), theophylline, cromones, anti-IgE, and other systemic steroid-sparing therapies. 
Relievers are medications used on an as-needed basis and designed to reverse bron-
choconstriction and thereby relieve its symptoms. They include rapid-acting inhaled 
beta-agonists, inhaled anticholinergics and short-acting theophylline. As stated before, 
the relationship between bronchoconstriction and asthma symptoms is more clear than 
between inflammation and symptoms. Therefore patients perceive more direct benefit 
from reliever medication which address bronchospasm (i.e. bronchodilators) than from 
medications that are aimed at controlling the underlying inflammation, for which (in-
haled) corticosteroids (or leukotriene modifiers) are the medications of choice. However, 
although patients will not perceive direct benefit, especially in the long-term, controller 
medication are the most important component of treatment, since they address under-
lying inflammation. These differences in expected perceived advantages of medication 
need to be addressed in consultation to improve patient adherence.
Costs and cost-effectiveness
The Dutch governmental organisation for health and environment ‘Rijksinstituut voor 
Volksgezondheid en Milieu’ (RIVM) has assessed costs for asthma in the Netherlands in 
2007 [22]. Total healthcare costs were € 287 million per year, which amounts to € 530 per 
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patient per year. Costs for asthma medication account for nearly 70% of total healthcare 
costs for asthma. Other costs constitute physiotherapy (10.8%), regular monitoring in 
secondary care (9.5%), hospitalisation (5.7%), and regular monitoring in primary care 
(4.5%). Furthermore, there are additional costs for loss of productivity, which range 
from € 340 per year for employed patients between 15-25 years, to € 2000 per year for 
employed patients between 55-65 years. Loss of productivity can be mainly ascribed to 
inability to work due to asthma exacerbations. Therefore, to achieve a reduction in costs 
for asthma, medication-usage and exacerbation frequency are the most appropriate 
targets. A more patient tailored approach of medication prescription, instead of a one-
size-fits-all approach, would ideally reduce total medication use, without loss of control 
on asthma symptoms. Another effective measure to reduce costs would be to decrease 
the asthma exacerbation rate, since this would decrease both costs for hospitalisations 
and costs due to loss of productivity.
Asthma management
In the Netherlands 80% of patients with asthma are managed in primary care, 10% 
are managed solely by a pulmonary physician and 10% are managed by both [22]. In 
primary care the recommended frequency of assessment of current asthma control is 
once to twice a year when asthma is controlled, to as often as every two weeks when 
asthma remains uncontrolled [1,8,13,23]. In clinical practice, the actual frequency of 
assessment may vary widely between different general practitioners and between in-
dividual patients. This can be caused by several factors, such as lack of patient or doctor 
adherence to the recommended monitoring frequency, which may be explained by a 
perceived lack of benefit. However, with the advent of integrated disease management 
[IDM] programs, a more uniform approach to asthma management is arising [23]. IDM 
programs are commonly used for COPD and include individualised targets, exercise 
programs, regular monitoring and self-management [24] . For asthma, these programs 
are currently initiated by large conglomerates of primary care practices. The content is 
based on recent guidelines and reviewed by several stakeholders, such as primary care 
physicians, pulmonary physicians and health insurance companies [13, 21].
When monitoring asthma, the aim is to achieve and maintain control of clinical 
manifestations for prolonged periods of time. Additional aims include prevention of 
exacerbations, minimising side-effects of medication, and keeping asthma costs as 
low as possible [1,8,13,25]. The severity of clinical manifestations of asthma is generally 
classified into controlled, partly controlled and uncontrolled asthma [1,8]. This classifica-
tion is based on several clinical parameters: presence/absence of daytime symptoms, 
limitations in activity, nocturnal symptoms/awakening, the need for reliever therapy 
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and lung function [1,8,13]. Current control on asthma can be measured by the Asthma 
Control Questionnaire (ACQ), which is a composite questionnaire that incorporates all 
these parameters [26]. According to international guidelines, the current aim of asthma 
management, is to achieve controlled asthma [1,8,13]. However, in practice, 45% of 
patients are partly controlled and 30% of patients are uncontrolled [27-29]. In these 
patients a step-up of asthma medication is advocated to achieve controlled asthma 
[1,8,13,25]. However, for patients who are considered partly controlled, the benefits 
of stepping up treatment might be limited and should be weighed against potential 
harms, because the dose-response relationship of inhaled corticosteroids (ICS) flattens 
at higher levels, while the risk of side-effects such as cough, pneumonia and adrenal 
insufficiency increases [30,31]. This dilemma in asthma management is captured in the 
notion that patient preferences/goals should be taken into account before stepping up 
treatment when asthma is partly controlled [8,13]. To clarify this dilemma, we performed 
a trial, in which we compared a treatment strategy aiming for controlled asthma, with a 
strategy that accepted partly controlled asthma, using asthma control, asthma related 
quality of life, exacerbation rate, medication prescription levels and costs as outcome-
comparators. Chapter 2 contains the published version of the protocol for this study, 
describing study procedures, measurements and algorithm, while study results are 
presented in chapter 4.
Another dilemma in current guidelines involves the choice of type of medications in 
a step-up or step-down of treatment. Guidelines do not give clear advice on whether 
to increase/decrease inhaled corticosteroids (ICS) or add/remove long-acting beta-
agonists (LABA) [1,8,13]. Some guidelines also include the options of adding/removing 
leukotriene modifiers or theophylline at certain treatment levels (See figure 1.2).
There is a need to identify which individual patients would benefit most from a 
step-up/step-down in ICS and which would benefit most from a step-up/step-down in 
LABA. If medication prescriptions are tailored to an individual patient’s needs, the lowest 
possible effective dosage can be prescribed, thereby maximizing asthma control and 
minimising therapy-related side-effects and costs. Currently it is recommended to assess 
symptoms and lung function in asthma management. However, these measurements 
do not provide sufficient information to appropriately choose between different types 
of medication in an individual patient. An additional measurement of airways inflamma-
tion would enable a more tailored decision making, since inflammation is the underly-
ing process in asthma and it is the main target for inhaled corticosteroids. Recent studies 
showed that biomarkers, such as fractional exhaled nitric oxide (FeNO), might provide 
the required additional information on bronchial inflammation [32]. However, the use of 
FeNO in asthma management has led to contradicting results. Some studies on tailoring 
treatment based on FeNO showed an increased proportion of patients with ‘controlled 
asthma’ [33] and a reduction in ICS dosage [4]. In contrast, other studies showed an 
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increase in ICS use [34-36]. However, most of these studies have been performed in sec-
ondary care patients, which have more severe asthma. Also, the choice of cut-off points 
for FeNO and the role the FeNO-measurement had in asthma management decisions 
differed between these studies. To date, it remains unclear, whether FeNO is a useful 
adjunct test to symptom assessment and lung function, when assessing asthma control 
in adult patients in primary care. Therefore, we address this topic in chapter 3.
Furthermore, it is unknown whether the pursuit of controlled asthma with additional 
guidance by a measure of airway inflammation (FeNO) improves our aim to achieve and 
maintain controlled asthma, and/or leads to a more tailored medication prescription, an 
improved asthma related quality of life, lower exacerbation-rates and/or reduced costs 
of treatment. To that end, we added a third strategy that aimed for controlled asthma ad-
ditionally driven by Fractional exhaled Nitric Oxide (FeNO), to our previously described 
study that compared aiming for partly controlled asthma with aiming for controlled 
asthma. In chapter 2 we describe the study protocol and the specific measurements 
regarding the use of FeNO. Chapter 4 describes the results of our study.
Reduction of future risk, defined as the occurrence of (severe) exacerbations, or pro-
longed periods of loss of control, is another important aim in the management of asthma. 
Obviously, improving control on asthma symptoms by regular monitoring and finding 
Figure 1.2. Medication at different treatment steps
Adapted from figure: Management approach based on control, chapter 4 of the GINA guideline 2012 [5].
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the optimal management strategy, should result in a reduced frequency of exacerbations 
and prolonged periods of loss of control. Therefore, we also addressed the exacerbation 
frequency in our comparison of the three treatment strategies in chapter 4.
In addition to regular control visits, patients are provided with the option to use an 
(online) self-management plan to improve control on asthma and detect and prevent 
imminent exacerbations. Self-management preferably includes creating an individu-
alised Written Asthma Action Plan (WAAP) [37]. Multiple different types of WAAPs exist, 
but generally patients are provided with a diary in which they daily record their asthma 
symptoms, or a lung function measurement, or both. As a measure of lung function, 
Peak Expiratory Flow (PEF) is usually used, since it can be easily assessed at home using 
a handheld device (PIKO-1 device). In the WAAP several threshold levels of symptoms 
and/or PEF are pre-specified and if the daily measurements exceed these threshold lev-
els, the patient is advised to take a particular action. Hence these thresholds are called 
‘action points’. Examples of action points are that a patient can be advised to increase 
his inhaled corticosteroids when he starts experiencing breathlessness during activity, 
or a patient can be advised to immediately see a doctor if his PEF measurement is below 
50% of his personal best value. In order to be effective, an action point should detect 
an imminent exacerbation accurately and well before its onset. Although a number of 
different candidate action points have been proposed in the literature, most currently 
recommended action points have not been validated [1,8,13,38-41]. Furthermore, in 
most guidelines, thresholds for symptoms or PEF are not even specified and should be 
determined empirically by a physician (in conjunction with the patient), lacking any 
evidence base [8, 13]. Also, the optimum time point at which changes in symptoms or 
PEF may be detected prior to an exacerbation is largely unknown. If action points are in-
accurately selected, this potentially leads to over treatment (false-positive action points) 
or missed opportunities for early intervention (false-negatives). Therefore in chapter 5, 
we aimed to develop optimal action points, based on symptoms and/or PEF threshold 
levels for early detection of asthma exacerbations which allow timely intervention (with 
oral prednisone) in patients with mild-moderate asthma.
The Internet
The world is changing rapidly and already a large proportion of our time is spent online. 
Unsurprisingly, simultaneously we see the appearance of all sorts of online tools to 
monitor chronic diseases, such as apps and patient portals, and future self-management 
plans will be mainly online [42-44]. Often it is assumed that the results of measure-
ments of questionnaires online will be similar to pen & paper versions, and outcomes 
will therefore be interchangeable. For the Asthma Control Questionnaire, which had a 
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central role in our study in chapters 2,3 and 4, Juniper et al. have shown that a paper 
version of the questionnaire and an electronic version on a handheld device have similar 
results [26,45]. However, this might be different for an online assessment, since several 
other studies on other questionnaires have shown different results between offline and 
online applications [46,47]. Therefore, in chapter 6 we assessed the agreement between 
an online self-administered version of the ACQ and an interviewer-administered ACQ by 
a practice nurse during a routine control visit.
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Abstract
Background Despite the availability of effective therapies, asthma remains a source of 
significant morbidity and use of health care resources. The central research question of 
the ACCURATE trial is whether maximal doses of (combination) therapy should be used 
for long periods in an attempt to achieve complete control of all features of asthma. 
An additional question is whether patients and society value the potential incremental 
benefit, if any, sufficiently to concur with such a treatment approach. We assessed pa-
tient preferences and cost-effectiveness of three treatment strategies aimed at achiev-
ing different levels of clinical control:
1. sufficiently controlled asthma
2. strictly controlled asthma
3. strictly controlled asthma based on exhaled nitric oxide as an additional disease 
marker
Design 720 Patients with mild to moderate persistent asthma from general practices 
with a practice nurse, age 18-50 year, daily treatment with inhaled corticosteroids (more 
than 3 months usage of inhaled corticosteroids in the previous year), will be identified 
via patient registries of general practices in the Leiden, Nijmegen, and Amsterdam areas 
in The Netherlands. The design is a 12-month cluster-randomised parallel trial with 40 
general practices in each of the three arms. The patients will visit the general practice 
at baseline, 3, 6, 9, and 12 months. At each planned and unplanned visit to the general 
practice treatment will be adjusted with support of an internet-based asthma monitor-
ing system supervised by a central coordinating specialist nurse. Patient preferences 
and utilities will be assessed by questionnaire and interview. Data on asthma control, 
treatment step, adherence to treatment, utilities and costs will be obtained every 3 
months and at each unplanned visit. Differences in societal costs (medication, other 
(health) care and productivity) will be compared to differences in the number of limited 
activity days and in quality adjusted life years (Dutch EQ5D, SF6D, e-TTO, VAS). This is 
the first study to assess patient preferences and cost-effectiveness of asthma treatment 
strategies driven by different target levels of asthma control.
Trial registration Netherlands Trial Register (NTR): NTR1756
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Background
Despite the availability of effective therapies, asthma remains a source of significant 
morbidity and use of health care resources [1,2]. The societal costs of asthma are consid-
erable. Asthma negatively affects work productivity as well as labour force participation. 
Furthermore, a survey showed that in the Netherlands 30% of asthmatics needed urgent 
care in the past year, which was on average 8% more than in other European countries [3]. 
Under a system designed for acute rather than chronic care, patients are not adequately 
taught to care for their own illness. Sixty-two percent of patients visit their pulmonary 
specialists or general practitioners only if they have an acute health problem. Only 15% 
of Dutch asthmatics had a doctor-written action plan for their asthma [3]. In addition, 
there is a major discrepancy between patients’ perceived control of asthma and symp-
tom severity [4]. National and international guidelines define the goal of treatment as 
to achieve and maintain clinical asthma control [5,6]. Daily treatment with inhaled cor-
ticosteroids is recommended on a long-term basis as first-line therapy to keep asthma 
under clinical control in patients with persistent asthma. Short-term bronchodilators are 
used on an as-needed basis to reverse bronchoconstriction and relieve symptoms. The 
2006 updated international guidelines [6] introduced a management approach based 
on asthma control. According to the Global Initiative for Asthma (GINA) guidelines the 
levels of asthma control are defined as follows:
1) Partly controlled asthma is defined as the presence of any of the following: daytime 
symptoms ≥ twice per week, limitations of activities, nocturnal symptoms, need for 
reliever treatment, reduced lung function and exacerbations (further referred as suf-
ficiently controlled).
2) Controlled asthma is defined as daytime symptoms that are present ≤ twice per 
week and the absence of limitations of activities, nocturnal symptoms, need for 
reliever treatment, reduced lung function and exacerbations (further referred as 
strictly controlled).
3) Uncontrolled asthma is defined as ≥ 3 features of partly controlled or the presence of 
an exacerbation.
The level of asthma control can be assessed using composite measures such as the 
validated Asthma Control Questionnaire (ACQ) [7]. Each patient should be assessed to 
establish the current treatment regimen, adherence to the current regimen, and the 
level of asthma control. If asthma is uncontrolled on the current treatment regimen, 
treatment should be stepped up until control is achieved. If asthma is partly controlled, 
the guidelines recommend that a step-up in treatment should be considered.
Strictly controlled asthma can be achieved in the majority of patients with uncon-
trolled asthma by a treatment strategy with (high dose) inhaled corticosteroids alone or 
with combination therapy of an inhaled corticosteroid and a long-acting bronchodilator 
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[8]. Symptoms and lung function will improve and the number of awakenings and se-
vere exacerbation rate will reduce [9]. However, this is in marked contrast with the levels 
of control observed in community studies, where patients tend to be partly controlled 
[4]. Current guidelines show some ambiguity whether the treatment target should be 
controlled or partly controlled [6]. Another question is not only whether maximal doses 
of (combination) therapy should be used for long periods in an attempt to achieve 
complete control of all features of asthma, but also whether patients would value the 
potential incremental benefit sufficiently to concur with such a treatment approach [10]. 
In addition, there is only limited data available on the cost-effectiveness of treatment 
strategies aimed at different levels of asthma control [11,12].
Recently, the fraction of exhaled nitric oxide (FeNO) has been introduced as a non-
invasive marker of airway inflammation in asthma. The role of FeNO in titrating anti-
inflammatory treatment to the most effective dose of inhaled corticosteroids in asthma 
is still controversial [13]. Addition of FeNO as an indicator of control of asthma has led to 
higher [14] as well as lower [15] doses of inhaled corticosteroids without a difference in 
symptomatic asthma control. Adjustments to medication dose based on FeNO measure-
ments seem to reduce the number of exacerbations, but recent studies had insufficient 
power to reach statistical significance when adjusting for multiple exacerbations within 
patients [16]. Therefore, it is not yet determined whether FeNO measurements may 
indicate whether a step-up in treatment is effective or a step-down can be achieved 
without loss of asthma control and thereby contribute to the efficiency of asthma care.
Therefore, we aim to investigate whether a treatment strategy aimed at strict asthma 
control is more (cost-)effective as compared to a treatment strategy aimed at achieving 
sufficiently controlled asthma. In addition we postulate that a treatment strategy aimed 
at strict asthma control is more (cost-)effective when the treatment step is additionally 
guided by measurements of exhaled nitric oxide (FeNO) as compared to a treatment 
strategy aimed at achieving strictly controlled asthma or sufficiently controlled asthma 
without the addition of FeNO.
Preliminary results
Monitoring control
An internet application will be used to assist the physician/nurse practitioner/physician 
assistant in adjusting the treatment step according to the 3 treatment algorithms. In the 
Self-Management of Asthma Supported by Hospitals, Information and communication 
technology, Nurses and General practitioners (SMASHING) -project we have already 
used an internet application for monitoring Forced Expiratory Volume in 1 second (FEV1) 
and the asthma control questionnaire (ACQ) [17]. Furthermore, in this project we have 
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set-up electronic versions http://www.netquestionnaires.nl of the majority of question-
naires. In the OPPAS-project (UMCN) we have already explored the distribution of levels 
of asthma control in general practice patients with asthma [18].
Design
The study is a cluster-randomised parallel trial with 3 arms and 12 months follow-up 
(Figure 2.1). In order to avoid recruitment bias the identification of potential patients 
from the general practice information system will be performed before the allocation 
of a general practice cluster to a treatment strategy [19,20]. The 3 treatment strategies 
are defined as:
1 SUFF-strategy: achieving sufficiently controlled asthma based on conventional 
asthma control measures
2 STRICT-strategy: achieving strictly controlled asthma based on conventional asthma 
control measures
3 FeNO-strategy: achieving strictly controlled asthma based on conventional asthma 
control measures and an indirect marker of airways inflammation (FeNO).
General practices will be randomly assigned to the 3 groups using a computer gener-
ated permuted block scheme, ensuring concealment of allocation. Treatment assign-
ment will be stratified according to characteristics of general practices (solo/duo/etc 
practice, rural/urban). The patients will visit the general practice for an introduction visit 
and control visits at baseline, 3, 6, 9, and 12 months. In case of asthma exacerbations 
patients pay an additional visit to the general practice or chest physician.
Intervention
The level of asthma control will be based on a 3-monthly assessment of asthma symp-
toms, number and severity of exacerbations, FEV1, with or without the level of FeNO. 
Asthma symptoms will be assessed with the ACQ, which is closely associated with the 
level of asthma control from the GINA guidelines (Table 2.1). Step-ups in medication will 
be adjusted (Table 2.2), using specific algorithms for the 3 treatment strategies (Table 
2.3). The step-up in medication in the FeNO-strategy will be additionally guided by the 
level and change in FeNO according to recent recommendations and the latest available 
evidence [21]. This allows adjustment of the dosage of inhaled corticosteroids based on 
information of airways inflammation whilst the dosage of additional reliever medication 
is based on asthma control measures [21]. At each planned and unplanned visit dur-
ing the 12 months follow-up maintenance, therapy will be adjusted according to the 
relevant algorithm, using the internet-based asthma monitoring system by either the 
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Figure 2.1. Flowchart of the Accurate trial.
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nurse practitioner or general practitioner [17]. This allows the supervision of this process 
by a central coordinating nurse specialist.
Patients
720 Patients with mild to moderate persistent asthma (prevalent cases) will be recruited 
from general practices via patient registries in three regions in The Netherlands:
– Leiden University Medical Center (LUMC) general practice network LEON (240 pa-
tients, 40 general practices)
Table 2.1. Levels of Asthma Control
Characteristic Controlled
(All of the following)
Partly Controlled
(Any measure 
present in any week)
Uncontrolled
Daytime symptoms None (twice or less/week) More than twice/week Three or more features of 
partly controlled asthma 
present in any week




Need for reliever/ rescue 
treatment
None (twice or less/week) More than twice/week
Lung function (FEV1) Normal < 80% predicted
Exacerbations* None 1st moderate 
exacerbation
≥ 2 moderate exacerbation† or 
severe exacerbation
*modified from the GINA guidelines; the presence of an exacerbation influences the level of asthma control 
at baseline or at an exacerbation. If one or more exacerbations have led to an adjustment in treatment, this 
category starts at 0 again. At baseline: treatment levels only will be adjusted when exacerbations were pres-
ent ≤ 3 months prior to the study: † during the same treatment regime.
Table 2.2. Management approach based on control (GINA guidelines)
STEP 1 STEP 2 STEP 3 STEP 4 STEP 5
As needed rapid-
acting β2-agonist
As needed rapid-acting β2-agonist
Select one Select one Add one or more Add one or both
Low-dose ICS* Low-dose ICS plus 
long-acting β2-
agonist
Medium- or high 



















– Radboud University Nijmegen Medical Centre general practice network (240 pa-
tients, 40 general practices)
– Amsterdam Medical Center (AMC) general practice network (240 patients, 40 general 
practices)
Only general practices with a practice nurse (or nurse practitioner/or physician assistant, 
further referred to as ‘practice nurse’) will participate (70% of general practices in the 
Netherlands currently have a employed such a professional [22]). Based on previous re-
search experience in patients with asthma in general practice (SMASHING-project CME 
number P05.136), we estimate a response rate of 40% with an inclusion of 6 patients per 
‘standard’ practice (i.e. practice with 2,300 patients) and 40 ‘standard’ general practices 
per treatment strategy.
Inclusion criteria
(all of the following criteria)
– age 18-50 yr
– doctor’s diagnosis of asthma
– patients who need inhaled corticosteroids as controller medication (step 2-4 GINA 
guidelines)
– inhaled corticosteroids ≥ 3 months in the previous year
– written informed consent
– no exacerbation of asthma within 1 month before entry
Table 2.3. Treatment strategy algorithms
Strategy
Levels of asthma control
Controlled Partly controlled Uncontrolled
STRICT-strategy – 3 mo: no change
– > 3 mo: step-down
step-up: treatment choice step-up: treatment choice
SUFF-strategy step-down no change step-up: treatment choice
FeNO-strategy
- Low FeNo level step-down –  3 mo: no change/ 
change within current 
step to LABA
–  > 3 mo: step-down ICS
step-up: LABA
- Intermediate FeNo level no change step-up: treatment choice step-up: treatment choice
- High FeNo level step-up/change within 
current step to ICS
step-up: 1 x ICS step-up: 2xICS*
A raised FeNO level is indicative of eosinophilic airway inflammation; ICS=inhaled corticosteroids; LABA= 
long-acting β2-agonist. *until a maximum high dose of ICS is reached
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Exclusion criteria
– daily or alternate day oral corticosteroid therapy for at least 1 month before entering 
into the study
– inability to understand written and oral Dutch instructions
– active diseases likely to interfere with the purpose of the study, such as end-stage 
disease or inability to visit the general practitioner
Methods of measurements
At baseline, patient characteristics will be assessed including questions on atopy, 
smoking and symptom free days. In line with the Dutch national guidelines for general 
practitioners [3], patients are invited to visit their general practice every 3 months in 
order to titrate medication to the lowest level that is needed to achieve or maintain 
control. 3-Monthly care by the nurse practitioner will be organized similar to the advise 
in the national guidelines for general practitioners [5], including questions on asthma 
control, medication, adverse events and measurement of lung function. At all planned 
and unplanned visits questionnaires will be performed at home (Table 2.4). In addition, 
the ACQ will be performed at home monthly as an outcome measure. Peripheral blood 
will be obtained at baseline. Both paper and electronic versions will be used to collect 
the data, depending on the preference of a patient. Electronic versions in the ACCURATE 
project will be similar to those from the SMASHING project http://www.netquestion-
naires.nl . A coordinating nurse specialist will supervise the nurse practitioners.
Table 2.4. Instrument Table
Assessment of level 





















































































































FeNO FEV1 ACQ IPQ MARS BMQ FACCT SF-36 AQLQ TTO ASUI EQ-5D CostQ
Baseline X X X X X X X X X X X X X
Unplanned
visit
F X X X X X
3 months F X X X X X X
6 months F X X X X X X X X X X X X
9 months F X X X X X X
12 months X X X X X X X X X X X X X
X in all treatment strategies, F only in FeNO strategy
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Assessment of level of asthma control
At each planned and unplanned visit to the general practice a nurse practitioner will 
assess the level of asthma control with:
1. asthma control questionnaire (ACQ-score) [7]
2. lung function level (FEV1)
3. FeNO (only in the FeNO-strategy)
4. presence of exacerbations, now or in previous weeks
Asthma control questions
Asthma control will be assessed every 3 months with the Asthma Control Questionnaire 
(ACQ), which consists of 6 items with a 7-point scale (0 = totally controlled, 6 = severely 
uncontrolled) [7]. In addition, the ACQ will be completed monthly at home. The ACQ 
contains questions on respiratory symptoms over the previous week. The patients will 
be asked whether these symptoms were representative for the last 4 weeks. If not, the 
ACQ will be assessed from the most representative of the last 4 weeks. The optimal cut-
point for ‘strictly controlled’ asthma is defined as a mean ACQ score ≤ 0.75 and a score 
of ≥1.50 confirms ‘uncontrolled’ asthma [23]. We regard control to be sufficient if 0.75 < 
mean ACQ < 1.50.
Lung function measurements
Spirometry will be performed in the general practices according to national [5] and inter-
national guidelines [24]. For the baseline visit patients will be instructed to refrain from 
bronchodilator use for a specified number of hours before the scheduled spirometry 
test. Reversibility of airways obstruction will be measured 20 min. after administering 
4 single puffs of 100 μg salbutamol per metered dose-inhaler connected to a spacer 
(Volumatic®). The response will be expressed as ml and percentage change in predicted 
value of FEV1.
Exhaled nitric oxide
Fraction of exhaled Nitric Oxide (FeNO) will be measured in the general practices accord-
ing to international guidelines [25] with the NIOX-MINO (Aerocrine, Solna, Sweden) [26]. 
At baseline and at the last visit all patients will perform FeNO measurement, whereas at 
3, 6, and 9 months, FeNO only will be assessed in the FeNO Group. FeNO will be mea-
sured before spirometric manoeuvres, at an exhaled rate of 50 ml/sec maintained for 10 
seconds. Patients are not allowed to smoke at least one hour before the measurements. 
Results are expressed as the NO concentration in ppb (equivalent to nanolitres/litre) 
based on the first approved measurement. FeNO levels will be categorized into low 
when FeNO ≤ 25 ppb (absence of inflammation), intermediate 25 ppb < FeNO < 50 ppb 
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and high FeNO ≥ 50 ppb (presence of airway inflammation) [13]. Results will be adjusted 
for smoking (yes/no), gender and height [27].
Exacerbations
Patients will be instructed to pay an additional visit to their general practice if they expe-
rience worsening of asthma symptoms. In line with the national [5] and GINA guidelines 
[6] exacerbations of asthma are defined as acute or subacute episodes of progressively 
worsening shortness of breath, cough, wheezing, and chest tightness, or some combina-
tion of these symptoms [28] and will be treated by the general practitioner [5]. FeNO will 
be performed only in the FeNO strategy. Additional questionnaires and lung function 
will be performed at home (Table 2.4).
After an exacerbation is resolved the patient visits the nurse practitioner who will 
assess the current level of asthma control. GINA advises to incorporate the occurrence 
of exacerbations in the assessment of current asthma control, but is not entirely clear 
as to how to do that. Therefore, in the present study exacerbations are handled as fol-
lows. Questions will be asked on new respiratory symptoms, medication change and 
hospitalisation [28]. The exacerbation will be classified according to severity as based 
on the presence of respiratory symptoms, prescribed medication and/or hospitalisation. 
A moderate exacerbation is defined as a (sub)acute deterioration in symptoms and/or 
lung function with increased rescue bronchodilator use (or ICS) which lasts 2 days or 
more, not severe enough to warrant oral steroids (for 3 days or more) or hospitalisa-
tion. A severe exacerbation is defined as (sub)acute deterioration in asthma resulting 
in the need for oral steroids for 3 days or more or hospitalisation (as judged by the 
physician) [29]. Subsequently, the level of control will be assessed as based on Table 2.1 
and maintenance therapy will be assigned according to the treatment algorithm after 
exacerbation treatment is finished.
Assessment of cost-utilities and patient preferences
Costs
– cost questionnaires: health care consumption; absenteeism and productivity loss 
(CostQ) [30]
Patient preferences
– the Foundation for Accountability (FACCT) [31]
– the Brief Illness Perception Questionnaire (Brief IPQ) [32]
– the Beliefs about Medicines Questionnaire (BMQ) [33]
– Medication Adherence Report Scale (MARS) [34,35]
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Quality of life, patient utilities
– quality of life: Asthma Quality of Life Questionnaire (AQLQ) [36] and Short-Form 36 
(SF-36) [37]
– patient utilities: the Asthma Symptom Utility Index (ASUI) [38]. Patient utilities will 
additionally be assessed by the time-trade-off method by telephonic interview and 
a web-page (e-TTO) at each planned and unplanned period (exacerbation) [39]
– indirect utilities from the general public will be obtained using the SF-6D [37,34] and 
EQ-5D [40,41]. This allows the calculation of quality adjusted life years (QALYs).
– number of limited activity days by questionnaire
Analysis
The analysis will be carried out on an intention to treat basis. The data set will consist of 
all included patients from randomised practices.
Sample-size calculation
A minimally important change in patient utility (EQ-5D) has been defined as 0.074 point 
[42]. With 150 patients per treatment strategy we are able to detect at least a change 
of 0.06 points by net health benefit analysis [43] between the arms with a SD = 0.175 
EQ-5D points (baseline data SMASHING-project; trial registry number NTR826: SD = 
0.17) and a SD of €1000 for costs (SD = €816, usual care strategy [44]) and an increase in 
costs of €250 when a treatment strategy is not only more effective but also more costly, 
for a willingness-to-pay (WTP) of €30K (alpha = 0.05, one sided [43], beta = 0.20, one 
sided, rho costs-effects = 0) (Figure 2.2). With 40 clusters (general practices) per arm and 
assuming an intra-cluster correlation of 0.01, 0.07 and 0.11 the number of patients per 
cluster is 4, 5, and 6, and the total number of patients is 480, 600 and 720, respectively 
[45].
Data-analysis and presentation/synthesis
At baseline, data from all planned and unplanned contact will be collected according to 
the scheme in Table 2.4. The instruments include variables of:
– patient characteristics: age, sex, socioeconomic status, smoking status and smoking 
history
– medical outcomes: FEV1, FeNO, ACQ, current treatment step, asthma medication
– patient preferences: FACCT, IPQ, BMQ, MARS
– quality of life: AQLQ, SF-36
– patient utilities: ASUI, SF-6D and EQ-5D, QALYs, e-TTO, number of limited activity 
days
– costs: health care consumption; CostQ
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Economic evaluation
General considerations
The economic evaluation will compare differences in societal effects and costs to dif-
ferences in the number of limited activity days (cost-effectiveness analysis, CEA) and 
quality adjusted life years (cost-utility analysis, CUA). The analysis will have a 12-months’ 
time horizon, without discounting. Group averages will be statistically compared using 
two-sided bootstrapping and net-benefit analysis will be used to relate costs to patient 
outcome. Sensitivity analyses will be performed on the perspective (societal versus 
health care) and the applied utility measure (Dutch EQ5D, SF6D, e-TTO, AQLQ-5D).
 
Figure 2.2. Power curve of the required sample-size per treatment arm as a function of willingness-to-pay 
(WTP) for a range of increases in costs (delta Costs) when a treatment strategy is not only more effective but 
also more costly. The presented +sample-size is unadjusted for intra-cluster correlation.
A minimally important change in patient utility (EQ-5D) has been defined as 0.074 point. With 150 patients 
per treatment strategy we are able to detect at least a change of 0.06 points by net health benefit analysis 
between the arms with a SD = 0.175 EQ-5D points (baseline data SMASHING-project: SD = 0.17) and a SD 
of €1000 for costs (SD = €816, usual care strategy) and an increase in costs of €250 (delta Costs) when a 
treatment strategy is not only more effective but also more costly, for a willingness-to-pay (WTP) of €30K 
(alpha=0.05, onesided, beta=0.20, onesided, rho costs-effects=0).
With 40 clusters (general practices) per arm and assuming an intra-cluster correlation of 0.01, 0.07 and 




The primary end-point is the evaluation of the cost-effectiveness of treatment strategies 
by incremental net-benefit analysis [43]. Net health benefit addresses cost-effectiveness 
ratios by assuming values for the willingness-to-pay per unit of effectiveness.
Cost analysis
The cost analysis will include both medical (medication, visits, and hospitalizations) and 
non-medical costs (productivity losses, informal care). Purchased medication will be as-
sessed from electronic patient records (with written patient permission), complemented 
with the patient’s report on medication purchased elsewhere [46]. Other costs will be 
estimated using quarterly cost questionnaires (CostQ) [30]. Costs will be valued accord-
ing to standard prices charges [47] including time and travel costs.
Analysis of effectiveness
The differences in levels and changes in utilities based on EQ-5D, SF-6D, VAS, e-TTO and 
the number of limited activity days will be compared between the treatment strategies 
using a random-effects analysis accounting for within-patient repeated measurements 
and clustering on general practice.
Patient outcome analysis
Utilities will be assessed every three months. In the base case analysis, quality-adjusted 
life years (QALYs) will be estimated using societal utilities obtained using the Dutch 
EQ-5D tariff [48]. As sensitivity analyses, QALYs will be estimated using the SF-6D and 
individual utilities obtained using the e-TTO and visual analogue scale (transformed 
using a power transformation).
Ethical approval
Ethical approval was obtained from the Medical Ethics Committee of the Leiden Univer-
sity Medical Center (ABR no: 24488).
Discussion
The aim of the ACCURATE trial is to compare the cost-effectiveness and patient prefer-
ences of three asthma treatment strategies: 1) sufficiently controlled strategy, aiming to 
achieve sufficiently controlled asthma based on conventional asthma control measures 
(ACQ and lung function); 2) strictly controlled strategy, aiming to achieve controlled 
asthma also based on asthma conventional control measures; and 3) FeNO-strategy, 
aimed at achieving strictly controlled asthma based on conventional asthma control 
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measures plus an indirect marker of airways inflammation. For this purpose we will 
implement an internet-based programme, to be used by care providers in general 
practices.
To our knowledge, this is the first study to assess patient preferences and cost-effec-
tiveness of asthma treatment strategies aimed at different levels of control on asthma. 
Notably, the current study is fully investigator driven, granted by governmental funding 
rather than pharmaceutical funding. Current guidelines advise clinicians to ensure that 
asthma is strictly controlled, i.e. patients should not experience any symptoms. However, 
in daily practice, a considerable proportion of asthma patients continuously experience 
symptoms without consulting their physician [49]. This raises the question of patient’s 
preferences with regard to treatment aims. It is not yet known whether patients are will-
ing to conform to the stringent treatment aim of strictly controlled asthma, especially if 
it results in high doses of asthma medication and an increased likelihood of concurrent 
side effects. These uncertainties hamper implementation of current guidelines and 
therefore a great diversity in treatment exists. Furthermore, discordance in patient’s and 
medical treatment goals might result in unnecessary asthma symptoms and health care 
use.
A recent meta-analysis showed that FeNO guided treatment of asthma does not 
reduce the number of exacerbations; however it did reduce the daily dose of inhaled 
corticosteroids [50]. Our study may extend these findings by providing further under-
standing of the cost-effectiveness and patient preferences of FeNO guided treatment of 
asthma.
We hypothesize that:
1) a treatment strategy aimed at achieving strictly controlled asthma is more (cost-)ef-
fective as compared to a treatment strategy aimed at sufficiently controlled asthma;
2) a treatment strategy aimed at achieving strictly controlled asthma is (cost-)effec-
tive when the treatment step is additionally guided by measurements of fractional 
exhaled nitric oxide (FeNO) as compared to a treatment strategy aimed at strictly 
controlled asthma or sufficiently controlled asthma.
During the course of the trial the definition of asthma exacerbations has been changed. 
In our analysis we will use the definitions as proposed by the ATS/ERS task force [51]. By 
incorporating internet-based graphic feedback on a patients’ asthma control status and 
internet-based decision support based on current guidelines, we will enhance the feasi-
bility and standardization of the treatment advice. The results of this study will provide 
insight into the potential discordance between patient’s and medical treatment goals 
and the effect on health care costs from the societal perspective. The internet-based 
decision support methodology and results of our study may facilitate cost-effective 
implementation of future tailored treatment strategies for patients with mild to moder-
ate asthma in primary care.
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Abstract
Objective Established markers of asthma control, i.e. asthma symptoms and lung func-
tion, do not measure underlying bronchial inflammation and their results can contradict 
each other. Measuring fractional exhaled nitric oxide (FeNO) as a marker of eosinophilic 
airway inflammation may have added value for primary care asthma management. The 
aim of this study was to explore the added value of FeNO as an adjunct to symptoms and 
lung function when assessing asthma control in primary care.
Methods Cross-sectional analysis of two primary care adult asthma cohorts. We mea-
sured FeNO levels, lung function, and Asthma Control Questionnaire (ACQ) scores. 
Pearson correlation coefficients were calculated between FeNO, ACQ, FEV1%predicted, 
and reversibility. In a decision tree analysis patients’ asthma control was categorized 
according to the two established control markers, and subsequently with FeNO as an 
additional marker.
Results We included 307 patients (63% females). Correlations between FeNO, symptoms 
and lung function were weak (max. r=0.240). In 25.7% of patients all three markers were 
consistent in their interpretation of asthma control. In 28.1% the two established markers 
were consistent, but FeNO showed a contradictory result. In 46.3% the two established 
markers contradicted each other.
Conclusions We observed weak correlations between FeNO, symptoms and lung func-
tion in adults with asthma in primary care, which confirms that FeNO is an independent 
marker of asthma control. In almost half the study population the results of symptoms 
and lung function contradicted each other; in this group FeNO might fine-tune assess-
ment of asthma control and tailor therapy choices.
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Background
Asthma is a prevalent chronic airways disease that is mainly diagnosed and managed in 
primary care. It is characterised by recurrent respiratory symptoms, airflow obstruction, 
airway hyperresponsiveness and an underlying airways inflammation. Although airways 
inflammation varies in intensity, it remains persistent in asthma, even when symptoms 
are not present. Asthma can place severe limitations on daily life, and may even lead to 
life-threatening exacerbations. In order to reduce these complications, and to improve 
prognosis, it is important to achieve control of asthma, which is one of the main targets 
in asthma management according to different international guidelines [1-4]. On the 
other hand it is also important to avoid overtreatment and concomitant side-effects as 
much as possible. Therefore asthma control should be achieved with the lowest pos-
sible medication dosage and the choice between different types of asthma medication 
should be targeted to individual needs.
The management of asthma control in primary care is mainly guided by the severity 
of clinical symptoms as manifested in experienced limitations and ability to perform 
everyday life activities. It can be measured using short questionnaires like the Asthma 
Control Questionnaire (ACQ) [5]. Symptoms assessment is supplemented by spirometric 
measurement of airway obstruction and its reversibility after administering a broncho-
dilator [1]. However, both symptoms and lung function do not reflect the severity of the 
underlying chronic airway inflammation.
For several reasons, measuring airway inflammation and incorporating it as a marker 
of asthma control in asthmatic patients could be interesting for general practitioners 
(GPs). Firstly, it provides independent information in the assessment of asthma so it can 
be considered a separate domain of asthma control, just like symptoms and lung func-
tion are [6]. Secondly, asthma symptom control can be achieved with pharmacotherapy 
while underlying inflammation may still be present but ‘masked’, which may lead to an 
increased frequency of exacerbations [7,8]. Finally, airway inflammation is the target for 
inhaled corticosteroids (ICS), the cornerstone of pharmacotherapy in asthma.
During the last two decades, fractional exhaled nitric oxide (FeNO) has emerged as a 
more direct marker of eosinophilic airway inflammation [9]. Nitric oxide (NO) is produced 
in the bronchial epithelial cells as part of the inflammatory process [10]. It is measured 
in a simple, non-invasive manner in exhaled air and can therefore easily be applied in 
primary care, especially with the advent of small handheld NO-meters. Several studies 
have been performed to test the usefulness, accuracy and implications of measuring 
FeNO in managing asthma. They found that FeNO could predict asthma exacerbations 
[8] and response to ICS [11], was cost-effective [12] and could aid in optimizing titra-
tion of inhaled steroid treatment [12-14]. Besides, FeNO can predict changes in asthma 
control [15]. Other studies found no additional value when using FeNO [16-19]. These 
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differences in results might depend on cut-off values for FeNO, study populations, and 
how influential FeNO results were in therapy management-decisions. Since most studies 
have been performed in secondary care settings, the added value of FeNO needs to be 
studied in a primary care population, which is more heterogenous and differs in asthma 
severity. Furthermore, there is a need to identify how FeNO could aid in the assessment 
of current asthma control, and which patients could benefit most from a FeNO measure-
ment. Therefore, the aim of this study was to explore the added value of FeNO as an 
adjunct to symptoms and spirometry when assessing asthma control in primary care 
patients.
Methods
Design and study population
The study was a cross-sectional analysis of two available primary care cohorts of adult 
patients with asthma in the Netherlands. Cohort A consisted of patients who were 
referred by their GP for lung function testing in a primary care diagnostic centre in the 
period October 2008 until July 2010. Cohort B consisted of patients who were recruited 
from 128 general practices between June 2009 and July 2010 to participate in a longitu-
dinal multicentre trial (Clinical Trial number: NTR1756)[20]. Table 3.1 shows the inclusion 
and exclusion criteria for both cohorts.
All patients underwent FeNO measurement, followed by spirometry. The ACQ [5] was 
completed during the same session. Several patient characteristics that may influence 
FeNO levels were recorded: gender, age, height, smoking status, allergy status, and up-
per respiratory infection in the previous week. Both studies were approved by our local 
ethics committee and all subjects gave informed consent.
Measurement of asthma control markers
Asthma symptom control
Symptom control was measured using the six-item ACQ [5], a validated questionnaire 
that uses a 7-point scale (0=totally controlled, 6=severely uncontrolled). The ACQ has 
been shown to be an effective instrument to measure asthma control in general practice 
[21]. The six items comprise: nocturnal symptoms; symptoms when waking up; limita-
tions of daily activity; shortness of breath; wheeze; and use of bronchodilator rescue 
medication. Level of asthma symptom control was categorized as controlled (mean ACQ 
score ≤0.75) or uncontrolled (mean ACQ score >0.75) [22].
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Lung function
Spirometry was performed in accordance with international guidelines [23]. Reversibil-
ity was assessed after administration of 400 micrograms of aerosolized salbutamol and 
expressed as the percentage increase in FEV1. A cut-off of ≥12% was used for presence 
of reversibility. Airway obstruction was defined as prebronchodilator FEV1 % predicted 
<80% [1].
Fraction exhaled nitric oxide
FeNO was measured with a portable NIOX MINO® Airway Inflammation Monitor (Aero-
crine AB, Solna, Sweden). Patients exhaled 10 seconds at a flow rate of 50 ml/s, in accor-
dance with international recommendations [24]. FeNO levels were corrected for gender, 
height, smoking, allergy and recent upper respiratory infection by applying appropriate 
factors for adjustment [25]. A FeNO level of ≤25 parts per billion (ppb) was regarded as 
normal, >25 FeNO ≤50 ppb as intermediate, and FeNO >50 ppb as high (26]. In this study 
we defined FeNO >25 ppb as an indicator of uncontrolled asthma.
Analysis
First, correlations between FeNO, ACQ, percentage reversibility, and prebronchodilator 
FEV1 (forced expiratory volume in one second) percentage of predicted were calculated. 
Table 3.1. Inclusion and exclusion criteria for the two asthma cohorts
Cohort A Cohort B
Source Consecutive patients with asthma referred to 
primary care diagnostic centre for lung function 





Selection of patients: GPs diagnosis of asthma 
according to patients history OR at least once 
≥12% reversibility according to available 
database in diagnostic centre
Selection of patients: diagnosis asthma 
according to medical records GP
AND
ICS use at least three months within past year
AND
No exacerbation within one month before entry
AND
No serious comorbidity such as end-stage 
disease or inability to visit GP
16-40 years 18-50 years
Exclusion 
criteria
No successful FeNO-measurement or spirometry No successful FeNO-measurement or spirometry
No available information about height, smoking 
status, allergy status, upper respiratory infection 
preceding week
No available information about height, smoking 




FeNO: fractional exhaled nitric oxide
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Because FeNO values were not normally distributed according to a histogram and Kol-
mogorov-Smirnov test, they were log10-transformed for this part of the analysis. Pearson 
correlation coefficients were calculated with log10-FeNO levels for the two cohorts sepa-
rately. Next, patients were categorized according to their level of asthma control using 
the established markers of asthma control (i.e., symptom control and lung function), 
Table 3.2. Patient characteristics for cohorts A, B, and overall. Numbers are means (SD) unless stated otherwise
Cohort A Cohort B Overall
n (%) 147 (100%) 160 (100%) 307 (100%)
Females, n (%) 77 (52.4%) 115 (71.9%) 192 (62.5%)
Age, years a 29.7 (7.0) 40.7 (9.1) 35.4 (9.8)
Current smokersa, n (%) 44 (29.9%) 21 (13.1%) 65 (21.2%)
Allergic symptoms, n (%) 118 (80.3%) 129 (80.6%) 247 (80.5%)
Asthma medication use, n (%)
None 26 (17.7%) 16 (10.0%) 42 (13.7%)
Bronchodilator only 31 (21.1%) 11 (6.9%) 42 (13.7%)
ICS only 9 (6.1%) 12 (7.5%) 21 (6.8%)
ICS and bronchodilator 81 (55.1%) 121 (75.6%) 202 (65.8%)
Mean ACQ-score b 1.00 (0.33-1.83) 0.67 (0.33-1.33) 0.83 (0.33-1.67)
Controlled (mean ACQ ≤ 0.75) 58(39.5%) 81 (50.6%) 139(45.3%)
Uncontrolled (mean ACQ >0.75) 89 (60.5%) 79 (49.4%) 168 (54.7%)
FEV1 % predicted a 77.7 (13.6) 86.3 (17.9) 82.2 (16.5)
Obstruction (<80%) 85 (57.8%) 42 (26.2%) 127 (41.4%)
Reversibility, % b 6.8 (3.6-14.1) 4.0 (1.4-9.5) 5.43 (2.3-10.9)
Reversibility (≥12%), n (%) 42 (28.6%) 29 (18.1%) 71 (23.1%)
Uncorrected FeNO values, ppb b 12.0 (8.0-22.0) 16.0 (12.0-27.0) 15.0 (9.0-26.0)
Normal level (≤25 ppb), n (%) 111 (75.5%) 81 (50.6%) 192 (62.5%)
Intermediate level (25<FeNO≤50 ppb) 21 (14.3%) 51 (31.9%) 72 (23.5%)
High level (>50 ppb) 15 (10.2%) 28 (17.5%) 43 (14.0%)
Corrected FeNO values, ppb b d 18.9 (10.0-43.0) 25.6 (14.9-48.2) 22.4 (11.9-44.9)
Normal level (≤25 ppb), n (%) 87 (59.2%) 76 (47.5%) 163 (53.1%)
Intermediate level (25<FeNO≤50 ppb) 31 (21.1%) 49 (30.6%) 80 (26.1%)
High level (>50 ppb) 29 (19.7%) 35 (21.9%) 64 (20.8%)
a Parametric data: mean and standard deviation (SD)
b Non-parametric data: median and interquartile range (IQR)
c Ex-smokers were regarded as non-smokers if they had stopped at least four weeks before the date of the 
measurements
d For smokers FeNO levels were corrected by multiplying by 0.627, for males by 1.174, for allergic symptoms 
by 1.496, for upper respiratory infection by 1.235 and for height by 1.113(height in cm−170)/10
FEV1: forced expiratory volume in one second
ACQ: asthma control questionnaire
ppb: parts per billion
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with FeNO added as a third marker. This resulted in eight categories (see Figure 3.2). In 
the analysis of the flow diagram, the two cohorts were combined. Sensitivity analyses 
were performed using uncorrected instead of corrected FeNO values and using less strict 
cut-off values for uncontrolled symptom score (mean ACQ >1.50) and for uncontrolled 
FeNO level (FeNO>50ppb). The Statistical Package for the Social Sciences (SPSS) version 
16.0 was used for the statistical analyses. P-values <0.05 indicated statistical significance.
Results
Patient characteristics
147 patients in cohort A and 160 in cohort B could be analysed (Figure 3.1). Table 3.2 





























n = 9  
 
n = 8 
Figure 3.1. Flow diagram of the study population
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butions for the two cohorts. In both cohorts the majority of patients were treated with 
ICS (61.2% in cohort A and 83.1% in cohort B, respectively).
Correlations between markers of asthma control
Table 3.3 shows that correlations between log10-FeNO values and ACQ scores, FEV1 val-
ues, and reversibility were weak (maximum of r=0.24 for correlation between log10-FeNO 
and % reversibility in cohort B; p=0.002). The two spirometric markers of asthma control 
(i.e., % FEV1 predicted and % reversibility) showed moderate correlation (r= −0.63 and 
−0.50 in the respective cohorts; p<0.001).
Classification of asthma control levels
Figure 3.2 depicts the distribution of patients according to the two established markers 
of asthma control (i.e., ACQ and lung function), with FeNO as an additional marker. In 
total 144 (46.9%) patients were considered to be uncontrolled in terms of airway inflam-
mation. In 25.7% of patients (13.0% in category 1 and 12.7% in category 8) all three con-
trol markers were consistent in their interpretation of asthma control. Furthermore, in 
28.1% of patients, the two established markers were consistent in their interpretation of 
asthma control, but FeNO was contradicting (13.4% in category 2 and 14.7% in category 
7). In category 3 until 6 of figure 3.2 the results of the two established markers showed 
disagreement: asthma was controlled according to one marker and uncontrolled ac-
cording to the other. This comprised 46.3% of the total study population (142/307).
Sensitivity analyses
Using uncorrected FeNO values, only 25.7% of patients had uncontrolled FeNO levels. 
More patients ended up in categories 1 and 5, less in categories 2 and 6 (see footnote 
Table 3.3. Pearson correlation coefficients for the established markers of asthma control and FeNO for both 
cohorts





































As the correlation coefficient is a standardized ratio, its interpretation is independent whether variables are 
log-transformed or not.
*= correlation is statistically significant at the 0.05 level (2-tailed)
**= log10-FeNO level corrected for gender, height, smoking, allergy and upper respiratory infection
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d in figure 3.2). Adopting 50 ppb as the cut-off for uncontrolled FeNO led to only 20.9% 
of patients being considered uncontrolled. More patients ended up in categories 1, 3, 5, 
and 7, and less in categories 2, 4, 6, and 8 (see footnote e). Use of a less strict ACQ score 
cut-off (1.50 instead of 0.75) led to more patients ending up in categories 1, 2, and 3 but 
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Marked boxes indicate patients with conflicting asthma control according the two GINA markers. 
 
a Being controlled= mean ACQ ≤0.75; being uncontrolled= mean ACQ >0.75 
 
b Being controlled= no obstruction or reversibility; being uncontrolled= obstruction and/or 
reversibility. Obstruction= FEV1 <80% predicted; 
Reversibility = (FEV1-postbronchodilator minus FEV1-prebronchodilator)/ FEV1-prebronchodilator ≥12% 
 
c Being controlled= FeNO ≤25; being uncontrolled= FeNO >25 (corrected FeNO) 
d Sensitivity analyses: uncorrected FeNO levels lead to the following % in the 8 categories: 19.5%; 6.8%; 
 
13.0%; 5.9%; 23.1%; 4.2%; 18.6%; 8.8%, respectively 
 
e Sensitivity analyses: being controlled= FeNO ≤50; being uncontrolled= FeNO >50 (corrected FeNO) lead to 
 
the following % in the 8 categories: 21.2%; 5.2%; 14.3%; 4.6%; 24.1%; 3.3%; 19.5%; 7.8% 
 
f Sensitivity analyses: being controlled= mean ACQ <1.50; being uncontrolled= mean ACQ ≥1.50 lead to the 
 









Figure 3.2. Flow diagram for classification of asthma control based on the established markers, with FeNO 
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percentages of patients ending up in the separate categories, in all sensitivity analyses 
the overall percentages of patients with either three consistent markers of control, two 
consistent established markers but contradicting FeNO, or two contradicting established 
markers remained more or less the same.
Discussion
Main findings
We aimed to explore the added value of FeNO as an adjunct to symptoms and spirometry 
when assessing asthma control in primary care. We observed only weak cross-sectional 
relationships between symptoms, lung function (the two established markers of asthma 
control) and FeNO. This lack of correlation confirmed that FeNO can be considered to 
be an independent marker of asthma control in primary care patients. The analysis 
of the flow chart in figure 3.2 revealed that in 46.3% of the adult asthma patients in 
primary care, symptoms and lung function yielded contradicting results regarding the 
interpretation of asthma control. FeNO might serve as a third decisive marker of asthma 
control in those instances, since it is an independent marker measuring airways inflam-
mation, which is the central process to airway obstruction and hyperresponsiveness and 
the target for inhaled corticosteroid therapy. In 28.1% of patients the two established 
markers were consistent in their interpretation, but FeNO was contradictory.
Strengths and limitations of this study
This is the first study executed in a large heterogenous primary care sample where 
the added value of FeNO when assessing asthma control was examined for individual 
patients. By combining two primary care cohorts of patients, data from a larger study 
population could be analysed. As the cohorts consist of heterogeneous populations, 
including smokers, patients with recent upper respiratory infections, ICS use and 
allergies, this greatly enhances generalizability of the results. Cohort A consisted of a 
more heterogeneous group of asthma patients, including milder asthmatics and some 
patients who had been referred for spirometry by their GP because of worsening of their 
symptoms. This might explain the lower ICS use and the lower lung function values in 
this cohort. In cohort B the ACQ was completed not solely by the patient him- or herself, 
but together with a practice nurse [27]. Despite the differences between both cohorts, 
we combined them in our analysis, to assess the additional value of measuring FeNO 
when assessing asthma control in all types of asthma and in different circumstances. 
Final limitations are our cross-sectional design (i.e., we could not study the utility of 
FeNO when monitoring asthma), and the fact that our data did not contain detailed 
information about the dose of asthma medication for all patients, which would have 
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enabled us to look at possible modifications of pharmacotherapy in the patients in the 
respective asthma control categories when FeNO is added to their assessment.
It is not easy to define an ‘uncontrolled’ or increased FeNO in a particular patient. 
Although some prefer using a ‘personal best’ value [28], using fixed cut-off points is 
more widely accepted. Several studies have been performed in the general population 
[29,30] as well as in specialist care settings [31], to generate normal values. Based on 
these studies, we chose to use the 25 ppb cut-off. We are aware of the problem that, 
as shown in our sensitivity analysis, we might overestimate the percentage of patients 
being uncontrolled compared to using the less strict 50 ppb cut-off, which is also men-
tioned as a justified cut-off in the literature [26]. To date it is unclear what the longitu-
dinal consequences of normalizing FeNO are; therefore it is difficult to predict whether 
it is most important to demonstrate controlled disease by using a lower cut-off (and to 
avoid under treatment), or to prove uncontrolled disease by using a higher cut-off (and 
to avoid over treatment). However, even when using the less strict 50 ppb cut-off, the 
proportion of patients where FeNO provided additional information remained similar.
A final limitation of using FeNO in primary care are the high costs when purchasing a 
device, which currently has a refractory life of three years only, and the need of acquiring 
a new costly sensor every twelve months. However, Honkoop et al have shown that due 
to decreased medication usage and costs, adding FeNO is a cost-effective strategy [12].
Interpretation of findings in relation to previously published work
Most studies on FeNO have analysed whether FeNO could be used as a replacement for 
conventional asthma control markers. Only few studies have been performed about the 
relation between FeNO and other asthma control markers, and their results are inconsis-
tent. Some studies indicate that increased FeNO levels are associated with uncontrolled 
asthma [32] or are significantly related to changes in ACQ scores over time [33]. On the 
other hand, one study showed that FeNO was not associated with ACQ scores [34]. In 
the primary care setting, one study found a modest correlation between FeNO and a 
non-validated symptom score (r=0.4, p<0.05) [35] which disappeared when treatment 
with ICS was taken into account. In this same study the correlation between FeNO and 
FEV1 was weak (r=0.2, p=0.03). Another study found very weak correlations between 
FeNO, the ACQ and lung function, cross-sectional as well as longitudinal [36]. Finally, 
Hewitt et al showed that by adding FeNO to conventional markers they were able to 
lower ICS usage [18].
Our finding of only weak cross-sectional associations confirms that FeNO might serve 
as an independent, distinctive marker when assessing asthma control [37]. This weak 
cross-sectional association on its own is naturally no conclusive proof of added value. 
However, combined with results from previous longitudinal studies where the additional 
use of FeNO resulted in lower ICS usage [12,14,18], this points towards its added value 
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in the assessment of asthma control. In other words, FeNO does indeed seem to reflect 
another domain of asthma control than the current markers do: underlying inflamma-
tion rather than symptoms or (reversible) airway obstruction.
Implications for future research, policy and practice
Since asthma has a multi-dimensional nature, FeNO could provide GPs with additional 
information, especially in those patients where symptoms and lung function provide 
conflicting results. GPs might in the future define asthma control not only by symptoms 
and spirometry, but also by level of inflammation.
As presented in the flow chart analysis in figure 3.2, in a substantial percentage of 
patients (46.3%) the GP will be confronted with patients whose asthma is controlled 
according to one of the established markers (e.g. symptoms) but uncontrolled accord-
ing to the other (lung function), or vice versa. Although currently clinical symptoms are 
considered to be more important than lung function when assessing asthma control 
[1], it may still confuse the GP when these two markers contradict each other. In these 
patients, adding FeNO as a third marker could be decisive when judging the patient’s 
asthma control. In another 28.1% it is FeNO that gives contradicting results compared to 
the two established markers. As to date it is unclear which of the three markers should 
be the dominant one and future research should focus on establishing an order. The 
ultimate goal of improving the assessment of a patient’s asthma control level by adding 
FeNO are the therapeutic consequences. With this additional measurement, decisions 
regarding treatment could be guided on the actual pathophysiology. For instance, in 
circumstances where both symptoms and lung function show uncontrolled asthma 
and FeNO is controlled, patients should be prescribed LABAs, whereas ICS would be 
preferred if FeNO is uncontrolled. On the other hand, when symptoms are controlled, a 
GP might be more reluctant to prescribe high-dosed ICS when there is no sign of active 
bronchial inflammation. In case of uncontrolled FeNO and after checking compliance 
and inhaler technique, ICS could be started or increased as the risk of exacerbation 
should be considered [8]. Follow up of the patient remains necessary though, as not all 
elevated FeNO levels seem to respond to ICS [38]. Also, if symptoms and lung function 
are uncontrolled, it could be harmful for the patient to stop or reduce (ICS-) treatment 
in response to normal FeNO levels, as there are phenotypes of asthma that never have 
an increased FeNO level.
If FeNO is to be used as a new marker of asthma control in primary care, some im-
portant barriers remain. One important issue is whether FeNO testing is ‘robust’ enough 
to be applicable for all patients and in all circumstances. Levels of FeNO appear to be 
gender, age, and height dependent [25,29], which hampers interpretation of FeNO 
results in individual patients. Furthermore, raised FeNO levels are not exclusively due to 
asthma, but are also seen in atopic subjects [29], in patients with an upper respiratory 
 55
infection [39], after bronchodilation [40] and after a nitrate rich meal [41]. Conversely, 
levels are reduced by smoking [42], ICS use [43], and spirometry manoeuvres [40]. 
More recent studies concluded therefore that FeNO should be corrected for its main 
influencing factors, gender, height, smoking, allergy and recent upper respiratory infec-
tion [25,29,30]. Therefore, we chose to correct FeNO using the established adjustments 
for these influencing factors [25]. In our sensitivity analysis, however, we showed that 
results of categorizing patients differed only slightly if FeNO values are not corrected.
Conclusions
In conclusion, our cross-sectional study of adult patients with asthma in primary care 
demonstrated that FeNO correlates weakly with respiratory symptoms and lung func-
tion, which confirms that it might serve as an independent marker for assessing asthma 
control. If, in the future, FeNO would be incorporated as a marker of asthma control in 
primary care, it will enable ‘fine-tuning’ when categorizing asthma control in almost half 
of the patients. Although for the time being measuring FeNO is rather impractical and 
provides additional work, it is likely that these obstacles will resolve over time, especially 
since FeNO has been shown to be cost-effective. Prospective research on the impact of 
the additional use of FeNO in the subgroup of patients with conflicting symptom and 
lung function results on long-term results such as asthma control and exacerbation rate 
is needed, to be able to tailor asthma management in primary care.
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Abstract
Background Aiming at partly controlled asthma (PCa) instead of controlled asthma 
(Ca) might decrease asthma medication use. Biomarkers, such as the fraction of exhaled 
nitric oxide (FeNO), allow further tailoring of treatment.
Objective We sought to assess the cost-effectiveness and clinical effectiveness of pursu-
ing PCa, Ca, or FeNO-driven controlled asthma (FCa).
Methods In a nonblind, pragmatic, cluster-randomised trial in primary care, adults (18-
50 years of age) with a doctor’s diagnosis of asthma who were prescribed inhaled cor-
ticosteroids were allocated to one of 3 treatment strategies: (1) aiming at PCa (Asthma 
Control Questionnaire [ACQ] score <1.50); (2) aiming at Ca (ACQ score <0.75); and (3) 
aiming at FCa (ACQ score <0.75 and FeNO value <25 ppb). During 12 months’ follow-up, 
treatment was adjusted every 3 months by using an online decision support tool. Out-
comes were incremental cost per quality-adjusted life year gained, asthma control (ACQ 
score), quality of life (Asthma Quality of Life Questionnaire score), asthma medication 
use, and severe exacerbation rate.
Results Six hundred eleven participants were allocated to the PCa (n  = 219), Ca (n  = 
203), or FCa (n = 189) strategies. The FCa strategy improved asthma control compared 
with the PCa strategy (P  < .02). There were no differences in quality of life (P  ≥ .36). 
Asthma medication use was significantly lower for the PCa and FCa strategies compared 
with the Ca strategy (medication costs: PCa, $452; Ca, $551; and FCa, $456; P ≤ .04). The 
FCa strategy had the highest probability of cost-effectiveness at a willingness to pay of 
$50,000/quality-adjusted life year (86%; PCa, 2%; Ca, 12%). There were no differences in 
severe exacerbation rate.
Conclusion A symptom- plus FeNO-driven strategy reduces asthma medication use 
while sustaining asthma control and quality of life and is the preferred strategy for adult 
asthmatic patients in primary care.
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Introduction
Globally, an estimated 300 million persons have asthma [1], representing a consider-
able and increasing burden to patients, health care, and society at large. Asthma has a 
significant effect not only on an individual patient’s health-related quality of life but also 
on society and the economy through work absence, premature retirement, and high 
costs for asthma treatment [2-6]. Cost-effective treatment strategies are required to face 
the burden of asthma.
According to guidelines, the aim of asthma treatment is to achieve and maintain 
control of clinical manifestations for prolonged periods of time. Patient safety, including 
prevention of exacerbations and side effects of medication, and keeping in check the 
cost of treatment are also important goals [7-11]. The severity of clinical manifestations 
of asthma is classified into controlled asthma (Ca), partly controlled asthma (PCa), and 
uncontrolled asthma categories to direct treatment decisions [8]. In practice, symptoms 
in up to 75% of patients are controlled suboptimally (partly controlled or uncontrolled) 
[12-14]. In these patients a step up of asthma medication is advocated to achieve 
controlled asthma. Because the dose-response relationship flattens at higher levels of 
inhaled corticosteroids (ICSs) and the risk of side effects increases [15,16], the benefits of 
stepping up treatment to achieve Ca might be limited.
Recent studies have shown that biomarkers, including fractional exhaled nitric oxide 
(FeNO), help to distinguish between patients who benefit more from adding a long-
acting β-agonist (LABA) and those requiring a change in ICS dosage by providing ad-
ditional information regarding the level of bronchial inflammation [17-20]. However, in 
primary care the current recommendation is to guide treatment decisions based solely 
on controlling the clinical features of disease because assessments of biomarkers are un-
available, likely to increase health care costs because of expensive equipment, or both 
[8]. Recently, easy-to-use and cheaper handheld FeNO devices have been introduced 
[21]. To date, it is unknown whether in primary care the pursuit of improving asthma 
control through assessment of airway inflammation by using FeNO measurements is 
helpful to achieve and benefit from controlled asthma with regard to the patient’s qual-
ity of life, exacerbation rates, and cost of treatment.
To that end, we performed a 3-armed cluster-randomised trial comparing 3 strategies 
aiming at either PCa, Ca, or FeNO-driven controlled asthma (FCa).
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Methods
This was an entirely investigator-designed and investigator-driven study. A  detailed 
description of study procedures, sample size calculation, and measurements has been 
published elsewhere [22].
Setting and participants
General practices from both rural and urban areas in The Netherlands were invited to 
participate. Inclusion criteria were age of 18 to 50 years, doctor-diagnosed asthma ac-
cording to the Dutch national guidelines [10], a prescription for ICS for at least 3 months 
in the previous year, and asthma being managed in primary care. Exclusion criteria were 
significant comorbidity (at the general practitioner (GP)’s discretion), inability to under-
stand Dutch, and a prescription for oral corticosteroids in the previous month. The trial 
was approved by the Medical Ethics Committee of Leiden University Medical Center. All 
included patients provided written informed consent. The trial was registered at www.
trialregister.nl (NTR 1756).
Design overview
This was a nonblind, 3-arm, pragmatic, cluster-randomised trial with 12 months’ follow-
up of adult asthmatic patients in primary care. Cluster randomization was performed 
at the general practice level instead of the patient level to prevent intervention con-
tamination within practices. No specific eligibility criteria applied to clusters. At local 
information meetings, study procedures were explained to participants, and afterward, 
informed consent was obtained. When the list of participants for each practice had 
been completed, the general practices were randomly allocated to one of 3 treatment 
strategies by an independent researcher using a computer-generated permuted block 
scheme for groups of 3 general practices stratified according to region (Amsterdam, 
Leiden, and Nijmegen), urbanization grade (rural vs urban), and the practice nurse (PN)’s 
level of experience with asthma management (≥1 year vs <1 year). Allocation conceal-
ment applied to both the cluster and participant levels (Figure 4.1).
Interventions
The 3 treatment strategies targeting different levels of asthma control were defined as 
follows: (1) aiming at partly controlled asthma (PCa strategy), (2) aiming at controlled 
asthma (Ca strategy), and (3) aiming at FeNO-driven controlled asthma (FCa strategy). In 
all 3 strategies patients visited the PN of their general practice every 3 months over the 
course of 1 year. During these visits, the PN assessed current medication use and asthma 
control status by using the 7-item Asthma Control Questionnaire (ACQ) that includes 
lung function [23]. In addition, a FeNO measurement was performed in the FCa strategy. 
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FeNO values were expressed as the concentration in parts per billion and automatically 
adjusted for smoking, when applicable [24]. At each visit, a patient’s asthma control 
status was classified based on the ACQ score as controlled (ACQ score  ≤ 0.75), partly 
controlled (0.75 < ACQ score ≤ 1.5), or uncontrolled (ACQ score > 1.5) and additionally 
in the FCa strategy as 3 subcategories of FeNO: low/absence of airway inflammation for 
values at 25 ppb or less, intermediate at 26 to 50 ppb, and high/presence of airway in-
flammation at greater than 50 ppb [19]. Treatment decisions were based on a dedicated 
algorithm for each strategy (Table 4.1). To increase the feasibility of implementing our 
strategies, we designed an online decision support tool. Current medication use and all 
measurements were entered into this decision support tool, which subsequently auto-
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Figure 4.1. Consort Flow diagram ACCURATE trial.
647 patients provided informed consent, of which 31 withdrew before the first visit to the general practice 
and before filling out online questionnaires. Since randomisation was performed at group level they were 
randomized, but they were unaware of their strategy before withdrawal. 5 participants visited their general 
practice once, but no analysable data was available since they never filled out online questionnaires.
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matically generated treatment advice based on the appropriate algorithm for each of 
the 3 treatment strategies (Table 4.1). Patients’ current medication use was classified as 
an asthma treatment step ranging from 0 (only short-acting β-agonists) to 5 (oral pred-
nisone) based on the US National Asthma Education and Prevention Program guideline 
[7]. When treatment was to be adjusted, in the PCa and Ca strategies professionals 
and patients could choose any (combination of ) type or types of asthma medication 
they preferred within a certain treatment step (for all possibilities, see Table 4.E1 in this 
article’s supplement), whereas the FCa strategy offered more guidance toward adding/
removing LABAs or ICSs (Table 4.1).
Table 4.1. Treatment advice for the three strategies at possible levels of asthma control







PCa step-down open † no change step-up: treatment choice open∫
Ca – 3 mo: no change
– > 3 mo: step-down
step-up: treatment choice 
open †





step-down open † –  3 mo: no change/ change 
within current step to LABA
–  > 3 mo: step-down ICS §
–  3mo: step-up: LABA




no change step-up: treatment choice 
open †





current step to ICS ‡
step-up: 1 × ICS step-up: 2 x ICS ¶
*  Adjusted for smoking
†  When the treatment advice was open, Nurse Practitioners (General Practitioners) could choose which 
types of medication were increased/decreased or added/removed. With the exception of solely treating 
with LABA, which was not allowed, according to the guidelines [1-4].
‡  If the participant did not use ICS, or used ICS in combination with LABA, the advice was to change treat-
ment by starting ICS or to replace LABA by a higher dose of ICS. This effectively kept patients in the same 
treatment step [1]. Otherwise the advice was to step up treatment by increasing ICS dosage.
§  If the participant did not use LABA and used a medium to high dose of ICS, the advice was to reduce 
ICS dosage and add LABA, which effectively kept patients in the same treatment step [1]. Otherwise the 
advice was to remain on current treatment. If FeNO results of patients remained low at different visits to 
the Nurse Practitioner, the advice was to step down ICS-usage if possible (solely LABA was not allowed).
║  Patients were advised to add LABA to their current treatment. If they already used LABA, the advice was 
to step-up treatment open. If patients remained uncontrolled with a normal FeNO we advised to review 
the asthma diagnosis and assess concomitant diseases such as gastro-oesophageal reflux or depression.
¶  Increase ICS usage from low to high. If this was not possible increase ICS usage and add LABA/montelu-
kast.
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All unplanned doctor’s office visits for increased symptoms of asthma were treated 
at the GP’s discretion, irrespective of the participant’s experimental assignment. When 
symptoms had normalized, patients additionally visited the PN’s office, where asthma 
control was reassessed and therapy was adjusted by using the assigned treatment 
strategy.
Outcomes and follow-up
The primary outcome was the societal costs per quality-adjusted life year (QALY) gained. 
Patients filled out online questionnaires at home every 3 months to assess QALYs and 
costs from a societal perspective. QALYs were obtained by calculating the area under the 
health state utility curve based on the Dutch tariff of the EuroQol classification system 
(EQ-5D) [25]. Total costs were obtained by adding the costs of 3 relevant categories: all 
health care costs, productivity loss, and intervention costs, including additional costs for 
the measurement of FeNO [26]. Costs in Euros were converted to dollars by using the 
purchasing parity index [27].
Secondary outcomes were asthma control, asthma-related quality of life (Asthma 
Quality of Life Questionnaire [28]), number of days with (asthma-related) limitations of 
activity, medication adherence (Medication Adherence Report Scale (MARS) [29]), severe 
exacerbation rate, lung function, FeNO value, and total medication use.
Severe exacerbations were defined as hospitalizations or emergency care visits be-
cause of asthma, or systemic use of oral corticosteroids for 3 or more consecutive days 
[11]. Unplanned doctor’s office visits for increased asthma symptoms were recorded, as 
were experienced symptoms and received treatment, allowing severe exacerbations to 
be distinguished from moderate exacerbations and periods of loss of control.
Total medication use was assessed by obtaining all medication prescriptions from 
local pharmacy records and from the Dutch Foundation for  Pharmaceutical Statistics 
[30]. All ICS prescriptions were expressed as beclomethasone equivalent values based 
on recommendations by the Dutch pharmaceutical guidelines [31] and a panel of respi-
ratory experts to allow comparisons between strategies.
Statistical analysis
Patients were analysed according to the intention-to-treat methodology. Statistical un-
certainty of the cost-effectiveness ratio was analysed by using the net benefit approach 
[32]. The net benefit is defined as follows:
λ×ΔQALY−Δ costs,
where λ is the willingness to pay for a gain of 1 QALY. This way, the observed QALY differ-
ence is reformulated into a monetary difference. The probability of cost-effectiveness at 
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different λ levels was assessed in an acceptability curve. All outcomes pertained to the 
individual participant’s level and were adjusted for clustering within general practices. 
Outcomes from the clinical perspective were analysed with the Stata 11.0 xtmixed com-
mand for multilevel linear regression, adjusting for clusters at the practice level, repeated 
measurements within patients, and baseline values (StataCorp, College Station, Tex). For 
a detailed description of statistical procedures, see the Methods section in this article’s 
Supplement.
Results
Recruitment and baseline characteristics
Figure 4.1 provides the flowchart of the study. Between September 2009 and January 
2012, 611 asthmatic patients participated, of whom 219 (in 44 clusters) were allocated 
to the PCa strategy, 203 (43 clusters) to the Ca strategy, and 189 (44 clusters) to the FCa 
strategy. All initially started general practices (clusters) completed the study.
Participants’ baseline characteristics were similar for the 3 strategies (Table 4.2). Table 
4.E2 in this article’s Supplement shows a comparison between participants and those 
who declined participation. Participants were slightly older, and their asthma was less 
controlled.
Process outcomes
Asthma control during the study, as measured by using the ACQ, was significantly better 
in the FCa strategy than in the PCa strategy (ΔACQ score, −0.12; 95% CI, −0.23 to −0.02; 
P = .02; see Table 4.E3 in this article’s Supplement). No significant differences were found 
between the PCa and Ca strategies or between the FCa and Ca strategies (P ≥ .15; see Fig 
E1, A, in this article’s Supplement). The percentage of participants who achieved Ca at 
12 months’ follow-up was 55% for the PCa strategy, 68% for the Ca strategy, and 61% for 
the FCa strategy (1-way ANOVA for different outcomes at 12 months: PCa vs Ca, P = .01; 
PCa vs FCa: P = .28; and FCa vs Ca: P = .75).
During the study, 41 (6.7%) patients withdrew, and 6 (1.0%) were lost to follow-up 
(Figure 4.1). One participant in the Ca strategy died during the study because of a non–
study-related cause. Rates of withdrawal and loss to follow-up were similar between the 
strategies.
The study treatment algorithm was effective in leading to markedly different treat-
ment advice for the 3 strategies (P < .001, Pearson χ2 test; see Table 4.E4 in this article’s 
Supplement). Overall, participants did not adhere to the treatment algorithm 30% of 
the time: 66% of the advice given was to decrease treatment, 32% was to increase treat-
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ment, and 2% was to remain on current treatment (see the Results section in this article’s 
Supplement for more detail).
Primary outcome
There were no significant differences in QALYs between the strategies (P ≥ .36, Table 4.3). 
Costs per patient for asthma medication were significantly less in the strategies aimed 
at PCa and FCa compared with Ca (PCa, $452; Ca, $551; and FCa, $456). Costs for asthma-
related contacts with health care professionals, costs because of loss of productivity, 
and annual societal costs showed no significant differences (Table 4.3). The FCa strategy 
showed the highest probability of cost-effectiveness over a wide range of willingness-
to-pay values ($0-$125,000/QALY). Specifically, at a willingness-to-pay threshold of 
$50,000/QALY [31], the FCa strategy was 86% likely to be the most cost-effective (PCa 
strategy, 2%; Ca strategy, 12%; Figure 4.2).
Secondary outcomes
There were no differences in asthma-related quality of life between the strategies 
(Asthma Quality of Life Questionnaire differences, P  ≥ .60; see Fig E1, B). Neither the 
number of days with asthma-related limitations of activity per year nor the adherence 
to medication (MARS) showed significant differences between the strategies (see Table 
Table 4.2. Baseline characteristics
Partly Controlled Controlled FeNO
Patients (n) 219 203 189
Clusters 44 43 44
Sex % F 68.4 65.8 72.3
Mean age (SD) 38.9 (9.3) 39.9 (9.8) 39.5 (9.3)
Asthma duration in years (SD) 18 (13) 16 (12) 20 (14)
BMI (SD) 26.8 (5.9) 26.0 (4.9) 26.1 (5.1)
Allergy (defined as total IgE >100) in % 56 52 55
FEV1 (SD) in % predicted 92.4 (17.2) 93.0 (17.0) 93.1 (17.0)
Baseline FeNO in ppb (SD) 27.3 (30.4) 24.7 (29.8) 24.5 (21.7)
Beclomethason equivalent dose in mcg (SD) 831 (701) 825 (639) 853 (642)
Long Acting Beta Agonist (LABA) use (% yes) 49 52 47
Mean baseline ACQ (SD) 1.08 (0.84) 0.93 (0.80) 0.99 (0.73)
Current Smokers (% yes) 13 16 14
Previous Smokers (% yes of current non-smokers) 32 35 31
SD = standard deviation
%F = percentage female
BMI = Body Mass Index
IgE = immunoglobulin E
FEV1 = Forced Expiratory Volume in one second
Ppb = parts per billion
Mcg= microgram
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4.E5 in this article’s Supplement). An additional analysis on the adherence to treat-
ment advice after the visit to the PN also showed no significant differences between 
the strategies (see the Results section in this article’s Supplement). The total number of 
severe asthma exacerbations was 63 for the PCa strategy (0.29 exacerbations/patient/y), 
58 for the Ca strategy (0.29/patient/y), and 37 for the FCa strategy (0.19/patient/y), and 
the odds ratios for experiencing 1 or more severe exacerbations between the strategies 
showed no significant differences (see Table 4.E6 in this article’s Supplement).
In accordance with the significant differences in asthma medication costs between 
the PCa and Ca strategies and between the FCa and Ca strategies, asthma medication 
prescriptions at 12 months were highest in the Ca strategy for ICSs, LABAs, and monte-
lukast (Table 4.3 and see Figure 4.E2, A, in this article’s Supplement).
Discussion
In this pragmatic cluster-randomised trial in patients with mild to moderately severe 
asthma in primary care, we found that a treatment approach aiming at PCa instead of 
Ca significantly decreases asthma medication use and associated costs, whereas asthma 
control, quality of life, and severe exacerbation rates remain similar. However, a strategy 
aiming at Ca that is additionally driven by a FeNO measurement seems to be the pre-
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Figure 4.2. Cost-effectiveness acceptability curve.
This figure shows the probability that a strategy is the most cost-effective compared to the other two strate-
gies at different willingness-to-pay per QALY levels from a societal perspective, which includes all health-
care costs and costs due to loss of productivity.
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the highest probability of cost-effectiveness, and improves asthma control compared 
with the PCa strategy.
To our knowledge, this is the first study in which asthma treatment strategies pursu-
ing different levels of control are compared from a comprehensive health economic, 
patient, and clinical perspective. With respect to patient utilities based on the EQ-5D, 
there was no additional gain in the Ca and FCa strategies compared with the PCa strat-
egy, which is in line with a previous study comparing utility scores between the Ca and 
PCa strategies [33]. Interestingly, total societal costs were lowest for the FCa strategy, 
including lower costs for asthma medications. As a result, the FCa strategy had a greater 
than 86% chance of being the most cost-effective strategy for a willingness to pay up to 
the commonly cited threshold of $50,000 per QALY [32].
An important clinical finding is that by using FeNO as a biomarker, medication could 
be better tailored to an individual patient’s needs. Therefore compared with aiming for 
Ca as such, the FCa strategy decreased the cumulative daily dose of ICS and the daily 
use of LABAs and montelukast. In addition, although not statistically significant, we 
observed the lowest severe exacerbation rate and the lowest use of prednisone in the 
FCa strategy (see Fig E2). Therefore our results are in line with studies in secondary care 
showing that tailoring treatment based on FeNO values reduced corticosteroid expo-
sure, exacerbation rates (in pregnant women), and possibly long-term corticosteroid-
related side effects [15,20,34].
In previous studies the use of FeNO as an adjunct to primary care management has led 
to an increased proportion of patients with controlled asthma [35], a similar reduction in 
ICS dosage as in our study [18], or no differences [36]. In contrast to our results in studies 
by Szefler et al [17], De Jongste et al [37], and Shaw et al [38] and in a meta-analysis by 
Petsky et al [39], the addition of FeNO measurement did not reduce or even increase ICS 
use. These differences might be attributed to the choice of FeNO cutoff points for dose 
increase because cutoff points are critical in asthma treatment algorithm studies [40]. In 
our study a relatively high cutoff point (50 ppb vs 20 ppb (Szefler et al [17]), 25 ppb (De 
Jongste et al [37]), and 26 ppb (Shaw et al [38]) was used, leading to fewer step ups of 
treatment in response to FeNO measurements. In addition, low FeNO values in our study 
led to advice to step down treatment, even when symptoms were present.
In terms of a patient’s perspective and for clinical outcomes, the present study 
showed no additional benefit for pursuing Ca compared with accepting PCa as a suf-
ficient treatment goal, whereas it did increase asthma medication use and associated 
costs. In our study approximately 60% of all patients achieved Ca compared with 65% 
to 71% in the Gaining Optimal Asthma Control (GOAL) trial, whereas exacerbation rates 
and asthma-related quality of life are similar between the studies [41]. In the GOAL trial 
57% to 88% of patients required the highest ICS dose (ie, 2000 μg of beclomethasone 
equivalent), and in half of their study, the population received LABA supplementation. 
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Furthermore, 5% to 11% of patients required daily oral corticosteroid therapy of 0.5 mg/
kg for 4 weeks [41]. Therefore even though aiming for Ca might be successful in the 
majority of patients, as was shown in the GOAL trial, the comparison with our results 
shows that it is accompanied by much higher daily medication use, offers no additional 
benefits compared with accepting PCa as a sufficient goal, and is also not beneficial from 
a societal perspective because of increased costs.
In our study the Ca strategy had the lowest percentage of uncontrolled patients but 
was still the most expensive strategy. Interestingly, Accordini et al [42] showed that un-
controlled asthma is approximately 4 times ‘more expensive’ and Gold et al [13] showed 
that PCa might be associated with increased use of health care resources. However, both 
studies were based on cross-sectional analyses. Therefore increased use of health care 
resources by patients with PCa either did not occur longitudinally in our study or was 
compensated by the increased costs for medication and health care use in the Ca strategy.
The results of this study do not seem to be negatively influenced by study design 
or selection bias. Randomization was performed after inclusion of patients, thereby 
preventing selection bias. This study had a pragmatic approach with regard to in and 
exclusion criteria and included a wide spectrum of patients in the full range of asthma 
control from both rural and urban areas, including smokers. The absence of differences 
for most of the outcomes on effectiveness does not seem to be explained by missing 
data. We observed that 14.8% of data were missing overall. However, the frequency of 
missing values was not associated with a particular intervention arm, and sensitivity 
analyses with different methods of imputation all showed similar results (see this ar-
ticle’s Supplement).
The power calculation for this study was based on the cost-utility measurements, and 
our study was underpowered for some secondary outcomes, including severe exacerba-
tions. Because the severe exacerbation rate was lowest in the FCa strategy (see Table 
4.E6), we do not expect that another preferred strategy would be found when the study 
was adequately powered for exacerbations.
A potential limitation of our study is that the GP’s diagnosis of asthma was not reas-
sessed. However, Lucas et  al [43] showed that asthma was correctly classified in 73% 
of primary care patients of all ages in The Netherlands. Furthermore, in real life, these 
patients are being treated for asthma, and this will affect the clinical usefulness of any 
treatment strategy. A  difference in adherence to treatment might also exist between 
the strategies, especially in the FCa strategy, because an additional measurement can 
provide more insight and subsequent adherence. However, the MARS questionnaire re-
garding adherence and 2 additional analyses (see this article’s Supplement) showed no 
significant differences between the strategies. Therefore we expect that results cannot 
be ascribed to differences in adherence.
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Another limitation is that the magnitude of the differences in effectiveness was small 
and of limited clinical relevance. For instance, the effect sizes for asthma-related quality 
of life within the strategies were very similar, and differences between the strategies 
were well below the clinically important range of 0.5 points [44]. Moreover, the 95% 
confidence limits were generally incompatible with the existence of clinically important 
differences.
In this study all patients were treated similarly, irrespective of the baseline phenotypic 
characteristics of their asthma. Recent studies have shown that distinct phenotypes 
might preferentially benefit from more personalized treatment approaches [45,46], and 
future research should focus on which phenotypes benefit most from a strategy aimed 
at a Ca, FCa, or PCa approach.
In conclusion, treatment aimed at achieving and maintaining Ca as such offers no 
additional benefits from the health economic, patient, and clinical perspective over 
aiming for PCa. Therefore in primary care it seems justifiable to aim for PCa instead of Ca 
because asthma medication costs and use are lower, with no apparent loss in terms of 
clinical outcomes.
However, if feasible, the preferred strategy for achieving and maintaining Ca is to 
additionally guide treatment with a FeNO value as a biomarker because this strategy 
appears to be the most cost-effective and leads to more tailored asthma medication 
prescription while clinical asthma control improves.
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Lung function measurements were based on percentage predicted pre-bronchodilator 
FEV1, as determined by using routine practice-based spirometry, according to interna-
tional guidelines [E1]. FeNO measurements were performed before spirometry by using 
the NIOX-MINO (Aerocrine, Solna, Sweden), according to international guidelines [E2].
Outcomes
During the study, several identical parameters were measured with different question-
naires. In this article the most common questionnaires are mentioned. For a detailed 
overview of all outcomes, please contact the authors.
Health economic outcomes
Participants reported their use of health care resources and hours of absence from work 
every 3 months in the cost questionnaire [E3]. Health care costs included emergency 
department visits, hospital admissions, medication use (all drugs), and all contacts 
with health care professionals, complementary care, and paramedical professionals. 
Productivity costs consisted of hours of absence from work multiplied by standardized 
average hourly wages for the participant’s sex and age [E3]. Actual costs of medication 
prescriptions were obtained from pharmacy records [E4]. Costs for FeNO were based on 
the current price of FeNO measurements. Finally, all prices were converted to the price 
level of 2013 according the general Dutch consumer price index [E5].
Clinical and patient outcomes
For the online assessment of the ACQ at home, percentage predicted FEV1 was assessed 
by means of handheld spirometry (PIKO-1, NSpire Health, Oberthulba, Germany).
Statistical analysis
For the cost analyses, missing cost questionnaires, EQ-5Ds, and pharmacy records were 
imputed by using multiple imputation, creating 5 data sets, with the UVIS command 
from Stata 11.0 (StataCorp). A QALY was calculated by assessing the area under the utility 
curve from the outcomes of the 3-month EQ-5D over a period of 1 year [E6]. Differences 
and statistical uncertainty of QALYs and costs were calculated by using nonparametric 
bootstrap estimation with 5000 random samples (1000 for each of the 5 data sets), 
combining the 5 multiple imputation sets by using Rubin’s rules [E7]. Subsequently, the 
net benefit approach was applied to reformulate the QALY difference into a monetary 
difference and include statistical uncertainty [E8].
The net benefit is defined as follows:
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λ × ΔQALY − Δcosts
where λ is the willingness to pay for a gain of 1 QALY. On the basis of these monetary 
differences, a model of net monetary benefit was constructed to assess the probability 
of cost-effectiveness for the 3 strategies. This probability was calculated across a range 
of different values of society’s willingness to pay (λ) for an incremental outcome gain. 
This allowed the generation of a cost-effectiveness acceptability curve, plotting the 
probability of cost-effectiveness for each of the strategies at different willingness-to-pay 
values.
All outcomes from the patient and clinical perspective were analysed by using the 
Stata xtmixed command for multilevel linear regression, adjusting for clusters at the 
GP level, repeated measurements within a patient, and baseline values. Strategy-time 
interactions were assessed to detect any differences between the groups in particular 
time periods. If these interactions had no significant influence on results, the assess-
ment was repeated without the strategy-time interactions. In a subanalysis the effect of 
missing data on results was analysed by means of imputation of results using the last 
observation carried forward or cluster means.
For exacerbations, we assessed mean exacerbation ratios, and for comparisons 
between treatment strategies, we used a multilevel mixed-effects logistic regression. 
This way we determined for each 3-month study period whether either an exacerbation 
had or had not occurred, thereby ensuring independence of events and diminishing the 
influence of frequent exacerbators on outcomes [E9].
Sample size calculation
The sample size calculation was based on a minimally important change in patient 
utility (EQ-5D), which has been defined as 0.074 points [E10]. With 150 patients per 
treatment strategy, we are able to detect a change of at least 0.06 points by net health 
benefit analysis [E11] between the arms with an SD of 0.175 EQ-5D points (baseline data 
SMASHING project: SD, 0.17), an SD of €1000 for costs (SD, €816; usual care strategy 
[E12]), and an increase in costs of €250 when a treatment strategy is not only more 
effective but also more costly, for a willingness-to-pay value of €30,000 (α  = .05, one 
sided [E11]; β = .20, one sided; rho costs effects = 0). With 40 clusters (general practices) 
per arm and assuming an intracluster correlation of 0.01, 0.07, and 0.11, the number of 
patients per cluster is 4, 5, and 6, and the total number of patients is 480, 600, and 720, 
respectively [E13]. The mean cluster size of 4.7 patients per cluster was lower than the 
anticipated 6 in the study protocol. The number of clusters was extended from 120 to 




Because of the pragmatic design of the trial, PNs were allowed to discuss the treatment 
advice offered by the algorithm to make a final (shared) decision on a treatment change. 
Randomization of practices should have led to an equal distribution of PNs who tend 
to choose more (or less) aggressive treatments (or deviations from the protocol) across 
the 3 trial arms. However, it is possible that participants might wish to deviate more 
from the algorithm in a certain treatment strategy. Therefore in an exploratory analysis 
the frequency and reasons for noncompliance with treatment advice were assessed. 
There were no significant differences in deviations from protocol. When the advice was 
to step down treatment, 49% of patients were afraid of an increase in symptoms, in 33% 
of cases the GP/NP was afraid of loss of control, in 10% of cases asthma medication had 
recently been switched and patients did not want to step down too quickly, and 8% of 
patients had a variety of other reasons. When the advice was to step up treatment, 29% 
of patients or physicians refused the use of prednisolone or a referral to a pulmonary 
physician (which was advised when patients were already taking high-dose ICSs with 
LABAs), in 28% GPs/NPs did not want to increase medication, in 14% the medication 
had recently been stepped up and patients did not want to step up too quickly, in 11% 
patients were worried about side effects, and in 11% patients had not been sufficiently 
adherent on the current dosage, and other reasons were present in 7% of patients. To 
explore the sensitivity of our results to adherence with treatment advice, we repeated 
the main analysis including only the patients with an adherence rate to treatment deci-
sions of at least 75%. The results of this sensitivity analysis were very similar to those for 
the whole group (results not shown).
Also, at the start of each visit to the PN, participants were asked which medications 
they had actually used in the previous months, and sometimes these levels did not cor-
respond with the prescribed medication level from the previous visit. To assess whether 
a difference in adherence existed, we analysed the correspondence between the pre-
scribed medication and the medication the participants had used. In 66% of cases these 
levels matched, in 18% patients were using less medication than they were supposed 
to use, and in 16% they were using more. There were no significant differences in devia-
tions from medication adherence between the treatment strategies.
Missing data
There were no significant differences in odds ratios for missing data between the strate-
gies: Ca versus PCa, 0.95 (0.69-1.31, P = .77); FCa versus PCa, 0.96 (0.69-1.33, P = .80); and 
Ca versus FCa, 0.99 (0.71-1.39, P  = .97); 14.8% of all measurements in the study were 
missing. An exploratory reanalysis of all questionnaires was performed after imputation 
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by using either last observation carried forward or cluster means. No significantly differ-
ent outcomes were obtained (data not presented).
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Supplement Tables
Table 4.E1: Medication equivalent dosages
Medication Level Medication Total daily dosage





Level 1 Beclomethason powder 400mcg
Beclometason aerosol 200mcg 
Beclomethason extrafine 200mcg 
Budesonide powder 400mcg 
Budesonide aerosol 200mcg 
Fluticason powder 200mcg 
Fluticason aerosol 200mcg 
Ciclesonide aerosol 160mcg 
Montelukast 10mg 
Level 2 Beclometason powder 800mcg
Beclometason aerosol 500mcg 
Beclomethason extrafine 400mcg 
Budesonide powder 800mcg 
Budesonide aerosol 400mcg 
Fluticason powder 500mcg 
Fluticason aerosol 500mcg 
Ciclesonide aerosol 320mcg 
Formoterol/budesonide powder 400/12mcg 
Salmeterol/fluticason powder 200/100mcg 
Salmeterol/fluticason aerosol 250/50mcg 
Formoterol/beclomethasone aerosol 200/12mcg 
Beclometason powder + LABA 400mcg + laba 
Beclometason aerosol + LABA 200mcg + laba 
Beclomethason extrafine + LABA 200mcg + laba 
Budesonide powder + LABA 400mcg + laba 
Budesonide aerosol + LABA 200mcg + laba 
Fluticason powder + LABA 200mcg + laba 
Fluticason aerosol + LABA 200mcg + laba 
Ciclesonide aerosol + LABA 160mcg +laba 
Montelukast + LABA 10mg +laba 
Beclometason powder + Montelukast 400mcg +mont 
Beclometason aerosol + Montelukast 200mcg +mont 
Beclomethason extrafine + Montelukast 200mcg +mont 
Budesonide powder + Montelukast 400mcg +mont 
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Table 4.E1: Medication equivalent dosages (continued)
Medication Level Medication Total daily dosage
Budesonide aerosol + Montelukast 200mcg +mont 
Fluticason powder + Montelukast 200mcg +mont 
Fluticason aerosol + Montelukast 200mcg +mont 
Ciclesonide aerosol + Montelukast 160mcg +mont 
Level 3 Formoterol/budesonide powder 800/24mcg
Salmeterol/fluticason powder 500/100mcg 
Salmeterol/fluticason aerosol 500/100mcg 
Formoterol/beclomethasone aerosol 400/24mcg 
Beclometason powder + LABA 800mcg + laba 
Beclometason aerosol + LABA 500mcg + laba 
Beclomethason extrafine + LABA 400mcg + laba 
Budesonide powder + LABA 800mcg + laba 
Budesonide aerosol + LABA 400mcg + laba 
Fluticason powder + LABA 500mcg + laba 
Fluticason aerosol + LABA 500mcg + laba 
Ciclesonide aerosol + LABA 320mcg + laba 
Beclometason powder + Montelukast 800mcg + mont 
Beclometason aerosol + Montelukast 500mcg + mont 
Beclomethason extrafine + Montelukast 400mcg + mont 
Budesonide powder + Montelukast 800mcg + mont 
Budesonide aerosol + Montelukast 400mcg + mont 
Fluticason powder + Montelukast 500mcg + mont 
Fluticason aerosol + Montelukast 500mcg + mont 
Ciclesonide aerosol + Montelukast 320mcg + mont 
Formoterol/budesonide powder + Montelukast 400/12mcg + mont 
Salmeterol/fluticason powder + Montelukast 200/100mcg + mont 
Salmeterol/fluticason aerosol + Montelukast 200/100mcg + mont 
Formoterol/beclomethasone aerosol + Montelukast 200/12mcg + mont 
Beclometason powder + LABA + Montelukast 400mcg + laba + mont 
Beclometason aerosol + LABA + Montelukast 200mcg + laba + mont 
Beclomethason extrafine + LABA + Montelukast 200mcg + laba + mont 
Budesonide powder + LABA + Montelukast 400mcg + laba + mont 
Budesonide aerosol + LABA + Montelukast 200mcg + laba + mont 
Fluticason powder + LABA + Montelukast 200mcg + laba + mont 
Fluticason aerosol + LABA + Montelukast 200mcg + laba + mont 
Ciclesonide aerosol + LABA + Montelukast 160mcg +laba +mont 
Level 4 Formoterol/budesonide powder 1600/48mcg
Salmeterol/fluticason powder 1000/100mcg 
Salmeterol/fluticason aerosol 1000/100mcg 
Formoterol/beclomethasone aerosol - 
Beclometason powder + LABA 1600mcg + laba 
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Table 4.E1: Medication equivalent dosages (continued)
Medication Level Medication Total daily dosage
Beclometason aerosol + LABA 1000mcg + laba 
Beclomethason extrafine + LABA 800mcg + laba 
Budesonide powder + LABA 1600mcg + laba 
Budesonide aerosol + LABA 800mcg + laba 
Fluticason powder + LABA 1000mcg + laba 
Fluticason aerosol + LABA 1000mcg + laba 
Formoterol/budesonide powder + Montelukast 800/24mcg + mont 
Salmeterol/fluticason powder + Montelukast 500/100mcg + mont 
Salmeterol/fluticason aerosol + Montelukast 500/100mcg + mont 
Formoterol/beclomethasone aerosol + Montelukast 400/24mcg + mont 
Beclometason powder + LABA + Montelukast 800mcg + laba + mont 
Beclometason aerosol + LABA + Montelukast 500mcg + laba + mont 
Beclomethason extrafine + LABA + Montelukast 400mcg + laba + mont 
Budesonide powder + LABA + Montelukast 800mcg + laba + mont 
Budesonide aerosol + LABA + Montelukast 400mcg + laba + mont 
Fluticason powder + LABA + Montelukast 500mcg + laba + mont 
Fluticason aerosol + LABA + Montelukast 500mcg + laba + mont 
Ciclesonide aerosol + LABA + Montelukast 320mcg + laba + mont 
Level 4.5 Formoterol/budesonide powder + Montelukast 1600/48mcg + mont
Salmeterol/fluticason powder + Montelukast 1000/100mcg + mont 
Salmeterol/fluticason aerosol + Montelukast 1000/100mcg + mont 
Beclometason powder + LABA + Montelukast 1600mcg + laba + mont 
Beclometason aerosol + LABA + Montelukast 1000mcg + laba + mont 
Beclomethason extrafine + LABA + Montelukast 800mcg + laba + mont 
Budesonide powder + LABA + Montelukast 1600mcg + laba + mont 
Budesonide aerosol + LABA + Montelukast 800mcg + laba + mont 
Fluticason powder + LABA + Montelukast 1000mcg + laba + mont 
Fluticason aerosol + LABA + Montelukast 1000mcg + laba + mont 
Level 5 Oral prednisone na
LABA = Long acting beta agonist Mont = montelukast
Table 4.E2. Comparison of baseline characteristics of participants and asthma patients who declined their 
invitation (non-participants)
Non participants Participants
Total (n) 788 644
Mean age (in yr) 35.7 38.3
% Females 68.5 68.1
Mean ACQ 0.62 0.97
% Strict control 68.2 48.4
% Partial control 18.0 27.2
% Uncontrolled 13.9 24.4
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Abstract
Background Our aim was to validate optimal action points in written action plans for 
early detection of asthma exacerbations.
Methods We analysed daily symptoms and morning peak expiratory flows (PEFs) from 
two previous studies. Potential action points were based on analysis of symptom scores 
(standard deviations), percentage of personal best PEF, PEF variability in relation to a 
run-in period, or combinations of these measures. Sensitivity and specificity for predict-
ing exacerbations were obtained for each action point. The numbers needed to treat to 
prevent one exacerbation and the time interval between reaching action point criteria 
and the start of the exacerbation were calculated. Based on these parameters, the opti-
mal action points for symptoms, PEF and PEF plus symptoms were determined, and their 
performance compared with published guidelines’ action points.
Results The optimal action points were, for symptoms, statistical variability (standard 
deviations) and, for PEF, <70% of personal best. The combination of PEF plus symptoms 
performed best, with improved specificity and earlier detection. The main benefits as-
sociated with using these action points was to reduce false positive rates for detecting 
exacerbations.
Conclusion Early detection of asthma exacerbations can be improved using a compos-
ite action point comprising symptoms and PEF measurements over 1 week.
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Introduction
Exacerbations of asthma are common and, even when asthma is mild, constitute a sig-
nificant health risk [1]. Assessing future risk of adverse events, including exacerbations, 
and educating patients to use a self-management plan is recommended [2–6].
Self-management includes developing individualized Written Asthma Action Plans 
(WAAPs). WAAPs specify the level of symptoms or peak expiratory flow (PEF) (called 
action points, APs) at which to adjust medication (usually starting oral corticosteroids) 
in order to either prevent or reduce the severity of exacerbations. To ensure effective 
intervention, an AP should detect an imminent exacerbation well before its onset.
Gibson et al. [7] and Gibson and Powell [8] have previously validated several APs us-
ing quality control analysis (QCA). However, in the Global Initiative for Asthma (GINA) 
guidelines and the Dutch national guidelines, thresholds for symptoms or PEF are not 
specified [3, 9]. Although APs in the current British Thoracic Society (BTS) and US National 
Heart Lung and Blood Institute (NHLBI) guidelines are more specific, these APs have not 
been validated [2, 5, 6]. The optimum time point at which changes in either symptoms 
or PEF may be detected, or the relevant thresholds reached prior to an exacerbation are 
largely unknown. This lack of validation means that physicians often determine APs for 
individual patients empirically. If APs are inaccurately selected, this potentially leads to 
over treatment (false-positive APs) or missed opportunities for early intervention (false-
negative APs).
In this study, our aim was to develop optimal APs based on symptoms and/or PEF 
threshold levels for early detection of asthma exacerbations that allow timely interven-
tion in patients with mild-to-moderate asthma. Subsequently, we aimed to validate the 
performance of the optimized APs in a similar but separate study population
Methods
We analysed asthma symptoms, morning PEFs, the occurrence of exacerbations and 
the use of prednisone using data from written daily diaries from two previous studies 
[10, 11]. The development dataset was obtained from a randomised controlled trial 
designed to compare the effects of 6 months of treatment with regular inhaled salbuta-
mol, salmeterol or placebo [10]. The validation dataset was obtained from a single-blind 
placebo-controlled trial that explored the use of fractional exhaled nitric oxide (FeNO) to 
guide treatment in chronic asthma [11]. The follow-up period was 1 yr.
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Subjects
There were 165 patients in the development dataset and 94 in the validation dataset, all 
with stable mild-to-moderate chronic asthma [10, 11].
Daily diaries
In both studies, daily diary recordings included symptoms of daytime and night-time 
chest tightness/wheeze/dyspnoea, cough, sputum production, exercise impairment, 
and either appearance of or increased frequency of nocturnal awakening. All were 
scored on a 0–3 scale or by a yes/no response where appropriate. The best of three 
PEF measurements was also recorded each morning and evening. Missing data were 
interpolated using the mean of the recordings from the previous and following days.
Exacerbations
Exacerbations were defined in both studies using a composite daily asthma score. The 
scoring criteria were similar between the two studies, but differed regarding the use of a 
β-agonist ‘reliever’ and nocturnal awakening (table 5.1 in Taylor et al. [10] and table 5.2 in 
Smith et al. [11]). In brief, major exacerbations were defined as a visit to the emergency 
department, a PEF <40% personal best (pb) for ≥1 day, a PEF <60% pb for ≥2 days plus 
an increase in symptoms, or a PEF <60% pb for ≥1 day and PEF <75% pb for ≥2 days with 
an increase in symptoms.
During the study, courses of prednisone were administered in response to de-
teriorating symptoms and/or peak flows, or at the discretion of patients or clinicians 
independently of diary data. Prednisone use for ≥3 days is widely used as a definition 
for exacerbations [4]. Therefore, as a sensitivity analysis, we also assessed the predictive 
utility of APs using this alternative definition





Number of patients (n) 164 94
Mean age (years) 38 (range 18-64) 44 (range 12-73)
Sex Male = 73 (45%)
Female = 91 (55%)
Male = 35 (37%)





1-400µg/day 34% 53% 
401-1000µg/day 36% 45% 
>1000µg/day 22% 2% 
Mean symptom score during run-in period (maximum = 6.0) 0.55 (range 0-2.06) 0.56 (range 0-2.65)
Mean personal best PEF during run-in (l/min) 508 (range 305-755) 448 (range 230-705)
* Beclomethasone equivalent.
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Action points
A range of pre-specified APs was evaluated. For symptoms, we assessed APs used in 
currently recommended WAAPs: the occurrence of nocturnal awakening or the ap-
pearance of any symptoms [2, 3, 6, 9]. Additionally, we evaluated APs based on QCA 
of symptoms using standard deviations from the mean symptom score during run-in 
for each patient. To this end, we developed a composite daily symptom score (range 
0–6), which combined all daily recorded individual symptoms and ‘reliever’ β-agonist 
use, with higher scores representing more severe symptoms (table 5.5a,b in this Article’s 
Supplement). The mean score and its standard deviation were determined per patient 
during the run-in period when asthma was well controlled. Subsequently, occasions 
characterised by deviation from the mean by more than one, two or three standard de-
viations were evaluated as potential APs. In patients without any symptoms during the 
run-in, the mean symptom score and standard deviation was 0. In these cases, the one, 
two and three standard deviation thresholds were set at 0.17, 0.34 and 0.50, respectively, 
representing the minimal possible changes in composite symptom score.
For PEF, the APs were derived from percentages of personal best morning PEF mea-
surement obtained during the run-in period (% pb), or QCA based on the approach 
outlined by Gibson et al. [7] and Gibson and Powell [8]. We also analysed whether 
combining PEF and symptoms as a composite AP might perform better, since using 
single outliers of PEF or symptoms alone might result in relatively high false positive 
rates for exacerbation prediction. Therefore, we assessed whether a combination of 
symptom and PEF thresholds were reached on the same day, and also within a 1-week 
time window. Finally, we assessed the performance of the APs currently recommended 
by the NHLBI, which are based on both symptoms and PEF (‘yellow zone’) [2]. As it is not 
clear whether reaching the threshold for either symptoms or PEF alone is sufficient or 
both are required, we analysed both options.
For each patient, every week in the diary recordings was coded as either a ‘stable week’, 
when no exacerbation occurred, or ‘pre-exacerbation week’ for the week prior to an exac-
erbation. For all stable and pre-exacerbation weeks, we assessed whether the AP(s) either 
predicted a future exacerbation (when one or more of the daily recordings in that week 
fulfilled criteria for that specified AP), or predicted that a future exacerbation would not 
occur (when daily recording(s) did not reach the defined thresholds) (figure 5.1).
Analysis
All analyses were performed with STATA (release 11; StataCorp, College Station, TX, USA). 
Contingency tables for each AP threshold were constructed to calculate performance 
characteristics including sensitivity, specificity, accuracy and area under the receiver 
operating characteristic (AUC) curve for predicting an exacerbation. In addition, for 
each AP threshold we assessed the (potential) number needed to treat (NNT) in order to 
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prevent one exacerbation, given a hypothetical perfect treatment and early detection, 
defined as the number of days before the onset of an exacerbation the AP was reached 
for the first time in a pre-exacerbation week. NNT was calculated by dividing the total 
number of times an AP was reached (true positives and false positives) by the number of 
times it accurately predicted a future exacerbation (true positives).
The APs that performed optimally were grouped within four categories: 1) symptoms 
solely; 2) PEF solely; 3) symptoms and PEF on the same day; and 4) symptoms and PEF 
within 1 week prior to an exacerbation, using the development dataset. Optimal perfor-
mance was defined as a sensitivity of ≥75% combined with the best trade-off between 
early detection and potential NNT. To determine this outcome, we plotted the number 
of days on which an exacerbation was predicted before its occurrence against the NNT 
for a series of different APs (figure 5.2).
To assess the external validity of the optimal APs derived from the development da-
taset, their performance was assessed and compared with several published APs using 
the validation dataset [11].
 
Figure 5.1. The use of action points in an 8-week peak flow chart with an exacerbation at the half-way 
point. The dotted lines indicate the thresholds of potential action points, on the left based on % of personal 
best (pb) peak expiratory flow (PEF), and on the right based on individual standard deviations for PEF. The 
observation period is divided into weeks before and during the exacerbation, and weeks of normal control, 
respectively coded as pre-exacerbation weeks and stable weeks. In this example, we have highlighted the 
action points PEF 70% pb and PEF -3 SD. The action point PEF 70% pb is reached twice, once as a false posi-
tive in a stable week and once accurately 2 days before the exacerbation in the pre-exacerbation week. The 
action point PEF -3 SD is never reached in this example, representing a false negative prediction for the 
pre-exacerbation week (marked X).
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Results
The development dataset consisted of daily recordings from 164 patients. 88 exacerba-
tions, defined using diary data, occurred during 18 months of follow-up. Exacerbations 
occurred in 39 different patients, a mean rate 1.8 per patient per year, ranging from 1 to 
13. 147 exacerbations, defined as the use of a course of oral prednisone, occurred during 
the follow-up interval.
In the validation dataset, 94 patients provided daily recordings. 22 exacerbations oc-
curred. Exacerbations occurred in 17 patients and the mean rate was 1.5 per patient per 
year (range 1 to 5). Oral prednisone was used on 75 occasions.
The characteristics of patients from both studies are listed in table 5.1.
Action points
The performance of 25 potential APs was analysed (a complete overview of results 
is presented in tables 5.4a–d of the Supplement). Six APs were based on symptoms, 
eight on PEF, nine on combinations of symptoms and PEF on the same day, and two on 
combinations of symptoms and PEF within 1 week. In general, APs based on standard 
deviations of symptom scores performed better than pre-defined absolute levels of 
symptoms. This judgment was based on lower NNTs for the former approach. PEF using 
% pb resulted in considerably lower NNTs than using standard deviations.
The optimal symptom AP was a score that increased by more than two standard de-
viations more than the run-in mean, and this detected exacerbations 2.9 days before oc-
currence with 88.5% sensitivity, 86.3% specificity and a NNT of 24. For PEF, the optimally 
performing AP was a PEF <60% pb, which is also currently proposed by the BTS as the 
threshold for commencing oral prednisone treatment [5]. It had a sensitivity of 78.2%, 
specificity of 98.7% and a NNT of 3. However, it detected exacerbations only 1 day before 
their occurrence. The optimal combination (symptoms and PEF) comprised a symptom 
score increase of more than two standard deviations plus PEF decrease to <70% pb. 
This combination detected exacerbations 1.4 days before their occurrence with 80.5% 
sensitivity, 98.3% specificity and a NNT of 4. Within a 1-week window, this symptom–PEF 
combination detected exacerbations 4.1 days (mean) before their occurrence with a 
sensitivity of 85.1%, specificity of 97.2% and a NNT of 6 (table 5.2).
The performance characteristics of optimal APs in the validation dataset are presented 
in table 5.3. In general, the sensitivities for each of the optimal APs differed somewhat 
from those obtained using the developmental dataset, whereas specificities remained 
similar. For each optimal AP, the number of days before the onset of an exacerbation at 
which the AP predicted future exacerbations was better in the validation dataset, i.e. 
between 0.4 and 1.0 day earlier.
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For both versions of the AP recommended by the NHLBI, the combination of ‘appearance 
of any symptoms’ plus PEF <80% pb performed best (table 5.3). It detected exacerbations 
4.9 days before onset, with a sensitivity of 100% and specificity of 86.8%. However, the 
NNT is 43, whereas it is 12 for the optimal AP from the development dataset (figure 5.2).
Table 5.2. Performance characteristics in the development dataset of the optimal action points per cat-
egory.














Symptoms (>2SD) Symptoms PEFs 2.9 88.5 86.3 86.3 0.87 24
Use of prednisone 2.7 76.9 86.6 86.5 0.82 17
PEF
(<70% pb)
Symptoms PEFs 2.9 90.8 93.9 93.9 0.92 11
Use of prednisone 2.6 61.2 93.9 93.5 0.78 10
PEF
(<60% pb)*
Symptoms PEFs 1.0 78.2 98.7 98.6 0.88 3
Use of prednisone 1.2 38.1 98.7 98.0 0.68 4
Symptoms + PEF: same day∫ Symptoms PEFs 1.4 80.5 98.3 98.2 0.89 4
Use of prednisone 1.4 47.6 98.3 97.7 0.72 4
Symptoms + PEF: within 1 
week†
Symptoms PEFs 4.1 85.1 97.2 97.1 0.91 6
Use of prednisone 3.5 54.4 97.2 96.7 0.76 5
Early Detection is a description of how many days before the onset of an exacerbation this action point will 
predict the future occurrence of the event. It was assessed by calculating the mean number of days that 
this action point’s thresholds were reached for the first time in the week preceding the exacerbation, from 
all predicted exacerbations.
Sensitivity, specificity and accuracy refer to this action point’s ability to correctly predict an exacerbation and 
how often exacerbations are missed or falsely predicted.
AUC is a measure of the overall accuracy of a prediction, with 1.0 representing a perfect prediction with 
100% sensitivity and 100% specificity, and 0.5 representing a random guess and therefore the model has no 
predictive properties. In general, AUC values of less than 0.7 do not have clinical significance.
NNT is the number of times this action point is positive per predicted exacerbation. It is a measure of how 
often an intervention is applied unnecessarily to prevent one exacerbation.
∫  For Symptoms and PEF on the same day the optimal combination consisted of a composite symptom 
score >2SDs of the mean plus PEF <70% of personal best
†  For Symptoms and PEF within one week the optimal combination consisted of a composite symptom 
score >2SDs of the run-in mean plus PEF <70% of personal best, with a seven day time window being 
allowed for either threshold to become positive.
* Action Point advised by the British Thoracic Society [5]
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The comparable data using the alternative definition of ‘use of oral prednisone’ are 
also reported in tables 5.2 and 5.3, and tables 5.4a–d in this article’s Supplement. In 
general, sensitivities were considerably lower, overall accuracies were similar, early 
diagnosis was slightly later, but the NNTs were better.
Discussion
The present study provides the most comprehensive data to date of the performance 
characteristics of a range of symptom and/or PEF thresholds at which patients might 
intervene to abort an asthma exacerbation or to reduce its severity. For symptoms, a 
change of more than two standard deviations in a composite symptom score provided 
optimum outcomes. For PEFs, a decrease to <60% pb was optimal. However, an AP 
based on a combination of changes in symptom score (more than two standard devia-
tions) and PEF (<70% pb) occurring during a 1-week period performed even better. This 
combination predicted exacerbations 5 days before their occurrence, thus allowing 
sufficient time to intervene, whilst the NNT remained low.
Table 5.3 Performance characteristics in the validation dataset of optimal action points derived from the 
development dataset and of the NHLBI action point [2].














Symptoms (>2SD) Symptoms PEFs 3.3 75.0 86.2 86.2 0.81 59
Use of prednisone 4.1 60.0 86.9 86.6 0.73 19
PEF (<70%pb) Symptoms PEFs 4.2 100 92.5 92.6 0.96 24
Use of prednisone 3.6 53.3 93.0 92.5 0.73 12
PEF
(<60% pb) *
Symptoms PEFs 1.8 100 97.6 97.6 0.99 8
Use of prednisone 2.3 18.7 97.5 96.6 0.55 12
Symptoms + PEF: same
day
Symptoms PEFs 1.7 75.0 98.3 98.2 0.87 8
Use of prednisone 2.1 29.3 98.5 97.6 0.64 5
Symptoms + PEF: within 1 
week
Symptoms PEFs 5.1 75.0 97.4 97.3 0.86 12
Use of prednisone 4.8 33.3 97.6 96.8 0.65 7
NHLBI criteria changes in 
Symptoms AND in PEF∫
Symptoms PEFs 4.9 100 86.8 86.9 0.93 43
Use of prednisone 4.0 70.7 87.5 87.3 0.79 16
NHLBI criteria changes in 
symptoms OR in PEF†
Symptoms PEFs 6.5 100 47.5 47.6 0.74 176
Use of prednisone 6.1 100 48.2 48.8 0.74 46
Descriptions are similar to the ones provided below Table 5.2
* Action point advised by the British Thoracic Society [5]
Since the NHLBI action point can be interpreted in two ways, we provided both: ∫ appearance of any symp-




Figure 5.2 a, b. The number of days that the exacerbation is predicted before its occurrence is plotted 
against the (potential) number needed to treat (NNT) in order to prevent one exacerbation, for a series of 
different action points. The lower left corner represents the optimal action point, i.e. early prediction and 
low NNT. a) Exacerbations are defined using the definition described in the Methods section. b) Exacerba-
tions are defined as a ’’use of oral prednisone’’. Action point 1: symptoms (Sy) 2 SD; 2: peak expiratory flow 
(PEF) 70% personal best (pb); 3: PEF 60% pb; 4: Sy 2 SD + PEF 70% pb; 5: Sy 2 SD + PEF 70% pb within 1 
week; 6: National Heart Lung and Blood Institute (NHLBI). a) and b) similar results are shown, although the 
differences are larger in a). Action points 3, 4 and 5 perform similarly, with a slight increase in NNT for each 
day the exacerbation is diagnosed earlier. The optimum depends on the trade-off between NNT and early 
detection. To allow sufficient time to successfully intervene, we opted for number 5. Action points 1, 2 and 
6 perform considerably worse, due to the high NNTs.
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Previously, in a Cochrane review, Powell and Gibson [12] compared the use of WAAPs 
based on symptoms with those based on PEF [12]. Results showed that these were 
equivalent with regard to outcomes, i.e. hospitalisations or unscheduled doctor visits. 
Our data indicate that combining symptoms and PEFs provide added value. Clearly, it 
is not practical for patients to do the necessary calculations and therefore, in practice, 
an AP based solely on PEF <60% pb might be optimal. Nevertheless, with the advent of 
internet-based applications (‘Apps’), the use of seemingly complex APs is now feasible 
[13]. Although compliance with paper diary recordings is generally poor [14], such an 
approach is feasible with electronic recordings [15] and is of particular relevance in 
patients with difficult or brittle asthma.
The fact that a ‘both/and’ combination of symptoms and PEF performed better than 
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Figures 5.3a and 3b. Changes in PEF (a) and symptom scores (b) from day −14 to day +10 before and after 
an exacerbation, using the mean PEF and symptom score data from each exacerbation in the development 
dataset.
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vary discordantly, and one of these parameters may change in isolation, especially in 
‘poor perceivers’. APs with threshold levels based solely on either symptoms or PEF are 
susceptible to these variations. Using a more stringent threshold, such as PEF <60% 
pb, can solve this issue, but has the disadvantage of late detection of an imminent 
exacerbation. Therefore, using a 1-week window for the symptoms plus PEF provided 
the best AP as it detected exacerbations 5.1 days before occurrence, at only a slight 
cost in specificity and NNT. To assess whether symptoms or PEF drive earlier detection 
using the AP with a one week time window, we performed a subgroup analysis of the 
74 predicted exacerbations. There was no consistent pattern as to whether changes in 
symptoms preceded PEFs or vice versa. Symptoms occurred earlier in 25 subjects, the 
threshold for PEF changes was reached earlier in 23, and in 26 there was no discordance.
Previously, Gibson et al. [7] analysed nine different APs and showed that QCA of daily 
PEFs performs better than percentages of personal best PEF (in contrast to the present 
data) or percentage predicted of PEF. Gibson et al. [7] reported that the optimal QCA AP 
detected 91% of exacerbations and falsely predicted an exacerbation in 23% of periods 
of normal control. Tattersfield et al. [16] analysed the false positive rate of APs based on 
the median values of PEF and symptoms at 2 days before the start of an exacerbation. 
They found a false-positive rate of 6.4% using the advent of night-time symptoms, 26% 
for morning PEF and 30% for daytime symptoms. Thamrin et al. [17] analysed daily fluc-
tuations in PEF and, by calculating conditional probabilities of future decreases in lung 
function, predicted the risk of exacerbations with a sensitivity of 68.8% and specificity 
of 67.4%. The AUC was 0.85, which is only slightly lower than AUCs of most optimal APs 
in this study [17].
The time course of changes in symptoms and PEF that constitute an asthma exacer-
bation is important in determining the optimum time for intervention. If changes can 
only be identified after the time at which intervention is likely to be effective, then the 
rationale for using WAAPs would be weak. Previous data suggest that symptoms and 
PEF start declining 5–10 days before exacerbations [16, 18]. The changes in PEFs and 
symptom scores associated with exacerbations in our patients are illustrated in figure 
5.3a and b. Based on these findings, we systematically analysed the 7-day period preced-
ing exacerbations. We found that changes in the optimal APs occurred between 1.7 and 
5.1 days before the defined onset of an exacerbation (table 5.S4). The onset of action of 
systemic corticosteroid is within 12–24 h, and so the APs would be reached in sufficient 
time to allow for steroids to have a modifying effect. The effectiveness of quadrupling 
the dose of inhaled corticosteroids was recently investigated by Oborne et al. [19], and 
might have resulted in greater clinical benefits if commenced at the times calculated to 
be optimal in our study
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Our study has several possible limitations. First, we selected criteria for acceptable sensi-
tivity and specificity (see Statistical analysis section), as we aimed to balance early detec-
tion of exacerbations against potential overdiagnosis. Secondly, the composite symptom 
score(s) used in the two studies were not externally validated. It is not certain whether 
applying QCA to alternative scoring systems such as the Asthma Control Questionnaire 
or the Asthma Control Test would give similar results [20, 21]. However, given the overall 
similarity between results using both of our datasets, there is reason to believe that 
QCA is a valid approach to optimising APs independently of the exact scoring system 
used. Thirdly, APs were based on parameters that were incorporated in the definition 
of an exacerbation. Our study was not designed to be explanatory but rather to model 
predictive performance, and as such is methodologically sound. Our definition of major 
exacerbations, i.e. either emergency room visits or changes in PEF plus symptoms for ≥2 
days, is in accordance with recent criteria for severe exacerbations [4]. Furthermore, in 
modified forms, our definition has been used in several previous studies [10, 11, 22, 23]. 
However, accepting that the definition of an exacerbation is important in the interpreta-
tion of our data, we performed additional analyses using ‘use of oral prednisone’ as the 
definition of an exacerbation (tables 5.2 and 5.3 and table 5.4 of the Supplement). The 
order of optimal APs was similar with regard to early detection and NNT (fig. 5.2b). Using 
this definition, the sensitivity to detect exacerbations was considerably lower when using 
PEF either solely or in combination with symptoms, whereas it was only slightly lower us-
ing symptoms alone (table 5.S4). This implies that the decision to administer prednisone 
depended more on symptoms than on PEF. Given that the sensitivity was <75%, and 
the NNT was high, we concluded that the analysed APs did not perform well enough 
to predict exacerbations defined as ‘use of oral prednisone’. Such events were generally 
less severe than the exacerbations defined a priori using composite symptom scores and 
PEFs. It is therefore arguable that our APs performed well in predicting events of higher 
severity and in which earlier intervention is clinically desirable.
In conclusion, the optimal AP for the early detection of asthma exacerbations consists of 
a greater than two standard deviations increase in a composite symptom score and a fall in 
PEF to <70% pb, occurring within a 1-week window. With the advent of handheld computer 
technology, there is potential to use these criteria more readily in day-to-day practice, and 
thus reduce the impact of exacerbations, particularly in patients with a history of frequent 
exacerbations. Prospective studies or further analyses using other published datasets should 
be carried out to confirm the present findings, and together they should be used to revise 
and improve the empirical recommendations offered in current guidelines.
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Supplement Tables
Table 5.4a. Performance characteristics of all action points based solely on Symptoms.
The action point ‘nocturnal awakening’ was considered positive whenever a patient had awoken due to 
asthma symptoms; ‘appearance of any symptoms’ was positive whenever a patient had experienced any 
breakthrough symptoms; ‘severe symptoms’ whenever the composite symptom score was two or more, 
or yes in case of nocturnal awakening. The action points based on SD are positive whenever the result of a 
composite symptom score was higher than respectively 1, 2, or 3 standard deviations from a mean symp-
















Symptoms PEFs 2.5 83.9 86.3 86.3 0.85 26
Use of prednisone 2.6 77.6 86.7 86.6 0.82 16
Appearance of any 
symptoms
Symptoms PEFs 5.4 100 42.0 42.4 0.71 94
Use of prednisone 5.2 97.7 42.3 42.9 0.70 57
Severe symptoms Symptoms PEFs 3.0 90.8 79.5 79.6 0.85 36
Use of prednisone 3.2 91.2 79.9 80.0 0.86 21
Symptom score 
>1SD
Symptoms PEFs 3.6 95.4 77.3 77.4 0.86 38
Use of prednisone 3.4 91.8 77.7 77.8 0.85 23
Symptom score 
>2SD
Symptoms PEFs 2.9 88.5 86.3 86.3 0.87 24
Use of prednisone 2.7 76.9 86.6 86.5 0.82 17
Symptom score 
>3SD
Symptoms PEFs 2.7 74.7 90.9 90.8 0.83 19
Use of prednisone 2.6 61.9 91.1 90.8 0.77 14
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Table 5.4b. Performance characteristics of action points based solely on Peak Flow.
‘PEF 2 days 85% of personal best’ was considered positive whenever PEF was lower than 85% of the person-
al best PEF on two consecutive days; ‘PEF % of personal best’ whenever PEF was lower than the designated 
percentage of that patients personal best PEF score; ‘PEF SD’ whenever PEF was lower than respectively 1, 














PEF 85% pb on 2 
consecutive days
Symptoms PEFs 4.4 87.4 78.8 78.8 0.83 38
Use of prednisone 3.7 82.3 79.0 79.1 0.81 24
PEF <80% pb Symptoms PEFs 4.4 94.3 80.4 80.5 0.87 33
Use of prednisone 3.5 87.1 80.6 80.7 0.84 21
PEF <70% pb Symptoms PEFs 2.9 90.8 93.9 93.9 0.92 11
Use of prednisone 2.6 61.2 93.9 93.5 0.78 10
PEF <60% pb Symptoms PEFs 1.0 78.2 98.7 98.6 0.88 3
Use of prednisone 1.2 38.1 98.7 98.0 0.68 4
PEF <1SD Symptoms PEFs 4.4 95.4 71.3 71.4 0.83 49
Use of prednisone 3.7 87.1 71.5 71.6 0.79 32
PEF <2SD Symptoms PEFs 3.3 89.7 85.3 85.3 0.87 26
Use of prednisone 2.5 76.9 85.5 85.4 0.81 18
PEF <3SD Symptoms PEFs 2.7 70.1 92.6 92.5 0.81 17
Use of prednisone 2.6 54.4 92.8 92.3 0.74 13
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Table 5.4c. Performance characteristics of all action points that combined thresholds for both Symptoms 
and PEF, where both thresholds were reached on the same day. For example ‘symptoms 1SD and PEF 80%’ 
was positive whenever the composite symptom score was higher than 1 standard deviation from the mean 
symptom score and PEF was lower than 80% of that patients personal best. For a further description see 
table 4a and 4b.











Symptoms >1SD and 
PEF <80% pb
Symptoms PEFs 2.6 89.7 92.1 92.1 0.91 14
Use of prednisone 2.3 77.6 92.4 92.2 0.85 10
Symptoms >2SD and 
PEF <70% pb
Symptoms PEFs 1.4 80.5 98.3 98.2 0.89 4
Use of prednisone 1.4 47.6 98.3 97.7 0.72 4
Symptoms >2SD and 
PEF <60% pb
Symptoms PEFs 0.3 67.8 99.6 99.4 0.84 2
Use of prednisone 0.5 30.6 99.5 98.7 0.65 2
Symptoms >3SD and 
PEF 60% pb
Symptoms PEFs 0.3 55.2 99.8 99.5 0.77 2
Use of prednisone 0.5 23.1 99.7 98.8 0.61 2
Appearance of 
symptoms and PEF 
<80% (NAEPP)
Symptoms PEFs 3.9 94.3 83.3 83.4 0.89 28
Use of prednisone 3.1 85.0 83.5 83.6 0.84 18
Appearance of 
symptoms and PEF 
<70% pb
Symptoms PEFs 2.7 90.8 94.4 94.4 0.93 10
Use of prednisone 2.4 60.5 94.4 94.1 0.78 9
Appearance of severe 
symptoms and PEF 
<70% pb
Symptoms PEFs 1.6 81.6 97.4 97.3 0.90 6
Use of prednisone 1.6 51.0 97.5 97.0 0.74 5
Nocturnal awakening 
and PEF <70% pb
Symptoms PEFs 1.3 75.9 98.1 97.9 0.87 5
Use of prednisone 1.2 44.2 98.1 97.5 0.71 5
Symptoms >1SD and 
PEF >1SD
Symptoms PEFs 2.6 92.0 89.0 89.0 0.90 19
Use of prednisone 2.7 75.5 89.2 89.1 0.82 14
Symptoms >2SD and 
PEF >2SD
Symptoms PEFs 1.8 81.6 95.5 95.4 0.89 9
Use of prednisone 1.8 60.5 95.6 95.2 0.78 7
Symptoms >3SD and 
PEF >3SD
Symptoms PEFs 1.7 56.3 97.9 97.7 0.77 6
Use of prednisone 2.1 41.5 98.0 97.4 0.70 5
Table 5.4d. Performance characteristics of action points that used a Time Window for thresholds of Symp-
toms and PEF. For example ‘7 day timeframe 2SD symptoms, 70% personal best PEF’ was positive whenever 
the composite symptom score was higher than two standard deviations above the mean symptom score 
on a certain day and the PEF result was lower than 70% of that patients personal best PEF on that day, or on 


















Symptoms PEFs 3.4 81.6 97.7 97.6 0.90 5




Symptoms PEFs 4.1 85.1 97.2 97.1 0.91 6
Use of prednisone 3.5 54.4 97.2 96.7 0.76 5
Table 5.5a. Symptom score used in developmental dataset [8]. Each symptom was scored between 0 and 
1. Zero meant that symptom was not experienced, and 1 was the maximum score for that symptom. For 
symptoms scored between 0-3, i.e. chest tightness, we adjusted results (0=0, 1=0.33, 2=0.66, 3=1). B2-us-
age was scored as 0 when no ‘reliever’ medication was used; 0.16 for 1 or 2 puffs; 0.33 for 3 or 4; 0.5 for 5-8; 
0.66 for 9-12; 0.83 for 13-16; and 1 for >16 uses of reliever medication per day. Nocturnal awakening scored 
0 if it had not occurred that day and 1 if the patient had awoken due to symptoms.
Symptom Score
Morning and evening chest tightness 0-1





Total daily composite symptom score 0-6
Table 5.5b. Symptom score in the validation dataset [9]. Symptoms were scored between 0-5. 0 = no symp-
toms, 1 = symptoms for one short period, 2 = symptoms for two or more short periods, 3 = symptoms most 
of the time that did not affect normal daily activities, 4 = symptoms most of the time that did affect normal 
daily activities, and 5 = symptoms so severe as to disrupt daily activities. This score between 0 and 5 was 
recalculated between 0-3 (i.e. 0=0, 1=0.6, 2=1.2, 3=1,8, 4=2.4, 5=3). Nocturnal awakening and B2-usage 
were scored similarly as in the development dataset (see description Table 5a).
Symptom Score
Limitations and symptoms 0-3
Nocturnal awakening 0-1
B2-usage 0-1
Total daily composite symptom score 0-5
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Abstract
Background Online self-management programmes for asthma have recently become 
available. International guidelines suggest that the Asthma Control Questionnaire 
(ACQ) can be used in these programmes. In order to assess the current level of control 
and guide therapy, the same cut-off values are being used as in conventional asthma 
management. However, results might differ between different types of administration 
of the ACQ.
Aims To assess the agreement between an online self-administered version of the ACQ 
and an interviewer-administered version at a routine visit.
Methods Cross-sectional data from primary care asthma patients in the Asthma Control 
Cost Utility Randomised Trial Evaluation (ACCURATE) trial aged 18–50 years and pre-
scribed inhaled steroids were analysed. We selected patients who self-administered an 
ACQ online and subsequently had an ACQ completed by a nurse practitioner within 7 
days at a trial-related control visit. ACQ scores were calculated and agreement assessed 
by paired t-tests, Pearson’s correlation coefficient and a Bland-Altman plot.
Results A total of 351 patients were eligible (68% female, mean age 40 years). The time 
interval between the two versions was 3.2 days. There was a significant difference of 
0.14 (95% CI 0.09 to 0.20; p<0.001) between the results of the online self-administered 
ACQ (mean 1.04±0.04) and the interviewer-administered ACQ results (0.90±0.04). The 
Pearson correlation coefficient was 0.79. The limits of agreement (−0.86, 1.14) exceeded 
the predefined minimal clinically important difference between results (±0.5). The 
Bland-Altman plot therefore showed insufficient agreement.
Conclusions Assessment of asthma control by the ACQ is influenced by the type of 
administration. Our results suggest that better control of asthma is perceived when 
interacting with a caregiver than by online self-assessment.
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Introduction
Online monitoring of asthma symptoms provides an opportunity of optimising patient-
centred daily control. Online self-management programmes have therefore been 
developed which offer similar questionnaires to those being used in daily practice for 
assessment of asthma control. This policy is advocated in current guidelines which state 
that composite symptom scores such as the Asthma Control Questionnaire (ACQ) can be 
used in different settings by both patients and care providers to assess current asthma 
control [1-4].4 As a consequence, even though the ACQ was originally developed and 
validated for guided self-administration, it is now administered in a variety of ways — 
for example, in self-management plans using pen and paper or internet applications 
[5,6], self-administered but under guidance of a professional during regular control 
visits, or interviewer-administered by a practice nurse (PN), general practitioner or chest 
physician based on patients’ responses [1- 3]. Recent studies did not show statistically 
significant differences between paper and electronic versions of the ACQ [7] or between 
a postal-administered version and a version under guidance of a healthcare professional 
[8]. However, little is known about the agreement between online self-administered and 
interviewer-administered versions of the ACQ.
The aim of this study was to assess the agreement between an online self-adminis-
tered version of the ACQ and an interviewer-administered ACQ by a PN during a routine 
control visit in adults with asthma.
Methods
Patients
The ACQ results of patients collected in the Asthma Control Cost Utility Randomised 
Trial Evaluation (ACCURATE) trial were used [9]. The trial was approved by the Medical 
Ethics Committee of the Leiden University Medical Center, Leiden, the Netherlands, 
and compares three different treatment strategies for asthma in primary care. Patients 
were included in the study if they were aged 18–50 years, had a doctor’s diagnosis of 
asthma, and had received a prescription for inhaled corticosteroids in the previous year. 
Patients were excluded if they suffered from significant co-morbidity, if they were un-
able to understand written or oral Dutch instructions, or if they had been prescribed oral 
corticosteroids in the previous month.
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Observations
In the ACCURATE trial, patients visited the general practice where ACQs were admin-
istered by a PN (interviewer-administered ACQ). Appointments were scheduled at 
approximately three-monthly intervals at a convenient time for both practices and 
participants. In addition, patients completed online questionnaires monthly at home, 
including the ACQ (online self-administered ACQ). Since the time between completion 
of the two versions of the ACQ was variable, we only selected observations from patients 
who self-administered an ACQ online and subsequently visited the PN for a trial-related 
control visit within 7 days. This time window was selected because it lies well within the 
advised range of 2–14 days for assessing reproducibility of instruments [10]. We excluded 
measurements where online self-administered ACQs were completed after the visit to 
the PN because trial-related medication changes might influence asthma control. We 
used a cross-sectional design to ensure that each participant was included only once.
Asthma Control Questionnaire (ACQ)
The ACQ consists of six questions on symptoms and one on pre-bronchodilator percent-
age predicted forced expiratory volume in one second (FEV1% predicted). In the present 
study, FEV1% predicted was assessed with a hand-held spirometer (PIKO-1) in the online 
self-administered ACQ and by routine spirometry in the interviewer-administered ACQ. 
In the online self-administered version, patients completed the questionnaire online 
at home without supervision, whereas in the interviewer-administered version the PN 
completed all questions based on patient responses. An overview of all methods of ACQ 
assessment is shown in Table 6.1. All questions were scored on a 7-point scale from 0 to 
6 (where 0=good control, 6=poor control), and the composite ACQ7 score is the mean of 
the seven responses. The minimal important difference (MID) between results is 0.5 [11]. 
Current control of asthma was divided into three levels: controlled (ACQ <0.75); partly 
controlled (0.75≥ACQ<1.5); uncontrolled (ACQ ≥1.5) [1,3].
Statistical analysis
Paired t-tests were used to assess whether there were systematic differences between 
online self-administered and interviewer-administered ACQ results. The strength of the 
relationship was assessed using Pearson correlation coefficients. A Bland-Altman plot 
was used to assess the agreement between the two versions. In order to interpret a 
Bland-Altman plot, a clinically significant difference had to be predefined and results 
agreed sufficiently if they remained within this limit [12]. In the present study the MID of 
0.5 was used for this purpose.
Linear regression and correlation analysis were performed to asses whether the 
time between self-administered and interviewer-administered questionnaires, age of 
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participants, smoking behaviour, years of asthma history, or differences in sex between 
patients and PNs influenced ACQ results. All analyses were performed with STATA Ver-
sion 11 (StataCorp LP).
Results
Of 611 patients participating in the ACCURATE trial, 351 visited the PN within one week 
after completion of the online questionnaire at home and were therefore eligible for the 
current analysis. Their mean age was 40.0 years, 68% were female, the mean inhaled cor-
ticosteroid dose was 861mcg beclomethasone equivalent, and 50% used a long-acting 
bronchodilator (Table 6.2). There was a statistically significant difference between the 
online self-administered (mean±SE 1.04±0.04, range 0–4.1) and interviewer-adminis-
tered ACQ results (mean±SE 0.90±0.04, range 0–4.3) (difference 0.14; 95% CI 0.09 to 0.20; 
p<0.001). The Pearson correlation coefficient was 0.79.
Table 6.1. Different types of assessment of the Asthma Control Questionnaire
Types of assessment Description
Pen & Paper self-administration Filled out by patients themselves on a paper format
Postal administration Filled out by patients themselves on a paper format, after it was sent to 
them by mail
Electronic administration Filled out by patients themselves on a PDA electronic device
Online self-administration* Filled out by patients themselves online using a link sent to them by email
Administration under guidance of a 
professional
Filled out by patients themselves at the office of a professional. 
Afterwards the professional discusses results with the patient
Interviewer-administration* Filled out by professionals based on patients’ responses on the different 
questions of the ACQ during an interview
* Used in the current study
Table 6.2. Baseline characteristics of participants of the current study and a comparison with the baseline 
characteristics of non-participants of the current study out of the entire sample of 611 patients in the AC-
CURATE trial
ACCURATE
Participants current study Non-participants p
Number of patients n=351 n=260
Interviewer-administered ACQ baseline 0.95 (95%ci 0.87-1.03) 0.99 (95% CI 0.88-1.09) 0.58
Mean age (in yr) 39.8 ± 9.2 (range 18-51) 39.5 ± 8.6 (range 18-50) 0.66
Gender, % female 68% 70% 0.69
Inhaled corticosteroid dose (mcg) * 849.3±38.8 (range 0-4000) 811.0±40.2 (range 0-4000) 0.51
Use of long-acting β-agonists (in %) 47.2% 52.5% 0.20
* in Beclomethasone equivalent
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When comparing the level of control, in 23% of patients the online self-administered 
version indicated a worse current level of control than the interviewer-administered 
version. This would lead to a step-up in maintenance treatment if the online self-
administered ACQ were to be used to guide treatment decisions, which would not occur 
with the interviewer-administered ACQ. In 6% of patients the level of control was better, 
potentially triggering a step-down in medication. Overall kappa was 0.54, indicating 
moderate agreement (see Table 6.3 and Figure 6.1).
The Bland-Altman plot showed a mean difference of 0.14 between the two versions 
and the 95% limits of agreement (at ±1.96SD from the mean) were at −0.86 and 1.14 
points. Both limits of agreement were beyond the predefined acceptable difference of 
(−)0.5 and therefore there was insufficient agreement between the two versions (Figure 
6.2). Since the dispersion of the difference increased as the mean increased, we repeated 
the Bland-Altman analysis after log transformation and obtained similar results: mean 
log-transformed difference 0.16 (95% CI 0.10 to 0.22, p<0.001), 95% limits of agreement 
−0.98 and 1.31.
Table 6.3: Comparison between the levels of control of the online self-administered and the interviewer 
administered ACQ-results.
ACQ Levels of control
Interviewer Administered
Controlled (n, %) Partly Controlled (n, %) Uncontrolled (n, %)
Online
Self-Administered
Controlled 139 (39.6) 11 (3.1) 3 (0.8)
Partly Controlled 49 (14.0) 62 (17.7) 8 (2.3)
Uncontrolled 8 (2.3) 23 (6.5) 48 (13.7)





























































Figure 6.1. Results of online self-admin-
istered Asthma Control Questionnaire 
(ACQ) results plotted against the results 
of the interviewer-administered version. 
On the x=y line of identity the results are 
identical and they agree sufficiently when 
they lie within the upper and lower mini-
mal important difference (MID=0.5). The 
three categories of current asthma con-
trol (controlled, partly controlled, and un-
controlled) are also depicted. Treatment 
decisions will differ if the asthma control 
category by the online self-administered 
and the interviewer-administered ver-
sions of the ACQ do not concur.
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The difference between the two versions of the ACQ exceeded the MID of 0.5 in 25.1% 
of patients, of which 79.5% had a higher result in the online self-administered version 
and 20.5% in the interviewer-administered version. The differences were especially 
prominent in uncontrolled asthma. Furthermore, when questions in the ACQ were as-
sessed separately, each question was significantly higher in the online self-administered 
version (p<0.03), except the question on FEV1 % predicted which showed no significant 
difference (p=0.39, Table 6.4).
The mean time between completion of the two versions of the ACQ was 3.2 days 
(95% CI 2.9 to 3.5). Linear regression and correlation analyses showed no significant 
association between the difference in ACQ scores and the time between visits (Pearson 
correlation coefficient (r)=0.03, p=0.54), age of participants (r=0.02, p=0.73), smoking 
behaviour (yes or no) (r=0.06, p=0.23), history of allergy (yes or no) (r=0.03, p=0.54), years 
of asthma history (r=0.04, p=0.52), and sex differences between patient and healthcare 
professional (r=0.01, p=0.81).








Total ACQ score# 1.04 0.90 0.14 (0.09 to 0.20) <0.001
ACQ Q1 (awoken) 0.61 0.50 0.11 (0.03 to 0.19) 0.01
ACQ Q2 (morning) 1.21 1.04 0.17 (0.08 to 0.26) <0.001
ACQ Q3 (limitations) 1.04 0.93 0.11 (0.01 to 0.21) 0.03
ACQ Q4 (shortness of breath) 1.57 1.41 0.16 (0.05 to 0.26) 0.003
ACQ Q5 (wheeze) 0.97 0.78 0.19 (0.10 to 0.28) <0.001
ACQ Q6 (B2-use†) 0.66 0.39 0.26 (0.19 to 0.34) <0.001
ACQ Q7 FEV1 in % predicted 92.7 91.9 0.83 (−1.05 to 2.72) 0.39
in l/min 3.16 3.13 0.03 (−0.03 to 0.09) 0.35
#  The total score is the mean of all 7 questions divided by seven. Each individual ACQ question (Q1-Q7) 
ranges between 0 and 6.
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Figure 6.2. Bland Altman plot showing the 
average scores of the online self-administered 
and interviewer-administered ACQ plotted on 
the x-axis against the difference between both 
results on the y-axis. The mean difference be-
tween the versions was 0.14. The predefined 
limits of sufficient agreement between both 
versions were the minimal important difference 
(MID) at +0.5 and −0.5 (dotted lines). The limits 
of agreement (±2 SD) are also shown at 1.14 
and −0.86 (solid lines). Both limits of agreement 
lie outside the MID and therefore there is not 




This study shows that the level of current asthma control is influenced by the type of 
administration of the instrument to assess control status. More severe symptoms were 
reported with the online self-administered questionnaire than with the interviewer-
administered questionnaire by a PN based on patients’ responses. This difference is of 
particular relevance due to the increasing use of questionnaires in clinical practice [13] 
and the appearance of online self-management programmes for asthma [5,6]. These 
programmes adjust therapy based on the same cut-off points of asthma control as 
those used in conventional asthma management, which may lead to different treatment 
advice in 29% (95% CI 24.6% to 34.1%) of cases.
Strengths and limitations of the study
Since we included patients from both rural and urban areas with the full range of un-
controlled to well-controlled asthma and less than 1% of all eligible patients for the 
ACCURATE trial were excluded due to exclusion criteria other than age, the strength 
of our study is that the 351 patients included comprise a representative sample of 
adult asthma patients aged 18–50 years. Also, the interviewer-administered ACQs were 
assessed by PNs in 119 different general practices so selection bias seems unlikely. A 
limitation of our study is that the results may perhaps not be applied straightforwardly 
to patients aged >50 years who were excluded because of the increased prevalence 
of chronic obstructive pulmonary disease and fixed airways obstruction in this group. 
Furthermore, online self-administered versions were always completed before the 
interviewer-administered version, which might have introduced an order bias. However, 
an analysis of 68 patients who self-administered an online ACQ within one week after 
a trial-related visit and in whom no trial-related change in asthma medication was pre-
scribed confirmed the higher ACQ results in the online self-administered version (differ-
ence 0.17, 95% CI 0.04 to 0.29, p=0.01). The time difference between administrations of 
the two versions probably did not influence the results since the correlation analysis of 
difference in ACQ results and time between both administrations showed no significant 
association (r=0.03, p=0.54) (data not shown).
The online self-administered ACQ was used in a previous study [6] and validated 
in a preceding pilot study (which was not formally published). We showed that the 
repeatability was very good (intraclass correlation coefficient (ICC) 0.86) and the agree-
ment was also very good (ICC 0.88). The obtained validation sample of subjects was a 
relatively homogeneous population with low mean scores for the ACQ (0.60) and no 
high results. Even though the ICC of 0.88 is slightly below the required 0.9 for validation 
[3], we considered the online version validated since the ICC is highly dependent on 
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between-subject variability. In our population sample the between-subject variation 
was relatively low and, therefore, the ICC of 0.88 underestimates the actual agreement. 
On the other hand, assessment by a PN based on patient responses is a non-validated 
method of assessment, albeit widely used. Therefore, in the present study we compared 
a validated method of assessment with a non-validated method of assessment which 
could (partly) explain the difference in results.
Interpretation of findings in relation to previously published work
Two previous studies compared a postal-administered version of the ACQ with a version 
under guidance of a healthcare professional [8], and an electronic version with a paper 
self-administered version [7]. In both studies the ICC and Pearson’s correlation were high 
and paired t-tests showed no statistically significant differences. Juniper et al. selected 
a more homogeneous group of only patients with uncontrolled asthma, whereas we 
included patients with the full range of asthma control. Furthermore, in the same study, 
Juniper et al. did find a significant difference between the electronic and paper versions 
of two other questionnaires with a more favourable outcome (i.e. fewer symptoms) with 
the paper version [7]. Also, in these studies, all assessments of the ACQ were completely 
self-administered while in our study it was completed by the PN based on patients’ 
responses. Therefore, the actual person administering the questionnaire might explain 
the difference in ACQ results. In a review of different methods of administration of ques-
tionnaires, Bowling showed that patients reported more symptoms in self-administered 
than in interviewer-administered questionnaires in a number of fields of medicine, 
although not consistently [14]. For certain asthma symptoms, McDonald et al. recently 
showed that patients and healthcare professionals rate the importance differently [15]. 
Hence, the differences may be explained by a different interpretation of the question 
between patients and healthcare professionals, or PNs may weigh patients’ answers 
and score their own interpretation. Finally, patients may express their symptoms more 
freely online or under-report symptoms when answering a PN due to social desirability, 
a known phenomenon when assessing highly sensitive personal behaviour [16].
Several previous papers have shown that patients reported more symptoms in an online 
self-administered questionnaire than in a paper self-administered version [14,17,18], 
suggesting that the format of an online questionnaire might have an effect. However, 
this was not a consistent finding[14,18,19] and we also showed very good agreement 
between the online self-administered version and a paper self-administered version in 
our pilot study.
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Implications for future research, policy and practice
Our results suggest that, during face-to-face contact with a healthcare professional, on 
average, symptoms of asthma are reported as less severe than with self-assessment of 
symptoms when the same questionnaire (i.e. the ACQ) is used. It remains to be seen if 
asthma is better controlled if guided by online self-administered (risking overtreatment) 
or by healthcare professional-administered measurement scales (risking undertreat-
ment). In order to guide treatment by the level of asthma control, the type of assessment 
— even when using standardised tools — should therefore be taken into account.
Our study also underscores the relevance of validating new methods of assessment 
of questionnaires before using them in clinical practice.
Conclusions
The level of asthma control measured by the ACQ depends on the type of administra-
tion. Symptoms of asthma are reported as less severe in the interaction with a healthcare 
professional compared with online self-assessment at home
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Assessment of asthma control: aim, parameters and cost-effectiveness
The aim of asthma management
In the presented ACCURATE trial in chapter 4 one of the main research questions was to 
identify the optimal aim of asthma management in primary care, with regard to control 
of asthma symptoms. Current guidelines suggest to aim for controlled asthma and to 
consider increasing treatment when asthma is partly controlled [1-5]. However, aiming 
for controlled asthma can lead to high doses of daily medication and associated costs 
and a less stringent aim, such as partly controlled asthma, might better balance pros and 
cons. Therefore, we assessed whether a strategy aimed at partly controlled asthma, in-
stead of controlled asthma, proved superior when comparing cost-effectiveness, clinical 
outcomes and patient preferences. Our results showed that aiming for partly controlled 
asthma is similar to aiming for controlled asthma in terms of asthma control, quality of 
life, asthma exacerbations and patient preferences, while it reduced asthma medication 
use and costs. The reduction in asthma medication prescription was achieved by both 
reducing the frequency that treatment was stepped-up during control visits (39% vs 
20%, respectively for Controlled asthma (Ca)-strategy vs Partly Controlled asthma (PCa) 
strategy) and by increasing the frequency of stepping-down treatment (30% vs 37%, re-
spectively for Ca vs PCa). As stated before, the currently recommended aim of guidelines 
is controlled asthma [1-5]. We showed that if we maintain this aim, instead of accepting 
both controlled and partly controlled asthma, it will lead to similar clinical outcomes, 
but at a higher treatment burden and associated costs, which effectively results in many 
patients being over treated in primary care. A possible explanation is that most trials 
have been performed in secondary or even tertiary care centers. In general, patients 
in these centers have more severe asthma, therefore more room for improvement and 
so they may benefit more from treatment. When management aims based on these 
secondary care studies are applied to primary care, where patients generally have less 
severe asthma, the risk of overtreatment ensues, with associated increased costs and 
side-effects such as cough, pneumonia and adrenal insufficiency. [6-8] Although this 
may appear surprising, a likewise development was seen in the last decade for another 
major non-communicable disease, diabetes. In the management of diabetes several 
more recent trials have assessed aiming for strict glycemic control (HbA1C <6%), i.e. 
achieving completely normal glycemic levels, similarly to the concept of total control/
no symptoms of asthma [9-11]. Although normoglycemia could be achieved and led to 
lower diabetes related cardiovascular complications, the resulting side-effects such as 
hypoglycemia led to significant morbidity and some subgroups even had higher mortal-
ity rates than the group aiming for less stringent control. In diabetes management this 
has led to a less stringent aim for most of the patients with diabetes (HbA1C<7%) and 
additionally different aims for certain subgroups. By aiming for partly controlled asthma 
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instead of controlled asthma, a similar transition could occur in primary care asthma 
management.
The use of FeNO in the assessment of asthma control
When treatment decisions are based on levels of asthma control, it is very important 
what kind of instruments are used to define asthma control. Using a composite control 
score, such as the ACQ7, has the advantage of providing one single score which can 
be monitored over time. Furthermore, it takes into account asthma symptoms, limita-
tions in activity, quick reliever use and lung function in one measurement. However, 
it is a ‘one size fits all’ approach and disregards (subtle) differences in disease severity 
on the separate domains between individuals with asthma. Also, if asthma symptoms 
and lung function show conflicting results when assessing current control on asthma, 
some debate on whether asthma is sufficiently controlled or not remains. Although 
clinical symptoms are currently considered to be more important than lung function, it 
may still confuse the physician when these two markers contradict each other. Further-
more, both of these markers give no direct information on inflammation, which is the 
underlying central process to airway obstruction, hyperresponsiveness and symptoms. 
Additionally, airway inflammation is the target of inhaled corticosteroids, the most 
important type of medication in asthma. Therefore, we chose to evaluate a third marker 
of asthma control that could give an indication of airways inflammation, and could aid 
decision making when the conventional markers contradict each other. The measure-
ment of the biomarker Fractional exhaled Nitric Oxide (FeNO) has this potential, since 
it is a non-invasive measure of airways inflammation in exhaled breath. In Chapter 3 we 
showed in a cross-sectional analysis that FeNO-results are non-concordant with either 
lung-function or symptoms. Therefore, it might have the potential to serve as adjunct to 
conventional markers of asthma control, especially since in 46% of asthma control as-
sessments the results of symptoms and lung function are conflicting. Additionally, FeNO 
showed a different level of control than the other, conventional, markers in another 28% 
of cases. The relevance of these results is that we can conclude that FeNO has no strong 
correlation with any of the conventional markers. If that had been the case, additionally 
using FeNO would give no clear benefit over conventional markers of asthma control. 
However, these results give no clear indication of an actual benefit of using FeNO, since it 
could also point towards FeNO being an inadequate marker of asthma control. Therefore 
a longitudinal assessment, using FeNO as an additional marker of asthma control, was 
required to assess whether FeNO has added value, which is partly why we performed the 
ACCURATE study described in Chapters 2 and 4.
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FeNO in therapy decision making
Other than serving as an additional marker of asthma control, another benefit of FeNO 
could be to guide the decision between different types of asthma medication. Currently 
commonly prescribed asthma maintenance medications in primary care are inhaled 
corticosteroids (ICS), long-acting beta agonists (LABA) and leukotriene modifiers (LTRA). 
Guidelines recommend a stepwise increase or decrease in medication [1-4]. The first 
step is to start with solely short-acting beta-agonists (SABA), in the second step ICS 
or LTRA are added to SABA. The third step has a wider range of options: either ICS is 
increased, or LABA is added to ICS or LTRA, or ICS and LTRA are combined, or a patient 
could additionally start using theophylline [2]. There is little or no evidence that one type 
of maintenance therapy is clearly superior over another, especially in the second and 
third treatment steps, which are predominant in primary care. Since FeNO is a marker 
of airways inflammation, it could help distinguish between patients requiring therapy 
aimed at reducing inflammation (i.e. ICS or LTRA) and patients requiring symptom relief 
(i.e. LABA). Therefore, the second main research question of the ACCURATE trial aimed 
to identify the usefulness of additionally measuring FeNO in therapy decision making. 
Our results show that the FeNO-guided Controlled asthma strategy (FCa) , in contrast to 
the Controlled asthma (Ca) strategy, reduces asthma medication use. Asthma medica-
tion levels are reduced to a similar level, as is achieved by the Partly Controlled asthma 
strategy (PCa). However, it does so at significantly higher levels of asthma control in the 
FCa strategy than in the PCa strategy, indicating a more targeted use of asthma medica-
tion. The additional measurement of FeNO only led to a treatment advice that differed 
from that in the conventional Ca strategy, when FeNO was considered low (<25 ppb) or 
high (>50 ppb). This was the case in 77% of treatment advices in the FCa-strategy. The 
additional benefits of a FCa strategy could be further improved if patients that have a 
stable intermediate FeNO score could be identified in advance and subsequently treated 
according to either the Ca or the PCa strategy, without the need to reassess FeNO.
Several other trials have shown conflicting results on the use of FeNO, such as an 
increase in ICS dosage [12-14], or no differences in asthma medications [15]. There are 
a number of explanations for these differences. First, in our study, we used the cut-off 
point of a FeNO outcome of 50 parts per billion to increase treatment, which was recently 
assessed as the most appropriate cut-off point [16]. This is relatively high compared to 
the cut-off points used in research in earlier stages of FeNO’s development. Second, 
we decided to include smokers in our study, and adjusted FeNO results for smoking, 
whereas smokers were usually excluded in other studies [12-14]. Third, patient adher-
ence might be higher if an additional, new measurement is performed, although results 
from the medication adherence questionnaire (MARS) [17] in our study do not support 
this theory. Fourth, in our study FeNO was used as an adjunct to conventional mark-
ers, whereas previous studies often assessed FeNO versus these conventional markers. 
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Fifth, in our FCa strategy several possibilities to step-down treatment were built into 
the algorithm (as well as step-up options) in contrast to various previous studies where 
the algorithm was mostly driven towards keeping medications levels similar or towards 
higher use of medication [12,13]. The final advantage of our FCa strategy was that it led 
to a different treatment approach for a specific subgroup of patients that tend to be 
overtreated when using solely symptoms and lung function measurements to deter-
mine current control on asthma [18]. Haldar et al. identified this subgroup of patients, 
who continuously experience uncontrolled asthma, due to consistently high levels of 
symptoms, while there is no concomitant airways inflammation. These high levels of 
symptoms will invariably lead to a step-up in treatment in both the Ca and the PCa strat-
egy, even though this will not reduce the experienced symptom load [18]. In contrast, 
the algorithm for treatment decisions in the FCa strategy added a FeNO measurement 
and if the FeNO result showed no signs of airways inflammation (i.e. FeNO<25), ICS use 
in these patients was down-titrated. In the ACCURATE study (chapter 4) 8.7% of par-
ticipants in the FCa strategy belonged to this subgroup (defined as those patients that 
scored ‘uncontrolled asthma’ according to symptom and lung function measurements 
(ACQ>1.5), while FeNO was low (FeNO<25), in ≥50% of all assessments). Therefore, for 
8.7% of participants, the FCa strategy led to an opposite treatment advice compared 
to the PCa and Ca strategy, safely down-titrating medication instead of increasing it. 
Consequently, we can conclude that the addition of FeNO in the assessment of current 
asthma control results in a targeted, more individualized, approach to asthma medica-
tion therapy.
Cost-effectiveness
With ever increasing healthcare costs, treatment should provide value for money and 
therefore studies on management of disease should be accompanied by an economic 
evaluation. To this purpose we calculated the societal costs per Quality-Adjusted Life 
Year (QALY) gained for each of the three strategies in the ACCURATE trial. This allowed a 
direct comparison of costs and utilities between the three strategies. Furthermore, since 
point estimates of costs and utilities are rather uncertain we used the net benefit ap-
proach, which allowed us to give a probability of cost-effectiveness at different societal 
Willingness-To-Pay (WTP) levels for one QALY [19].
Our cost-effectiveness acceptability curve (figure 4.2, chapter 4) shows that a 
strategy additionally guided by FeNO has the highest probability of cost-effectiveness 
throughout a wide range of WTP levels. At the commonly cited threshold of €40.000 
per QALY per year [19] the FeNO guided strategy had a probability of 83% of being the 
most cost-effective strategy. Some issues regarding this result need to be addressed. 
First, the costs for the use of FeNO were based on the use of a specific sensor that can 
perform a maximum of 100 measurements, which is the most expensive version. For 
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an individual general practice this is the most realistic sensor. However, for spirometry 
and blood sampling, conglomerates of general practitioners nowadays employ specific 
organisations or companies to perform these measurements. These organisations or 
companies could also perform FeNO-measurements and upscale to cheaper sensors 
with 1000 measurements, which would further reduce costs. Second, the only clear 
conclusion that can be drawn is that the FeNO guided control strategy is the most likely 
to be cost-effective. Which strategies come second and third is hard to say due to the 
design of this overall analysis. It seems that the PCa strategy performed worst. However, 
the PCa strategy performed better than the Ca strategy with regard to costs. Thus, in a 
direct comparison between the two, the PCa strategy would have a higher probability 
of cost-effectiveness. However, since the costs in the FCa strategy were even lower, this 
effect is nullified by the FCa strategy when analyzing all three together. Third, even 
though a 83% probability of cost-effectiveness is high and the differences in costs be-
tween the strategies are quite substantial, both the direct comparison in utilities and in 
costs showed no significant differences between the strategies, other than significantly 
lower asthma medication costs. These non-significant results can partly be ascribed to 
the wide confidence intervals in the different assessments of costs, which is inherent 
to this type of research and further increased in our study by the large heterogeneity 
in patient characteristics in this pragmatic trial. Fourth, since costs in primary care are 
generally low, results can be substantially influenced by outliers. However, by using a 
non-parametric bootstrap estimation with 5000 random samples and subsequently ap-
plying the net benefit approach we tried to minimise this effect. The reduction in asthma 
medication use, the similar levels of asthma control and quality of life, and the high 
probability of being the most cost-effective strategy, all suggest that the FCa strategy is 
the superior strategy and therefore a FeNO-measurement deserves to be implemented 
as an adjunct in the management of asthma in primary care.
Secondary outcomes of the ACCURATE trial
The primary outcome of the ACCURATE trial was the comparison of cost-effectiveness 
of the three strategies and our study was powered using these parameter. However, to 
decide on an optimal management strategy for asthma in primary care, other outcomes 
are important as well. Therefore, we also assessed current asthma control, patient prefer-
ences, asthma related quality of life and severe exacerbation rate. It is important to note 
that we observed no differences between the strategies for most of these outcomes, and 
that the magnitudes of even the statistically significant differences were small and of 
limited clinical relevance. On the other hand, we found that in all strategies participants 
had improved asthma control when comparing baseline values to results at twelve 
months. Furthermore, differences within a strategy (from baseline to 12 months) were 
usually higher than differences between strategies (at a certain point). The similarity of 
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improvement from baseline parameters in the three strategies can partly be ascribed 
to so-called regression to the mean, especially since participants had worse baseline 
asthma control than non-participants (chapter 4, Table 4.E2). Another explanation is that 
most likely in all three strategies patients were being more regularly assessed and treated 
than before the study. Two recent large primary care studies regarding the treatment 
of patients with mild to moderate asthma, showed no significant differences between 
different treatment strategies in multiple outcomes. However, similarly to our results, 
patients had improved compared to baseline [15,20]. Therefore, for patients with mild to 
moderate asthma the most important aspect of asthma management might be regular 
monitoring, which in itself has the largest effect on the improvement of asthma control. 
In addition to regular monitoring, distinctive asthma management strategies are likely 
to lead to only small fine-tuning effects on asthma management, rather than causing 
drastic effects on asthma control, patient preferences, quality of life and exacerbations.
With regard to patient preferences, there were no clear differences between the 
strategies, as measured by several questionnaires. On individual level though, when 
assessed with the Beliefs about Medication Questionnaire (BMQ) [21], some patients 
preferred remaining on the safe side and minimising the risk of exacerbations and loss 
of control, thereby risking overtreatment, while other patients preferred to minimise 
medication usage and side-effects. Assessing these preferences regularly in individual 
patients and subsequently selecting the appropriate target of asthma control and con-
comitant medication usage based on these preferences, might greatly enhance patient 
satisfaction.
How to address future risk?
Written Asthma Action Plans
In addition to measuring markers which indicate current asthma control, an asthma 
control assessment should also include measurements enable the prediction of the risk 
of future adverse events [1-4, 22]. Currently the most commonly used method to predict 
future risk, is the exacerbation frequency in the past year. If patients are defined as be-
ing at risk, controller-therapy can be increased as a preventive measure, which should 
reduce the chance of experiencing an exacerbation [22]. An alternative approach to 
predict future risk and subsequently minimise the chance of future exacerbations, is 
providing these patients with a Written Asthma Action Plan (WAAP). In a WAAP patients 
report their symptoms and/or lung function on a regular basis (daily/weekly) and re-
ceive feedback when control on asthma is deteriorating or an asthma exacerbation is 
imminent. The advantage of this approach over increasing asthma controller therapy, 
is that medication is only increased when asthma control of that person is actually de-
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teriorating. To adequately detect imminent exacerbations and simultaneously prevent 
unnecessary overtreatment when no exacerbation is imminent, the level of symptoms 
and/or lung function at which feedback is given to the patient, is of vital importance. 
This threshold level is called an Action Point and in our study we assessed the optimal 
characteristics of the Action Point that advices to start oral corticosteroids or to imme-
diately visit your GP/pulmonary physician. Previous research on optimal Action Points 
mainly assessed the sensitivity and specificity of predicting exacerbations [23-26]. We 
added two additional analyses in our research in Chapter 5. First, the (potential) Number 
Needed to Treat (NNT), which assessed how often an Action Point gives a false positive 
signal for each correctly identified imminent exacerbation. Second, we analysed all the 
daily results in the week before an exacerbation and assessed when an Action Point was 
positive for the first time. This is an important measure because the higher the number 
of days between the positive signal of the Action Point and the start of the exacerbation, 
the more time a patient has to take appropriate measures.
We discerned four ways of identifying Action Points, based on the type of information 
used. For each of these ways, we defined the appropriate threshold(s) that indicated the 
optimal Action Points. The four ways and their optimal thresholds were:
– Solely symptoms: symptom increase > 2 standard deviations above mean symptom 
score (>2SD)
– Solely peak flow: below 60% of personal best value (<60% pb)
– Symptoms and peak flow: symptom increase >2SD and peak flow <70% pb
– Symptoms and peak flow within one week: symptom increase >2SD and peak flow 
<70% pb, occurring within 1 week from each other
Overall, the Action Point that combined a symptom increase of >2SD and a peak flow 
decline to <70% pb within one week performed best. It predicts an imminent exacerba-
tion 4.1 days before its occurrence, with a sensitivity of 85.1%, specificity of 97.2% and 
a number needed to treat (NNT) of 6. We also assessed the predictive characteristics of 
several Action Points that are currently advised by international guidelines. The NHLBI 
advises the use of ‘appearance of any symptoms plus peak flow <80%pb’, which resulted 
in a much higher NNT of 28 [1]. The British Thoracic Society uses a peak flow <60%pb, 
which performed really well with regard to sensitivity, specificity and NNT, but its main 
disadvantage was that it predictedan exacerbation only one day before its occurrence 
[4]. Several guidelines give no direction as to what an Action Point should consist of, 
and solely state a WAAP with Action Points should be used [2,3]. This leaves the choice 
of threshold values for Action Points to the discretion of the physician . Theoretically, a 
physician-driven Action Points might be superior to our optimal Action Point, since it 
can be individualised to the asthma exacerbation characteristics of a specific patient. 
However, by using standard deviations from a mean symptom score and percentages of 
personal best, our Action Points also include individualised measurements. Therefore, it 
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is unlikely a non-validated Action Point will perform better, especially since we further 
validated our optimal Action Points in a different dataset.
The most feasible Action Points are those that consist solely of symptom scores, since 
they require no additional measurements. Unfortunately these Action Points had the 
worst performance characteristics and led to a huge number of false positive signals. 
Therefore a measure of lung function should be included. If that is not feasible, it is 
probably better not to use a Written Asthma Action Plan, than to use one that is quite 
seriously flawed.
In a pen & paper WAAP, calculation of a combined Action Point with a one week 
time-window is complex and non-feasible and assessing a mean symptom score and 
standard deviations similarly requires difficult calculations. Fortunately, there are now 
online self-management programs and mobile phone application (Apps), that can 
do the necessary calculations automatically. Another common problem with using a 
WAAP is patient non-adherence to filling in diary recordings. Apps could also improve 
this, by using automatic reminders when patients forget to fill in questions. However, 
even when using an App, patients still need to perceive enough benefit compared to 
all the effort required. Especially, if an Action Point with a peak flow measurement is 
used, which requires patients to have a peak flow device available when filling out the 
questionnaire. Therefore, the most feasible solution will be to prescribe a WAAP only 
to patients with a high risk of asthma exacerbations, those with a very severe course of 
previous exacerbations, or those keen on self-management.
Online assessment of current asthma control
In the management of chronic non-communicable diseases validated questionnaires 
play a pivotal role to monitor disease status. Usually patients visit their physician or 
practice nurse and fill in these questionnaires preceding or during the consultation 
visit. In recent years we have seen the advent of online self-management programs. 
In those programs patients fill in a questionnaire online and sometimes even receive 
immediate feedback without intervention of their physician or practice nurse [27-29]. 
In online asthma self-management programs, the Asthma Control Questionnaire (ACQ) 
by Juniper is a frequently used questionnaire [30]. The ACQ was originally designed and 
validated to be self-administered under guidance of a healthcare professional. There-
fore, even though the questions are exactly the same, when the ACQ is used online, this 
represents a different method than it was originally validated for. Of course this issue 
arises with many other questionnaires in online programs. In Chapter 6 we showed that 
when patients fill out an online questionnaire at home they report significantly more 
symptoms than when the ACQ is assessed by a practice nurse. Previous research on 
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questionnaires for certain psychiatric disorders also showed that patients report more 
symptoms in self-administered than in interviewer-administered questionnaires [31-
33]. Possibly patients express their symptom frequency and severity more freely during 
self-administration than when talking with a healthcare professional, especially in an 
online format. It seems preferable that a patient expresses his symptoms as freely as 
possible, because that gives the clearest indication of the burden of the disease for that 
patient. That would indicate a preference for the use of self-administration. However, 
the problem of validation remains. If non-validated online versions of questionnaires are 
used to guide treatment, and treatment decisions are based on the same cut-off points 
as are used in (interviewer-administered) validated versions, the possibility of overtreat-
ment looms large. Therefore, even though self-management and online assessment is 
the way forward, we should remain vigilant and validate new types of administration of 
questionnaires.
Directions for future research
Research in primary care
The results of our ACCURATE trial described in chapters 2 and 4 showed different results, 
with regard to levels of asthma control, exacerbation frequency, the use of FeNO and 
asthma related quality of life, in comparison to previous research [5,6,12-14, 22-26]. 
An important aspect explaining at least part of these differences in results, seems to 
be related to the choice of study population. The ACCURATE trial was a pragmatic trial, 
performed in primary care and included a wide variety of patients in the full range of 
asthma control, from both rural and urban areas and even including smokers. In contrast, 
a large proportion of previous research was performed in secondary or tertiary care 
centers, on selected subsets of patients, even though in the United States only roughly 
10% of all patients are treated in secondary care and less than 1% in tertiary care [34,35]. 
Since the healthcare system in the Netherlands is more oriented towards primary care, 
these percentages may be even lower in the Netherlands. While most clinical guidelines 
assume that results from studies in secondary or tertiary care centers can be applied 
to all patients with asthma, it is quite likely they can not, as the disease spectrum of 
patients in primary care may differ strongly from those in secondary and tertiary care. 
Since the majority of patients with asthma, and of most other diseases for that matter, 
are being treated in primary care, future research should be aimed at performing more 
large pragmatic trials in primary care, with as few in- and exclusion criteria as possible.
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Phenotypes of asthma
In our trial described in Chapters 2 and 4, participants were randomised to have their 
treatment goals set at either ‘partly controlled asthma’, ‘controlled asthma’, or ‘FeNO 
guided controlled asthma’. We showed that in general, FeNO guided controlled asthma 
is preferable, followed by partly controlled asthma. However, subgroups of patients may 
benefit from more stringent control on asthma, for example those with more frequent 
exacerbations. Therefore, future research should focus on the optimal aim of asthma 
management for subgroups of patients with different clinical phenotypes of asthma. 
Additionally, future research should take into account personal preferences regarding 
medication usage, side-effects, risks of asthma exacerbations and goals for asthma 
treatment. Also, according to our study algorithm, management decisions were the 
same for the FCa and the Ca strategy, if the FeNO score was intermediate (i.e. between 
25-50). Therefore in future research, patients with a stable intermediate FeNO score, may 
be managed without continuation of FeNO, since it is a costly measurement, which has 
no added value for these patients. Furthermore, in our research we decided to measure 
FeNO at every visit, independent of previous FeNO scores, current asthma control and 
current medication usage. Possibly, in the management of asthma, FeNO could be 
measured less often, and future research should identify the optimal frequency of as-
sessment. Another alternative use of FeNO would be as a diagnostic tool, to determine 
an individual patient’s asthma profile. Future research should analyse whether FeNO 
has the potential to differentiate between phenotypes of asthma, similarly as another 
inflammometer, the enose, has been used for that purpose in COPD [36].
Action Points
In chapter 5 we showed the best Action Point for Written Asthma Action Plans (WAAP). 
That Action Point requires calculations that are nearly impossible to implement in a pen 
& paper WAAP. Therefore future research should focus on creating and using online plat-
forms and IT-solutions for measurements and calculations. The feasibility of the use of a 
WAAP may be further increased by peak flow measurement devices that can automati-
cally communicate with the patient’s smartphone or be inserted into it (for example, My 
Spiroo-device, www.myspiroo.com). Alternatively, intelligent inhalers with sensors that 
automatically register peak flow (derivatives) while inhaling may signal the smartphone 
when medication is forgotten (for example smartinhalers, www.smartinhaler.com).
A WAAP normally contains several different Action Points in an increasing order of 
disease severity. The first warns patients, because they are experiencing more symptoms 
than normal. The second indicates a loss of control on asthma and advices to temporarily 
step-up ICS treatment. The third indicates an exacerbation is imminent and that a pa-
tient should take immediate action, such as starting oral corticosteroids, or immediately 
visit a GP/Pulmonary physician. In our study in Chapter 5 we have assessed the optimal 
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threshold levels for the third type of Action Point. Future research should assess the op-
timal thresholds for the other two types of Action Points. This future research will require 
a different balance between accuracy and NNT for each type of Action Point, since a false 
positive signal in an Action Point that solely gives a warning, is less detrimental than 
when it results in a course of oral prednisone.
Future research into different Action Points should also take into account that the 
level of asthma control may differ, depending on which criteria you use. As we showed 
in chapter 3, symptoms and lung function result in a different level of control in almost 
half of the patients. Individualised WAAPs might therefore be improved if FeNO would 
be included as an additional home monitoring device, although this will only be feasible 
if FeNO measurements will become a lot cheaper in the future.
Conclusion
In conclusion, we have provided the optimal Action Point for an (Written) Asthma Action 
Plan, which new Action Plans should incorporate. We also showed the disadvantages 
of copying questionnaires to a new format without proper validation and physicians 
should be aware of these differences when using new formats of questionnaires. Finally, 
we have shown that accepting ‘partly controlled asthma’ may be a strategy that is supe-
rior to aiming for ‘controlled asthma’. In addition, we have demonstrated the benefits 
of the additional use of a FeNO-measurement in asthma control assessments. For adult 
patients with asthma in primary care, our results should lead to the implementation of 
FeNO as an aid in the assessment of current control on asthma and to guide asthma 
therapy choices. If a FeNO measurement is not yet available, aiming for partly controlled 
asthma is a worthy alternative.
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This thesis aimed to contribute to the improvement of several components of the 
management of asthma in primary care. The main part of this thesis consists of the AC-
CURATE trial. In this trial we compared three different management strategies for adult 
patients with asthma in primary care. In the first management strategy, we targeted 
‘Controlled asthma’, which is the currently recommended aim in clinical guidelines. 
‘Controlled asthma’ means patients should experience hardly any symptoms of their 
asthma. A downside of this strategy is that it usually requires relatively high doses of 
medication. The second management strategy, targeted ‘Partly Controlled asthma’ and 
in this strategy some symptoms were allowed. This should lead to a lower requirement 
to step-up treatment in response to symptoms, which would lead to less medication 
usage and thus less side-effects. The third management strategy evaluated the use of 
adding a measurement of Fractional exhaled Nitric Oxide (FeNO), a possible indicator 
of airways inflammation. In the other two strategies, assessment of current control on 
asthma, was based on the conventional markers lung function and symptoms. Adding 
FeNO could aid in assessing current control and help guide therapy choices. In order to 
establish the best management treatment strategy, we assessed as many relevant indi-
cators as possible. Therefore we not only assessed clinical parameters, such as asthma 
control and exacerbations, but we also assessed the societal perspective, by performing 
a cost-effectiveness analysis and the patient’s perspective by measuring relevant issues 
such as quality of life and adherence. The conclusions from our trial can be summarized 
as follows:
• From a societal perspective, as well as a patient’s and a clinical perspective, a symp-
tom- plus FeNO-driven strategy is the preferred management strategy for adult 
asthma patients in primary care.
• Treatment aimed at ‘FeNO guided Controlled asthma’ improves asthma control with 
a high probability of cost-effectiveness and without increasing medication use and 
costs compared to aiming at ‘Partly Controlled asthma’.
• Treatment aiming at ‘Controlled asthma’ leads to increased asthma medication use 
and costs, without a significant improvement in asthma control, quality of life or 
exacerbation rate, compared to aiming at ‘Partly Controlled asthma’ or to aiming at 
‘FeNO guided Controlled asthma’.
• FeNO shows a weak correlation with respiratory symptoms and lung function
• If FeNO is incorporated as a marker of asthma control in primary care, it enables 
‘fine-tuning’ when categorizing asthma control in almost half of the patients
Additionally we performed two other studies. In the first study, we aimed to improve the 
usefulness of asthma action plans. In an asthma action plan a certain threshold level of 
symptoms or peak flow is defined, called an Action Point. If a patient’s symptoms or peak 
flow exceed that threshold level, the patient is advised to take immediate action. Usually 
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there are several different Action Points within one asthma action plan, each with their 
own threshold levels and with different actions to be taken. The most important Action 
Point is the one that indicates a severe exacerbation is imminent and advises to start 
oral corticosteroids or immediately visit a physician/hospital. In our study we aimed to 
identify the best threshold-levels for this Action Point. In order to decide the best thresh-
old levels it is important that they provide a good sensitivity and specificity with regard 
to detecting exacerbations. Furthermore, it is also important that an exacerbation is 
detected well in advance to allow appropriate treatment. Finally, it is also important 
that an Action Point has a low Number Needed to Treat, since false positive predictions 
will result in over treatment. Our results show that the optimal action point for the early 
detection of asthma exacerbations consists of two components:
• A ≥2 standard deviations increase in a composite symptom score from a mean 
symptom score acquired during a baseline, combined with a fall in PEF to <70% of 
personal best, both occurring within a one week window.
This Action Point detected exacerbations 4.1 days before occurrence, with a sensitivity 
of 85.1%, specificity of 97.2% and a number needed to treat (NNT) of 6.
Finally we explored the potential hazards of using a questionnaire in a different set-
ting than it was originally validated for. To this purpose we compared the results of an 
assessment of the Asthma Control Questionnaire online, with the results of that same 
questionnaire assessed by a practice nurse together with the patient. Both question-
naires were completed within one week of each other. We concluded that:
• Assessment of asthma control by the Asthma Control Questionnaire is influenced 
by the type of administration. Control over asthma symptoms is perceived as higher 






Astma is een veel voorkomende chronische aandoening van de luchtwegen. De ken-
merkende klachten zijn periodes van kortademigheid en een piepende ademhaling. 
Deze klachten zijn bij de meeste astmapatiënten niet continu aanwezig: astma kenmerkt 
juist zich door periodes van veel klachten afgewisseld met periodes van amper tot geen 
klachten. Daarnaast kunnen astma patiënten acuut (heel) ernstig kortademig worden. 
Dit wordt een astma-aanval of ‘exacerbatie’ genoemd. De klachten van astma worden 
veroorzaakt door een vernauwing van de luchtwegen, waardoor het moeilijker wordt 
om in en uit te ademen. Deze vernauwing is weer het gevolg van een chronische ontste-
kingsreactie in de luchtwegen. Deze ontsteking wordt niet veroorzaakt door bacteriën 
of virussen, maar is het gevolg van een reactie op allerlei allergische en niet-allergische 
prikkels in de lucht, zoals huisstofmijt, haren van huisdieren, pollen, sigarettenrook en 
mist. Om de klachten van astma onder controle te krijgen is het daarom erg belangrijk 
deze prikkels zoveel mogelijk te vermijden. Stoppen met roken is daarbij de eerste stap. 
Daarnaast is het goed om te weten of iemand ergens allergisch voor is, zodat dit ook 
zoveel mogelijk gemeden kan worden. Ook bestaan er verschillende soorten medicij-
nen voor astma. De belangrijkste twee soorten zijn ‘ontstekingsremmers’ en ‘luchtweg-
verwijders’. Ontstekingsremmers richten zich op het onderliggende ontstekingsproces 
en proberen dit proces  zoveel mogelijk te verminderen, terwijl luchtwegverwijders de 
luchtwegen open zetten. Mensen met astma merken vrijwel direct het nut van lucht-
wegverwijders en geven daarom vaak de voorkeur aan deze medicijnen. Het bestrijden 
van de onderliggende ontsteking is echter minstens net zo belangrijk.
Controle over astma in de huisartsenpraktijk
Om astma goed te kunnen behandelen en de klachten goed onder controle te houden, 
is het de bedoeling dat patiënten regelmatig voor een consult langskomen bij de huis-
artsenpraktijk. Tijdens dat consult wordt onder andere gevraagd naar het medicatie-
gebruik en naar de klachten die astma geeft, soms aan de hand van een vragenlijst. 
Daarnaast wordt er vaak ook een longfunctie-meting verricht. Tezamen geven deze 
metingen een beeld van hoeveel last iemand van zijn astma heeft. In de behandeling 
van astma gebruiken we hiervoor de term mate van controle over astma. In principe 
is het natuurlijk de bedoeling dat iemand geen of zo min mogelijk klachten heeft van 
zijn astma, ofwel ‘goed gecontroleerd’ astma heeft. Daarnaast bestaat er ook ‘voldoende 
gecontroleerd’ astma, waarbij een patiënt enige klachten van zijn astma ervaart, en 
‘slecht gecontroleerd’ astma, waarbij een patiënt veel klachten van zijn astma ervaart. 
Uit eerdere onderzoeken is gebleken dat goed gecontroleerd astma voor de meeste 
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patiënten een haalbaar doel is. Er zit echter wel het nadeel aan dat de meeste patiënten 
(hele) hoge doseringen medicatie moeten gebruiken om goede controle over astma te 
krijgen en sommigen hebben zelfs een kuur prednison nodig. Hoge doseringen medica-
tie geven een verhoogd risico op bijwerkingen en brengen hoge kosten met zich mee. 
Het is mogelijk dat streven naar voldoende controle in plaats van naar goede controle 
een betere afweging geeft tussen de klachten van astma zo goed mogelijk onder con-
trole houden enerzijds versus bijwerkingen en kosten anderzijds. In hoofdstuk 2 en 4 
hebben we daarom deze twee streefdoelen, ‘goede controle’ en ‘voldoende controle’, 
met elkaar vergeleken.
In hoofdstuk 4 wordt ook nog een derde streefdoel geanalyseerd en dat is ‘goede 
controle met behulp van een Fractional exhaled Nitric Oxide (FeNO) meting’. Om het 
nut hiervan uit te leggen is het belangrijk terug te gaan naar het consult bij de huisart-
senpraktijk. Tijdens dat consult wordt gevraagd naar klachten, deze zeggen iets over de 
hinder die een patiënt ervaart, en wordt de longfunctie gemeten, en dat geeft een beeld 
van de ernst van de vernauwing van de luchtwegen. Zoals gesteld in de inleiding speelt 
echter ook het ontstekingsproces in de longen een belangrijke rol in de ontwikkeling 
van klachten en zowel klachten als longfunctie geven onvoldoende aanwijzing over hoe 
ernstig het gesteld is met dat onderliggende ontstekingsproces. Een FeNO-meter is een 
apparaat dat de concentratie van stikstof monoxide in de uitgeademde lucht meet. Uit 
eerdere onderzoeken is gebleken dat dit mogelijk aanvullende informatie geeft over 
de mate van ontsteking in de luchtwegen. In hoofdstuk 3 hebben wij eerst gekeken 
of deze FeNO-meting inderdaad aanvullende informatie geeft. Hiervoor hebben wij 
de klachten, longfunctie en FeNO uitslagen van 307 volwassen astma patiënten met 
elkaar vergeleken. Als maat voor de ernst van de klachten werd gebruikt gemaakt van 
de Asthma Control Questionnaire (ACQ), een vragenlijst bestaande uit 6 vragen over 
de ernst van de astmaklachten. Voor de longfunctie uitslagen werd gebruikt gemaakt 
van een spirometer. Dit is een apparaat waarin een patiënt op bepaalde manier moet 
uitblazen en de uitslagen geven informatie over de longinhoud en de doorgankelijkheid 
van de luchtwegen. Uit het onderzoek in hoofdstuk 3 bleek dat de uitkomsten van de 
klachtenvragenlijst ACQ en van de longfunctie in 46% van de gevallen tegenstrijdige 
informatie gaven. De vragenlijst over ervaren klachten gaf dan bijvoorbeeld aan dat 
iemand weinig of geen klachten ervaart, terwijl de longfunctie meting liet zien dat de 
luchtwegen sterk vernauwd zijn. FeNO kan in dat geval van aanvullende waarde zijn. In 
nog eens 28% van de gevallen gaf FeNO een ander signaal dan zowel de klachten als de 
longfunctie. Als de FeNO meting verhoogde ontstekingswaardes laat zien, terwijl zowel 
longfunctie als de klachten vragenlijst aangeven dat astma goed onder controle is, kan 
FeNO als waarschuwing dienen dat er mogelijk meer klachten kunnen gaan komen in de 
toekomst. Aan de andere kant kan FeNO mogelijk richting geven in de medicatie keuze 
als er weinig of geen onderliggende ontsteking is, maar patiënten wel veel klachten en 
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een slechte longfunctie hebben. In dat geval zal een patiënt meer baat hebben bij de 
luchtwegverwijdende medicijnen, dan bij ontstekingsremmers. In hoofdstuk 4 hebben 
we vervolgens de uitkomsten van ‘goede controle met behulp van een FeNO meting’ 
vergeleken met de eerdergenoemde streefdoelen ‘goede controle’ en ‘voldoende con-
trole’.
We hebben voor de vergelijking van de drie streefdoelen 611 volwassen astma pa-
tiënten tussen de 18-50 jaar uit 131 verschillende huisartsenpraktijken gedurende een 
jaar gevolgd. Via loting werden alle huisartsenpraktijken samen met de deelnemende 
patiënten, verdeeld over de drie verschillende behandel streefdoelen. Alle patiënten 
van één huisartsenpraktijk hadden dus hetzelfde streefdoel. De patiënten kwamen 
vervolgens elke drie maanden langs bij de praktijk, in de meeste gevallen bij de prak-
tijkondersteuner. De ernst van de klachten werd gemeten met de ACQ vragenlijst, 
de huidige medicatie werd vastgesteld, er werd een longfunctietest verricht en in de 
FeNO groep werd ook een FeNO meting verricht. De praktijkondersteuner vulde al 
de uitslagen in een internetprogramma in, waarna automatisch een behandeladvies 
volgde dat gebaseerd was op het streefdoel van die patiënt en ook rekening hield met 
de huidige medicatie. De verschillen tussen de drie behandelstrategieën waren dat: bij 
‘goede controle’ de medicatie werd opgehoogd tot goede astma controle was bereikt; 
bij ‘voldoende controle’ de medicatie alleen werd opgehoogd bij slechte astma controle 
en geprobeerd werd de medicatie te verminderen bij goede astma controle; bij ‘goede 
controle m.b.v. FeNO’ de uitslag van de FeNO meting mede bepalend was voor de keuze 
om wel of niet de medicatie op te hogen of te verminderen en daarnaast een leidende 
rol had in welk soort medicijn (luchtwegverwijders of ontstekingsremmers) werd gege-
ven. De belangrijkste uitkomsten van het onderzoek waren de volgende:
– Er was geen significant verschil in (astma-gerelateerde) kwaliteit van leven, therapie-
trouw en aantal ernstige astma-aanvallen tussen de drie strategieën
– Streven naar ‘voldoende controle’ zorgt ervoor dat patiënten minder medicatie ge-
bruiken en dat de kosten lager zijn dan bij het streven naar ‘goede controle’, zonder 
dat dit ervoor zorgt dat een patiënt meer klachten ervaart
– Ook streven naar ‘goede controle m.b.v. FeNO’ leidt tot minder medicatie gebruik en 
lagere kosten dan streven naar ‘goede controle’
– Streven naar ‘goede controle m.b.v. FeNO’ leidt daarnaast tot significant minder 
symptomen van astma dan streven naar ‘voldoende controle’
– Streven naar ‘goede controle m.b.v. FeNO’ is het meest kosteneffectief
Wanneer alle uitkomsten van het onderzoek samen worden genomen blijkt dat de beste 
behandelstrategie van astma in de huisartsenpraktijk degene is waarbij gestreefd wordt 
naar goede controle met behulp van een FeNO meting. Het is de meest kosteneffectieve 
manier om astma te behandelen en het leidt tot het minste medicatie gebruik, terwijl 
astma wel goed onder controle blijft. Dit wijst er op dat de astma-medicatie gerichter 
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wordt gebruikt. Het streefdoel ‘goede controle m.b.v. FeNO’ moet dan ook ingevoerd 
gaan worden in de dagelijks praktijk. Aangezien een apparaat om FeNO te meten nog 
niet overal beschikbaar is, is een goed alternatief om te streven naar ‘voldoende controle’ 
zonder FeNO-meting. Ook bij deze strategie is er duidelijk minder medicatie nodig dan 
bij de huidig gangbare ‘goede controle’, terwijl de controle over astma niet verminderd.
Astma-aanvallen
Naast het behouden van controle over astma is het bestrijden en voorkomen van 
astma-aanvallen een van de belangrijkste onderdelen van de behandeling van astma. 
Een astma-aanval leidt regelmatig tot ziekenhuisopnames, langdurig ziek thuis zijn en 
nog steeds sterven er jaarlijks zelfs nog mensen als gevolg hiervan, ook in Nederland. 
De mogelijke ernstige afloop van een astma-aanval en de impact die het heeft op de 
gezondheid, zijn redenen om mensen die frequente of ernstig verlopende astma-
aanvallen hebben, extra goed in de gaten te houden. Daarom wordt hen vaak een 
astma-actie-plan meegegeven. In een astma-actie-plan wordt aan patiënten gevraagd 
om regelmatig (liefst dagelijks) de ervaren klachten op te schrijven in een dagboek. In 
de modernere versies kan dit ook online bijgehouden worden op een website, of op de 
smartphone in een App. Daarnaast wordt in sommige bestaande astma-actie-plannen 
gevraagd om ook een longfunctie meting te verrichten. Vaak gebeurt dit met een piek-
stroom meter, waarbij patiënten moeten uitblazen in een klein apparaatje. In het actie 
plan staat vervolgens beschreven bij welke hoeveelheid klachten, of bij welke waarde 
van een longfunctie meting, deze persoon in actie moet komen. Vaak wordt gebruik 
gemaakt van een kleurencode, bijvoorbeeld:
– Groen. Uw astma is goed onder controle
– Geel. U heeft enige klachten, vermijdt prikkels die uw astma kunnen verergeren
– Oranje. U heeft meer klachten dan normaal, verhoog (tijdelijk) uw medicatie
– Rood. Ga direct naar uw arts of start een prednisonkuur
Wil een astma-actie-plan goed werken, is het van belang dat de hoeveelheid klachten 
en de longfunctie waardes die bij een bepaalde kleur horen, een toekomstige astma-
aanval goed voorspellen. Als namelijk het astma-actie-plan geen signaal afgeeft terwijl 
iemand wel een astma-aanval krijgt, heeft het actie plan gefaald. En aan de andere 
kant bestaat het gevaar dat iemand teveel medicijnen krijgt als er een signaal wordt 
gegeven dat er een astma aanval aankomt, terwijl dit achteraf beschouwd niet waar is. 
In hoofdstuk 5 hebben wij voor het actiepunt dat hoort bij de rode kleur (ga direct naar 
uw arts, of start een prednisonkuur) uitgezocht welke hoeveelheid klachten en welke 
waarde van een longfunctie meting het beste gebruikt kunnen worden. Hiervoor heb-
ben wij een dataset geanalyseerd van 164 volwassen astma-patiënten die gedurende 
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anderhalf jaar dagelijks hun klachten en piekstroom meting invulden in een dagboek. 
Daarnaast werd bijgehouden wanneer zij een astma-aanval doormaakten. Door de 
klachten en piekstroom in de week voorafgaand aan een astma-aanval te vergelijken 
met de klachten en piekstroom in alle weken dat er geen astma-aanval optrad, werd 
gezocht naar een specifiek patroon voorafgaand aan astma aanvallen. Nadat we dit 
hadden gevonden, werd dit patroon bevestigd in een dataset van 94 andere volwas-
sen astma patiënten, die een jaar lang een soortgelijk dagboek hadden ingevuld. Het 
meest geschikte actiepunt maakt gebruik van meerdere metingen in de tijd en is alleen 
geschikt als de berekeningen automatisch uitgevoerd kunnen worden (zoals in een App, 
of in een online programma). Voor het geval dit niet beschikbaar is, en voor gevallen 
waarbij alleen klachten of juist alleen een piekstroom waarde kunnen worden gemeten, 
zijn ook nog 3 andere geschikte actiepunten in hoofdstuk 5 gepresenteerd.
Online vragenlijsten
Met de toenemende invloed van het internet op ons leven, zal ook de gezondheidszorg 
zich meer en meer online gaan afspelen. Op dit moment bestaan er bijvoorbeeld al 
meerdere patiëntenportalen. Hierin kunnen patiënten hun klachten bijhouden en extra 
informatie over hun ziekte vinden. Vaak hebben ook artsen toegang en kunnen zij direct 
zien hoe het met de ziekte van één van hun patiënten gesteld is. Ook zijn er al veel Apps 
waarin je de controle over een ziekte kan vervolgen, waaronder Apps die specifiek op 
astma gericht zijn. In al deze online tools wordt vaak gebruik gemaakt van vragenlijsten 
om de ernst van astma klachten in te schatten, bijvoorbeeld de al eerder genoemde ACQ 
vragenlijst. Er wordt hierbij vanuit gegaan dat de uitkomst van een vragenlijst die bij de 
huisarts wordt ingevuld, precies hetzelfde is als de uitkomst van diezelfde vragenlijst als 
die thuis achter de computer/telefoon wordt ingevuld. In hoofdstuk 6 hebben wij voor 
de ACQ vragenlijst uitgezocht of dit inderdaad het geval is. Hiervoor hebben wij van 351 
volwassen astma-patiënten de uitkomst van een online thuis ingevulde ACQ vergeleken 
met een ACQ die werd ingevuld op de huisartsenpraktijk bij de praktijkondersteuner. 
Beide versies werden binnen een week van elkaar ingevuld, zodat eventuele verschillen 
in uitkomst niet konden worden verklaard doordat de astma klachten in de tussentijd 
erg veranderd waren. Online bleken patiënten significant meer klachten aan te geven 
dan bij de huisarts. Daarnaast zou in 25% van de gevallen het gebruik van de online 
versie in plaats van de versie bij de praktijkondersteuner hebben geleid tot een ander 
behandeladvies. Voordat een reeds bestaande vragenlijst online gebruikt kan worden, 
is het dus belangrijk om opnieuw te testen of de uitkomsten wel hetzelfde zijn. Zo nodig 
moeten er nieuwe grenswaardes worden bepaald van wat als een normale score en wat 
als een afwijkende score moet worden beschouwd. 
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Algemene discussie
In hoofdstuk 7 worden alle uitkomsten van de verschillende onderzoeken nog eens 
op een rij gezet. Vervolgens worden er aanbevelingen gedaan hoe deze uitkomsten 
de behandeling van astma zouden moeten veranderen, waarbij er ook rekening wordt 
gehouden met de uitkomsten van eerdere onderzoeken door andere onderzoekers. Op 
het einde van deze discussie worden ook suggesties gedaan voor toekomstig onder-
zoek. Zo is het belangrijk om in toekomstig onderzoek niet alleen te kijken naar astma 
patiënten als een groep en te bepalen wat gemiddeld voor hen het beste streefdoel is, 
maar ook te kijken naar individuele astma patiënten en te achterhalen wat voor hen 
persoonlijk het beste streefdoel is. Ook moet er meer onderzoek in de huisartsenprak-
tijk gebeuren, omdat veel van de huidige richtlijnen gebaseerd zijn op gegevens van 
onderzoeken uit het ziekenhuis terwijl die patiënten niet goed vergelijkbaar zijn met 
patiënten die worden behandeld in de huisartsenpraktijk . Voor wat betreft de astma-
actie-plannen moet nog onderzocht worden wat het beste ‘gele’ en ‘oranje’ actiepunt is, 
omdat wij alleen naar ‘rood’ hebben gekeken. En als laatste staat de ontwikkeling van IT 
in de gezondheidszorg nog in de kinderschoenen en zouden er meer goede en veilige 
oplossingen voor het gebruik hiervan onderzocht moeten gaan worden.
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